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ABSTRACT 
This study was designed to investigate the role of adenosine, an endogenous 
cardioprotectant agent, without high potassium and as cardioplegic additive to high 
potassium solutions. Adenosine cardioplegia and potassium cardioplegia 
supplemented by adenosine (K + ADO) were investigated in terms of hemodynamic, 
metabolic and ultrastructural recovery in the isolated rat heart and in the in-vivo 
baboon model during periods of global myocardial ischemia, simulating the clinical 
situation during open heart surgery. The results obtained in both models show that 
adenosine improved postischemic hemodynamic function when used without high 
potassium cardioplegia. The combination of adenosine and high potassium was less 
effective in both models in terms of hemodynamic recovery; however, improved 
rhythm stability and coronary vasodilatation were still present. In addition adenosine 
alone was able to induce fast electromechanical arrest in the isolated rat heart. 
However, failure of even high concentrations of adenosine to limit ventricular 
fibrillation in the baboon exclude its use as cardioplegic agent on its own without 
additional interventions. It appears likely that adenosine without high potassium is 
cardioprotective via activation of A1 receptors and opening of ATP-sensitive 
potassium channels, a mechanism which is probably non-functional in a high 
potassium environment. 
In view of the limited cardioprotection achieved with the combination of adenosine 
and high potassium further studies should aim for additional interventions to induce 
cardioplegia with adenosine and normokalemic solutions. 
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ORGANIZATION OF THE THESIS 
This thesis deals with the role of adenosine in the field of intraoperative myocardial 
protection. Adenosine is a cardioprotective agent, especially during phases of 
induced or spontaneous regional or global ischemia, and it acts via multiple 
mechanisms. Additionally, adenosine might act as an alternative agent to high 
potassium solutions to induce cardiac arrest. This form of polarized arrest might offer 
certain advantages over commonly achieved cardiac arrest at depolarized 
membrane potentials. 
Chapter 1 gives an introduction to the historical development of cardioplegia and 
focuses on current concepts of cardioplegia and organ preservation in general. 
Clinically used cardioplegic solutions are compared with the exact composition and 
discussion of advantages and disadvantages. The impact of cardioplegic myocardial 
protection on operative mortality and postoperative complications at Groote Schuur 
Hospital is outlined in a further paragraph. Finally the physiologic and clinical roles 
of adenosine are discussed. 
Chapter 2 describes the models used in this thesis in detail. First, the isolated rat 
heart model according to Langendorff used in the pilot experiments is discussed in 
detail. The second model, the in-vivo baboon model developed for the studies, is a 
preclinical model, closely resembling the clinical setting. 
Chapter 3 explains the hypothesis under test. It explains the rationale for using 
adenosine as cardioplegic agent or as cardioplegic additive in the context of 
intraoperative myocardial protection. 
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Chapter 4 focuses on the effect of adenosine as cardioplegic agent and its effect 
on cardiac arrest in the isolated rat heart, which was used as a screening model. 
Further studies in the isolated rat heart highlight the effect of adenosine either as 
cardioplegic agent in a low potassium solution or as cardioplegic additive in a high 
potassium solution. The effects are demonstrated in a short-term (30 minutes) global 
ischemia model as well as in a medium-term (90 minutes) global ischemia model. 
Chapter 5 describes the studies in the primate model, used as a preclinical model. 
In a first set of experiments the crystalloid cardioplegic solution resulting in the best 
postischemic recovery amongst the various solutions used in South Africa was 
determined. All further studies were based on this solution, which was the St. 
Thomas' Hospital solution No. 2. In a second step, adenosine was added to a non-
cardioplegic (low potassium) solution and compared to St. Thomas' Hospital solution 
No. 2. The last set of experiments performed in the in-vivo baboon model included 
adenosine as adjunct to St. Thomas' Hospital solution No. 2. in a dose response 
study. 
Chapter 6 briefly describes some additional in-vitro studies comparing the activity 
of adenosine deaminase in various species, including man. These experiments were 
thought to determine the optimal adenosine concentration in cardioplegic solutions 
intended for clinical application. 
Chapter 7 includes a discussion and summary of the thesis and the models used. 
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ABBREVIATIONS USED IN THE TEXT 
Units of measurement: 
oc degrees Celsius min 
cm centimeter ml 
cS delta (change in) mm 
g gravitational force mMol 
gm gram mOsm 
h hour mV 
kg kilogram N 
kPa kilopascal ng 
L liter p 
M molarity /mol/L s 
m meter u 


















cyclic adenosine 3', 5'-monophosphate 
cyclic guanosine 3',5'-monophosphate 
creatine kinase 





















































endothelial cell growth factor 
endothelium derived relaxing factor (nitric oxide) 
ethytenediamine-tetraacetic acid 
fructose-6-phosphate 
flavin adenine dinucleotide (oxidized from) 













































nicotinamide adenine dinucleotide (oxidized form) 
dihydronicotinamide adenine dinucleotide (reduced form) 
nicotinamide adenine dinucleotide phosphate (oxidized form) 














tissue plasminogen activator 
tris (hydroxymethyl) aminomethane hydrochloride 









body surface area 
coronary artery bypass graft 
cardiac index 
cardiac output 





















intra aortic balloon pump 
let atrium 
left arterial pressure 
left ventricle 
first derivative of L V developed pressure 
left ventricular end diastolic pressure 
mean arterial pressure 
Plasmalyte B electrolyte solution 
pulmonary vascular resistance 
stroke volume 
stroke volume index 
systemic vascular resistance 
stroke work index 
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History of cardioplegia 
The evolution of cardiac surgery reflects a dilemma between the needs of surgeons 
for a still, bloodless operating field and the need of the myocardium for a continuous 
supply of oxygen and substrates. As a consequence of this dilemma the 
development of specialized solutions allowed a compromise between these two 
extremes. 
The beginning of open heart surgery 
The beginning of clinical open heart surgery dates back to 1953 when Lewis and 
Taufic in Chicago closed an atrial septal defect using inflow occlusion and moderate 
systemic hypothermia with surface cooling (Lewis, 1953). But only after the 
development of the heart-lung machine in 1954, by Gibbon, which took about twenty 
years, was it possible to develop and extend open heart procedures to today's level 
(Gibbon, 1954). It was, however, the correction of Fallot's tetralogy by Lillehei in 
1954 in Minneapolis, still using controlled cross-circulation from a donor, which 
initiated the explosive development of open heart surgery (Lillehei, 1955). Kirklin in 
Rochester using a modified Gibbon screen oxygenator (Kirklin, 1955) and Cooley in 
Houston using a bubble oxygenator, paved the way for further development 
(Cooley, 1957). 
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Hypothermia and intermittent aortic cross-clamping 
Before long the technique of hypothermia allowed only a short period of cardiac 
arrest, but suboptimal operating conditions became a limiting factor in extending the 
complexity of the surgical repair. Alternative techniques of keeping the coronary 
arteries perfused and the heart beating seriously obscured the operating field. 
Intermittent aortic cross-clamping seemed a possible alternative, but was still far 
from being ideal. 
Introduction of cardioplegia 
Cardioplegia by definition means: 'intentional reversible paralysis of the heart'. It was 
Melrose in 1955 who introduced the concept of 'elective cardiac arrest' based on 
animal and clinical studies (Melrose, 1955). The observation that ions in the 
extracellular medium had a profound effect on cardiac action was first established in 
the classical studies of Ringer in 1883. Whereas Hooker in 1929 suggested that 
potassium chloride might be able to alter the ventricular fibrillation observed in 
experimental animals (Hooker, 1929), it was Melrose who introduced the concept into 
clinical practice. It needs to be remembered, that this new concept came into 
existence for the purpose of improving exposure for the operation by providing the 
surgeon with a quiescent heart, rather than for protection of the myocardium (Figure 
1.1.) 
However, use of induced cardiac arrest fell into disfavor several years later after a 
report of some unexpected complications. They were seemingly related to the 
administration of potassium citrate and Helmsworth and associates (1959) described 
a focal area of microscopic myocardial injury believed to result from administration of 
a toxic substance. Swedish investigators, Bjork and Fors (1961 }, reported that less 
myocardial damage resulted after a period of ischemia alone than with potassium 
citrate or acetylcholine induced arrest. The outcome was that elective cardiac arrest 
was virtually abandoned for nearly 15 years (Figure 1.1. ). 
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With the abandonment of potassium induced cardioplegia, coronary perfusion 
became the technique of choice for myocardial preservation. The heart was kept 
beating and perfused through the aortic root. However, coronary venous return had 
constantly to be sucked from the beating heart during the operation. Many surgeons 
used electrically induced ventricular fibrillation to improve operative conditions. 
However, Buckberg, Hottenrot and coworkers (1975) at the University of California in 
Los Angeles showed that subendocardial necrosis was aggravated especially if the 
hypertrophic heart fibrillated spontaneously or if a normal heart was kept in 
ventricular fibrillation artificially. The reason being that the blood was diverted away 
from the subendomyocardium and even though the overall coronary flow increased 
in the fibrillating, compared with the empty beating heart, resistance to coronary flow 
rose progressively with increased period of fibrillation. Severe depression of left 
ventricular function associated with subendocardial necrosis was a consequence 
and subsequently the technique of ventricular fibrillation was largely abandoned. 
However, more and more surgeons turned to clamping the aorta or stopping 
coronary perfusion during the most difficult or critical steps of the operation so that 
continuous coronary perfusion became de facto intermittent. From St. Thomas' 
Hospital in London it was reported that for example continuous coronary perfusion of 
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the left coronary artery during aortic valve surgery was on the average only carried 
out during 70% of the overall aortic occlusion time. The usual pattern was to occlude 
the aorta for ten minutes and then to allow three minutes of coronary perfusion in 
order to correct the oxygen debt incurred during the ischemia. 
The return of cardiop/egia 
The concept of protecting the myocardium and producing a clear operative field had 
been kept alive in Germany by Holscher, who had published his work on the 
experimental study of various forms of cardiac arrest in the American literature 
(Holscher, 1961) (Table 1.1. ). However, it was the work of Bretschneider and 
Spieckermann published in 1964 that stimulated the first cardiac surgeon to initiate 
the new wave of cardioplegia (Bretschneider, 1964). Bretschneider published the 
principle of arresting the heart with a sodium poor, calcium free, procaine containing 
solution that became known as Bretschneider's solution (Table 1.1.). The principle of 
his solution was a sodium content equal to the intracellular sodium concentration to 
prevent generation of the action potential. The lack of calcium ions was intended to 
prevent excitation-contraction coupling and procaine was added to stabilize the cell 
membrane. Mannitol was added for osmotic reasons. S0ndergaard adopted 
Bretschneider's cardioplegic solution routinely for myocardial protection in clinical 
practice, achieving a remarkably low mortality of 6% in a consecutive series of 100 
aortic valve replacements (S0ndergaard, 1967). However, he used a 4° C cold 
blood/glucose mixture to perfuse the heart prior to cardioplegic perfusion. 
Kirsch at the university clinic in Hamburg worked on the theory that a cardioplegic 
agent should contain no component that would stimulate the breakdown of energy-
rich phosphates by activation of phosphorylases (Kirsch, 1970). Nor should it 
contain calcium, potassium, or sodium, as adenosine triphosphate (ATP) is used in 
membrane transport. Local anesthetics and magnesium, being membrane-stabilizing 
agents, were believed to slow the decay of organic phosphate in the cell (Table 
1.1.). From 1969, the Kirsch magnesium-aspartate-procaine bolus solution was in 
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regular clinical use in Rodewald's unit in the university clinic in Hamburg 
(Kirsch, 1972). 
Stimulated by this work, Hearse tested experimentally the individual components of 
the Bretschneider and Kirsch solutions in the isolated rat heart at the Rayne Institute 
at St. Thomas' Hospital in London (Hearse, 1976). In contrast to their ideas, he 
advocated the principle that cardioplegic solutions should retain as closely as 
possible extracellular, rather than intracellular concentrations of ions with only those 
additions that could individually be shown to be effective and then only in the optimal 
concentrations. He proposed the St. Thomas' solution which was based on Ringer's 
solution with its normal concentrations of sodium and calcium, to which was added 
16 mM per liter potassium chloride to arrest the heart instantly, 16 mM per liter 
magnesium chloride which had in this concentration been shown to have a marked 
effect additive to the potassium for myocardial protection, and 1 mM per liter 
procaine hydrochloride (Table 1.1.). This solution was introduced into regular clinical 
practice by Braimbridge at St. Thomas' Hospital in 1975 (Braimbridge, 1977). 
There had been, during the 1960s, some interest in cardioplegia in the United States 
(Greenberg, 1960). It was Gay and Ebert in 1973, who, quoting Kirsch and 
Rodewald's sizable clinical experience, used a 25 mM per liter solution of potassium 
chloride in 200 mM per liter of sodium with glucose and bicarbonate (Gay, 1973). 
They were able to protect isolated dog hearts against an hour of ischemia without 
microscopic damage, and they made the fundamental point that this improvement on 
the Melrose technique was due to the fact that their solution was isotonic. Tyers and 
co-workers emphasized the importance of the lower concentrations of potassium 
(Tyers, 1978; Todd, 1975). 
Clinical experience of cardioplegia was reported in the United States by Roe et al. 
who had introduced potassium-induced cardioplegia into his practice in San 
Francisco in 1973 and reported his initial series in 1976 (Roe, 1977). He reported an 
impressively low mortality at this time of 5.4 %. Tyers et al. in 1977 reported over 
100 consecutive patients in whom cardioplegia had been used (Tyers, 1977). The 
excellence of their myocardial protection was supported by the facts that over half 
the hearts had spontaneously defibrillated, the post-operative use of inotropic agents 
was infrequent, the immediate post-operative level of cardiac output was improved, 
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and the release of myocardial iso-enzyme levels was relatively low. He had used a 
25 mM per liter of potassium-enriched solution with some calcium in Normosol® at 
15° C. 
TABLE 1.1. THE EVOLUTION OF CARDIOPLEGIA 
1st generation: Melrose solution Melrose 1955 high ~ -citrate 
Hoelscher 1961 Mg2+ /Procaine 
2nd generation: German solutions Bretschneider 1964 low Na+/ 
Ca2+·free 
Kirsch 1970 Mg2+ /Procaine 
Hearse 1976 high ~/Mg2+ 
3rd generation: Extracellular solutions Gay-Ebert 1973 high~ 
4th generation: Blood cardioplegia Buckberg 1979 high ~ /blood 
By the end of 1978 coronary perfusion as a means of preserving the myocardium 
during a period of aortic occlusion had virtually disappeared from clinical practice 
throughout the world. The discussion by then was not whether but what sort of 
cardioplegia should be used clinically. There were initially three fairly well-defined 
geographical groups in this respect (Table 1.2.). The continent of Europe by and 
large, particularly east of the Rhine, used the sodium-poor, calcium-free magnesium 
and procaine containing solutions introduced by Bretschneider. Great Britain and 
much of western Europe used solutions based on an extracellular formula with 
potassium, magnesium and procaine added to Ringer's solution, such as the St. 
Thomas' solution. The United States used primarily potassium-enriched solutions 
containing little or no magnesium and no local anesthetic (Table 1.2.) A variant in 
American practice was the use of blood as a vehicle for infusing potassium into 
coronary arteries, a concept introduced by Buckberg in Los Angeles 
(Buckberg, 1979, Folette, 1978) (Table 1.1.). Blood was preferred to purely ionic 
solutions because of its better oxygenating and buffering capacities. 
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TABLE 1.2. REGIONAL DISTRIBUTION OF PREFERRED FORM OF 
CARDIOPLEGIA 
INTRACELLULAR COMPOSITION EXTRACELLULAR COMPOSITION 
Europe North America 
esp. Germany Great Britain 
The question today is not whether to use cardioplegia or not, but rather what sort of 
cardioplegia should be used. Today cardiac surgeons are faced with a multitude of 
different cardioplegic solutions and cardioplegic techniques being used clinically and 
experimentally. However, the question of ideal myocardial preservation during open 
heart surgery still remains unsolved. 
In summary, it was Melrose in 1955 who initiated the clinical use of chemical 
cardioplegia. Because of observations of myocardial damage with this technique 
there was a shift in the sixties to sustained coronary perfusion in order to 
approximate the normal state. In the seventies there was a revival of cardioplegia 
with reduced potassium concentrations or principles of sodium depletion or 
magnesium induced arrest. Blood cardioplegia came into existence in the eighties 
and was succeeded in the early nineties by the technique of continuous warm blood 
cardioplegia. 
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Current concepts of cardioplegia and organ preservation 
Principles and definitions 
Cardioplegia is a specialized form of organ protection and is historically the first form 
of intraoperative organ protection. Myocardial protection during open heart surgery 
includes all perioperative measures to protect the structure and function of 
myocardial tissue, including conducting tissue and endothelial cells (Table 1.3.). 
Myocardial protection during open heart surgery includes all preoperative, 
intraoperative and postoperative measures to reduce myocardial damage. 
Cardioplegia is defined as intentionally induced, chemical electromechanical arrest 
of the heart in diastole and was initially developed to improve operative conditions 
during open heart surgery and to prevent air embolism. 
The emphasis on protecting the ischemic heart came only later during the historical 
development. However, electrical arrest of the myocardium enhances structural and 
functional protection, as the major energy-consuming process of electromechanical 
activity is stopped. The term cardioplegia was probably first used by Lam in 1957, 
when describing his acetylcholine technique (Lam, 1957). 
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TABLE 1.3. MYOCARDIAL PROTECTION 
Definition.: all perioperative measures to protect the structure and function of 
myocardial tissue, conducting tissue and vasculature, including vascular 
smooth muscle and endothelium 
Cardioplegia: chemically induced, reversible electromechanical cardiac arrest 
Cardioplegic solutions: specifically formulated solutions to induce reversible cardiac 
electromechanical arrest in diastole and to protect the 
ischemic myocardial, conducting and vascular tissue 
Cardioplegic procedures: - high-volume cardioplegia 
- oxygenated crystalloid cardioplegia 
- blood cardioplegia (cold/warm/continuous/hot shot) 
- antegrade cardioplegia 
- retrograde cardioplegia 
- depending on the type of solution used 
Preservation solutions: partially modified cardioplegic solutions used for ex-vivo 
storage (storage via immersion or perfusion) 
Adaptation for specific requirements: - energy-depleted myocardium 
- neonatal myocardium 
- senescent myocardium 
Cardioplegic solutions 
The use of cardioplegic solutions is only part of the myocardial protection regimen 
used during cardiac surgery today. With regard to individual cardioplegic solutions it 
appears more appropriate to talk about myocardial protective measures as for 
instance high volume cardioplegia, oxygenated crystalloid cardioplegia, ante- or 
retrograde cardioplegia, intermittent cold blood cardioplegia or continuous warm 
blood cardioplegia (Table 1.3.). The protective measures used are in general 
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dependent on the type of solution used, but several measures can also be combined 
as an integral form of myocardial protection. 
Preservation solutions are either standard cardioplegic solutions used for 
intraoperative myocardial protection (St. Thomas' Hospital solution, Bretschneider 
HTK4 solution, Stanford solution etc.) or specially developed solutions for ex-vivo 
storage and subsequent transplantation (Collins solution, University of Wisconsin 
solution) (Table 1.4.). 
Generally the concept of a single solution protecting all organs equally effectively is 
not feasible, owing to different organ-specific needs. However some commercially 
available solutions like the University of Wisconsin solution are effectively used 
clinically to protect intraabdominal organs as well as the heart. 
However, recently concern has been raised about the intracellular composition of 
these preservation solutions including a high concentration of potassium 
( < 1 OOmM). Pearl et al. found impaired endothelial function after prolonged storage 
in University of Wisconsin solution (Pearl, 1994). Drinkwater et al. from the University 
of California, Los Angeles published a clinical study showing an increased rate of 
accelerated graft atherosclerosis when University of Wisconsin solution had been 
used for storage preservation (Drinkwater, 1995). 
TABLE 1.4. CARDIAC PRESERVATION SOLUTIONS 
PRESERVATION SOLUTIONS 
In-vivo protection I Ex-vivo orotection 
Cardioplegic solutions Storage Solutions Perfusion solutions 
St. Thomas' Collins Wicomb 
Bretschneider Euro-Collins Proctor 
Kirklin Sacks Copeland 
Stanford UW* Watson 
Legend: Cardioplegic solutions can be used for in-vivo and ex-vivo protection, whereas storage and 
perfusion solutions are developed purely for ex-vivo protection. 
* University of Wisconsin solution 
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Current concepts of myocardial protection during cardiac surgery 
The majority of cardiac operations performed today involve cross-clamping of the 
ascending aorta in order to facilitate the procedure by producing a still, bloodless 
operative field, but this inevitably causes myocardial ischemia. The intra-operative 
objective is to correct the underlying defect without causing additional damage, in 
other words causing no deterioration of myocardial function. Important factors in 
achieving this aim are pre-operative, intra-operative, and also anesthetic 
management (Table 1.5.). Surgical technique is important and finally the methods of 
intra-operative myocardial protection while the patient is on cardiopulmonary bypass. 
As started initially, cardioplegia is only one component of the complex term 
myocardial protection. 





preoperative energy status of the myocardium 
myocardial hypertrophy 
premed ication 







Legend: The three phases of perioperative myocardial protection. Cardioplegia is only one part of the 
whole cardioprotective strategy. 
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Mechanisms of injury 
lschemia 
lschemia is defined as the total absence of blood flow. lschemia causes irreversible 
injury if allowed to persist. Periods of ischemia shorter than those that produce 
irreversible injury may predispose the heart to reperfusion-related damage and 
myocardial stunning (Bolli, 1990). 
The reversibility of tissue injury 
The time sequence of cellular and subcellular events following myocardial ischemia, 
showing the progressive development, is listed in table 1.6. Jennings and colleagues 
(Jennings, 1961) have divided tissue Injury into a number of phases. However 
severe the ischemia, the cellular changes which occur during the early minutes are 
fully reversible. If adequate coronary flow is restored, there will be rapid and 
complete resumption of normal functional activity. If the duration of severity of 
ischemia is increased, reperfusion may not result in immediate return of normal 
contractile activity. However, several hours or days after the repletion of critical and 
limiting factors such as adenine nucleotide precursors, full recovery may be 
observed. Up to this stage cellular injury can be considered as reversible. However, 
beyond a certain point tissue injury becomes so severe that reperfusion will not 
result in resumption of full contractile activity. In this state, under certain conditions, 
reperfusion may even cause a major extension of damage (Hearse, 1973, 1977, 
1990). Irreversible injury occurs progressively with increasing numbers of cells 
becoming destined for cell death (Jennings, 197 4). The objective of effective 
myocardial protection is therefore either to reperfuse the tissue before the onset of 
significant irreversible injury or to use interventions which prevent or delay the 
critical transition from reversible to irreversible injury. 
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Effects on myocytes 
The time sequence of cellular events following myocardial ischemia is listed in table 
1.6. 
lschemia affects both the myocardium and the coronary vasculature as well as the 
conducting system. Mechanical function dwindles dramatically with the onset of 
ischemia. End-diastolic pressures increase and ventricular compliance decreases. 
These phenomena are manifestations of ATP depletion and intracellular calcium 
uptake. 
The contractile apparatus is the major consumer of ATP in the beating heart. When 
substrate substrate supply is cut off, ATP stores are rapidly consumed by 
mechanical activity. ATP is also required to dissociate the cross-bridges between 
actin and myosin. In the absence of ATP and the presence of calcium, cross-bridges 
are formed and an irreversible contracture, called rigor, results. 
lschemia induces a change within the contractile apparatus that reduces sensitivity 
of the proteins to calcium and reduces the maximal rate of ATP hydrolysis 
(Hess, 1981 ). The first of these effects is reversible. The sensitivity of the contractile 
apparatus to calcium returns to normal on reperfusion. However, the maximal activity 
of the myofibrillary ATPase remains depressed. The reduction in this enzyme activity 
explains the observed decrease in dP/dt (change in pressure with time) following 
ischemic injury. 
Adenine nucleotides are found in coronary sinus blood following a variable period of 
ischemia. Loss of adenine nucleotides from the myocardium results in sustained low 
cellular ATP levels. Up to three days are required for ATP levels to return to normal 
in the dog following only 15 minutes of normothermic ischemia (De Boer, 1980) 
Endogenous glycogen stores are utilized to generate ATP via glycolysis. This 
process continues only as long as cytosolic NADH+ levels are below the threshold 
for inhibition of glycolysis (Ravetto, 1975). The ongoing hydrolysis of ATP and the 
glycolysis itself contribute to steadily increasing levels of NADH+. Eventually, 
glycolysis ceases, and ATP production with it. ATP consumption continues until 
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stores are depleted. An ischemic contracture is the manifestation of severe ATP 
depletion. The resultant injury may be irreversible. Glycolysis results in the 
generation of high osmolality, acidosis, and altered redox states within the cell that 
can slow the generation of free radicals. 
There is a substantial body of evidence linking increased glycolytic flux rates to 
decreased ischemic injury (Owen, 1990). Decreased glycolytic flux is associated with 
increased severity of ischemic injury and may contribute to lethal injury, since lack of 
cytosolic ATP fails to provide the energy required to move calcium across the cell 
membranes (Opie, 1988). 
However, the regulation of glucose metabolism during ischemia remains poorly 
understood. Myocardial ischemia results in an increase in the rate of glycolysis and 
a switch from lactate uptake by the heart to lactate production and protons as 
metabolic end products. The glucose for glycolysis originates from both the 
breakdown of myocardial glycogen stores and the uptake of glucose from the blood 
(Lopaschuk, 1997). In a recent study by Cross et al. ( 1996) the authors found high 
endogenous glycogen to be protective during brief periods of no-flow ischemia. In 
contrast, during prolonged no-flow ischemia glycogen stores became fully depleted 
and myocardial injury occurred, which was exacerbated by the lower ischemic pH in 
these hearts, leading to increased Na+ - H+ exchange during reperfusion. The 
authors concluded, that the effect of high glycogen on the ischemic heart may be 
due to the differences in the extent of glycogen depletion during ischemia, which is 
linked to the extent and severity of ischemia. King et al. (1995) defined the 
conditions for a beneficial effect of glucose to the ischemic heart in a rat heart model 
investigating coronary flow and glucose delivery as determinants of contracture in 
the ischemic myocardium. The adequate coronary flow to deliver glucose and to 
remove end-product inhibition was found to be greater than 0.06 ml/g/min. In the 
surgical setting during cardioplegic arrest with the aorta crossclamped there is still 
residual non-coronary collateral flow from preexisting collaterals which may provide 
about 6-10% of the normal coronary flow, sufficient to remove the harmful 
accumulation of metabolites. Intermittent reinfusion of cardioplegia may have a 
similar effect. However, in conditions of prolonged total ischemia as occurs during 
storage for transplantation, glucose might be harmful as there is no adequate 
removal of end products. Tissue levels of lactate have been inversely correlated with 
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post-ischemia recovery (Neely, 1984). High concentrations have been found to 
cause mitochondrial injury (Armiger, 197 4 ). However, more recent data from isolated 
cell systems suggest that lactate alone is not sufficient to cause anoxic damage or 
predispose to reperfusion injury (Geisbuhler, 1990). There is now recurrent interest 
in the use of glucose-insulin-potassium (GIK) for treatment of acute myocardial 
infarction (Apstein, 1997) and in a curent meta-analysis Fath-Ordoubadi (1997) 
found a beneficial effect on hispital mortality. 
During ischemia, the mitochondria are unable to generate ATP. The activity of 
mitochondrial complex I (NADH: ubiquinone reductase) decreases significantly 
during ischemia and is further reduced on reperfusion. Changes occur within the 
cytochrome oxidase system that result in an univalent reduction of oxygen rather 
than the normal tetravalent reduction (Veitch, 1990). This change results in the 
generation of free oxygen radicals upon reperfusion. Free oxygen radicals may also 
be formed by the mitochondria during periods of ischemia. Post-ischemic dysfunction 
can result from the effects of lipid peroxidation caused by these free radicals. 
The other organelle affected by ischemia is the sarcoplasmic reticulum. Calcium 
released from the sarcoplasmic reticulum by Ca2+ -induced Ca2+ release intitiates 
contraction. Calcium uptake by the ATP-dependent Ca2+-pump initiates relaxation. 
This process consumes ATP (1 mM/2 mM Ca2+ transported) and is stimulated by 
calmodulin activity. lschemia interferes with calcium uptake by the sarcoplasmic 
reticulum through 
1) ATP depletion, 
2) reduction in calmodulin activity (Turla, 1985) 
3) change in intracellular pH. 
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Decreasing intracellular pH decreases calcium uptake (Turla, 1985). The effect of pH 
change decreases with time but ATP depletion (Ca2+-ATPase) and reversal of 
Na+/Ca2+ exchanges continue to depress sarcoplasmic reticulum function during 
ischemia (Krause, 1984). 
The consequence of reduced calcium uptake via the sarcoplasmic reticulum 
increases cytosolic free calcium concentrations. High levels of intracellular calcium 
in conjunction with calmodulin can activate phospholipases (Nayler, 1981; Krause, 
1984). During ischemia, calmodulin activity remains normal except in the 
sarcoplasmic reticulum (Turla, 1985). Calcium-calmodulin activation of 
phospholipase A2 may result in membrane damage with loss of intracellular contents, 
including creatine kinase (van der Vusse, 1983, Das, 1986). Elevated blood levels of 
the MB-CK isoform are indicative of myocardial injury. 
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TABLE 1.6.: CELLULAR CONSEQUENCES OF MYOCARDIAL ISCHEMIA 
ONSET OF SEVERE ISCHEMIA 
Disturbed transmembrane ion balance 
Utilization of dissolved oxygen 
Reduced mitochondrial activity and oxidative metabolism 
Reduced ATP production 
Reduction of creatine phosphate stores 
Reduction of amplitude and duration of action potential 
Leakage of potassium . 
ST segment changes 
Accumulation of sodium and chloride ions 
Catecholamine release 
Stimulation of adenyl cyclase 
Stimulation of glycogenolysis 
Net utilization of high-energy phosphate 
Accumulation of protons, carbon dioxide, and inorganic phosphate 
Stimulation of phosphofructokinase activity 
Increase of glycolytic flux 
Development of intracellular acidosis 
Reduction or blockage of mitochondrial electron transport 
Suppression of fatty acid oxidation 
Leakage of magnesium ions 
Utilization of glycogen 
Leakage of inorganic phosphate 
Accumulation of NADH 
Increased LOH and a-GPDH activity 
Accumulation and leakage of lactate 
Accumulation of fatty acyl CoA derivatives 
Depletion of creatine phosphate 
Leakage of adenosine, inosine, and other metabolites 
Vasodilatation 
Inhibition of adenine nucleotide transferase activity 
Possible stimulation of triglyceride synthesis and degradation 
Increasing cellular acidosis 
Suppression of PFK and G-3-PDH activity 
Slowing of glycolytic flux 
Cell swelling 
Increase in cytoplasmic ionized calcium content 
Possible exhaustion of glycogen reserves 
Inhibition of glycolysis 
Severe reduction of ATP 
Minor ultrastructural changes, for example, mitochondrial swelling 
Possible onset of contracture 
ONSET OF IRREVERSIBLE DAMAGE? 
Lysosomal changes activation of hydrolases and lipoprotein lipases 
Increasing cellular edema 
Loss of mitochondrial respiratory control 
Nonspecific electrocardiographic changes 
Ultrastructural changes in mitochondria and myofibrils 
Complete depletion of energy reserves 
Loss of mitochondrial components 
Leakage of enzymes to interstitial space and lymph 
Severe ultrastructural damage and membrane deterioration 
Disruption of mitochondria, myofibrils, and cell membranes 
CELL DEATH AND TISSUE NECROSIS 
(modified from Hearse, 1981) 
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Effects on coronary vasculature 
The changes that occur within the coronary vasculature during ischemia are rather 
subtle but no less deleterious to the heart. The purine metabolism of the coronary 
endothelium and the myocytes are closely related. Much of the adenine nucleotide 
salvage occurs in the vascular endothelium (Gerlach, 1985). lschemic injury affects 
the endothelium resulting in loss of nucleotides even after ischemia of short 
duration. 
The coronary capillary endothelium is the only site of uric acid production within the 
myocardium (Jarasch, 1981 ). Uric acid is produced from hypoxanthine and xanthine 
by the enzyme xanthine dehydrogenase. During ischemia, xanthine dehydrogenase 
is converted to xanthine oxidase by the action of a calcium-dependent protease 
(Jarasch, 1986). 
Xanthine oxidase converts xanthine and hypoxanthine to uric acid, but it also 
catalyses the formation of toxic oxygen radicals. These substances are formed on 
reperfusion and are capable of mediating reperfusion injury. This view is not 
universally accepted. Data acquired from ischemic rat hearts indicate that there is 
only minimal conversion of xanthine dehydrogenase xanthine oxidase (Kehrer, 
1987). Whether this observation is unique to the rat remains to be determined. 
Toxic oxygen radicals are formed in low concentrations in the normal heart. They are 
detoxified by endogenous superoxide dismutase, catalase and peroxidases. 
The activity of these free radical scavengers is dramatically reduced by ischemia 
(Otani, 1985). lschemia renders them ineffective during the reperfusion period; 
consequently, free radical mediated damage ensues. The activity of lytic enzymes is 
increased during ischemia. 
The vascular endothelium is a source of endothelium-dependent relaxing factor 
(EDRF}, which is probably nitric oxide (NO), and prostacyclin. These substances are 
critical for the maintenance of normal coronary flow. lschemia and possibly 
cardioplegic solutions themselves alter the responsiveness of the coronary 
vasculature to 5-hydroxytryptamine, which causes release of EDRF (Saldanha, 
1989, Pearl, 1994). Loss of normal endothelial function leads to pathologic modes of 
constriction by the coronary vessels and response to various biochemical 
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metabolites. lschemic injury may also leave the endothelium vulnerable to activation 
of platelets and neutrophils and their adhesion upon reperfusion, resulting in further 
injury (Olafsson, 1987). 
Specialized conduction cell damage 
The specialized conduction cells become non-functional early in the course of global 
myocardial ischemia in humans, and it may be speculated that their recovery takes 
longer than does recovery of myocytes. Some support for this is that five or so 
minutes after initially hyperkalemic reperfusion, the ventricular myocardium in some 
patients responds well and strongly to direct ventricular pacing, although it remains 
silent with atrial pacing or without pacing. Then, after a couple or more minutes, a 
sinus rhythm may appear. Also, when blood cardioplegia and uncontrolled 
normokalemic reperfusion are used, about 50 per cent of patients have transient 
atrioventricular conduction defects when the cardiopulmonary bypass is 
discontinued (Baermann, 1987). This appears to represent a formal specialized 
conduction cell stunning rather then necrosis, since the conduction defects have 
disappeared by the time of hospital discharge in half of the patients in whom it 
developed. Even third degree AV block persisting as long as two months have been 
observed to give way to sinus rhythm (Baermann, 1987). This speculation remains to 
be validated, however. 
Reperfusion 
At the cellular level, reperfusion is potentially the most destructive phase during the 
operative repair of a heart defect. Generation of oxygen radicals and calcium influx 
both occur during reperfusion of the myocardium. Both of these phenomena may 
injure the heart although the myocardium must be reperfused after regional or global 
ischemia if total necrosis is to be avoided. Several studies have demonstrated that 
injury may be accelerated or extended by interventions at the time of reperfusion 
(Simpson, 1987; Opie, 1989; Hearse, 1990). However, reperfusion, though in some 
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ways harmful, does improve many deleterious changes. The reason is that with the 
resumption of mitochondrial function ATP resynthesis restarts and reversible 
ultrastructural changes improve over time. 
The existence of this so-called reperfusion injury has been debated. However, 
descriptions of its characteristics, time course and mechanisms are convincing. 
Furthermore, evidence is mounting that reperfusion injury is indeed a process 
amenable to modification (either extension or regression) by intervention initiated at 
the time of reperfusion (Vinten-Johansen, 1985; Vinten-Johansen, 1986; Opie, 1989; 
Nakanishi, 1991; Nakanishi, 1995) . 
Cardiac surgeons have spoken extensively about reperfusion injury, possibly 
because they, unlike their cardiology colleagues, can modify the conditions under 
which reperfusion is conducted or the composition of the reperfusate with relative 
ease by means of extracorporeal technology, chemical cardioplegia and modified 
reperfusates. We can define reperfusion injury as pathology that is extended, 
accelerated or expressed de novo from the profile observed during ischemia, 
resulting from events occurring after reperfusion has been initiated. This definition is 
rather broad in that it takes into consideration that the rate of injury as well as the 
final long-term extent of injury may be altered by reperfusion or by reperfusion 
therapy. Deceleration of the rate of reperfusion injury in the early post-operative 
period may be important in counteracting myocardial stunning, which is defined as 
post-ischemic contractile dysfunction in the absence of morphologic injury or 
necrosis (Jennings, 1991; Appleyard, 1993; Mangano, 1993). 
The concept of reperfusion injury had its genesis in the 1960s and 1970s. Jennings 
et al. (Jennings, 1960) reported development of ultrastructural abnormalities after 
reperfusion, while Hearse and colleagues (Hearse, 1973; Hearse, 1977) 
demonstrated that the reintroduction of oxygen and the initiation of reperfusion were 
associated with abrupt myocardial injury. In the following decades, a series of 
experiments were performed to describe the pathologic characteristics of reperfusion 
injury or reoxygenation injury and researchers have striven to determine the 
mechanisms involved. 
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There is a burst of free radical production that peaks 2 - 4 minutes after reperfusion 
and continues for 3 hours or more after reflow. Much of the damage produced by 
toxic oxygen radicals is mediated by the hydroxyl radical OH (Burton, 1984). This 
entity is formed by the interaction of the superoxide radical, 02· and hydrogen 
peroxide via the Haber-Weiss reaction (Fridovich, 1978). The reactant 02· is formed 
by the conversion of hypoxanthine into xanthine by xanthine oxidase in the presence 
of oxygen. An alternative pathway for 02· generation is via one-electron reduction of 
0 2 catalyzed by the enzyme NADPH-oxidase that is present in neutrophils and is 
activated by the complement CSa. Complement activation is a frequent event during 
bypass. The hydroxyl radical is especially toxic because it has been shown to react 
with polyunsaturated fatty acids (a common membrane constituent) to form lipid 
hydroperoxides (Flamm, 1978). Lipid hydroperoxides are capable of causing 
sustained chain reactions resulting in extensive membrane damage and possible 
disruption of cellular integrity. 
Ultrastructural damage produced by the hydroxyl radical (OH·) includes vacuolization 
and edema of the vascular endothelium, severe swelling of the myocardial 
mitochondria and myocyte basement membrane bl ebbing (Krause, 1984 ). 
Membranous cellular debris was found in the vessels of septa! preparations exposed 
to 02· and OH·. The primary damage caused by free radicals is not the generation of 
holes in the cell membrane but rather inactivation of proteins critical to maintenance 
of cellular homeostasis. Free radical damage to the glycolytic pathway has been 
postulated to cause increased intracellular calcium by impaired sodium/hydrogen 
exchange with consequent calcium/sodium exchange. Functional changes induced 
by OH include significant decreases of developed tension and diminished ability of 
the sarcoplasmic reticulum to take up calcium. 
The diminished calcium uptake is a consequence of the uncoupling of calcium 
transport from ATP hydrolysis (Rowe, 1983); this effect is exacerbated by acidosis. 
Both radicals and excess calcium have been implicated in the decrease in NADH 
ubiqinone oxidase (complex I) activity in mitochondria on reperfusion with 0 2 
containing perfusate. Loss of complex I activity uncouples oxidative phosphorylation. 
Another effect of the generation of oxygen radicals is the production of arachidonic 
acid metabolites capable of mediating constriction within the coronary vasculature. 
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This effect, combined with direct damage to the vascular endothelium could, 
theoretically lead to microinfarcts in the areas of myocardium involved. 
Calcium influx 
Events during the ischemic period can expose the myocyte to a massive influx of 
calcium on reperfusion. The SR is unable to take up calcium normally because of 
depressed ATP stores and OH. - mediated injury. Five to 10 µM or greater 
intracellular calcium concentrations activate lytic enzymes and uncouple substrate 
oxidation from phosphorylation (Swan, 1953). The combined effects of 
mitrochondrial respiratory chain damage and calcium entry can be significant. 
Stunned, reperfused hearts have a fourfold greater than normal oxygen consumption 
at a given work load (Bavaria, 1991 ). It has been suggested that while a prolonged 
accumulation of total cell calcium may be indicative of irreversible cell damage 
(Shen and Jennings, 1972), an early transient increase in intracellular calcium levels 
may cause and be indicative of reversible reperfusion injury (Opie, 1991 ). Opie 
proposed first, that reperfusion after a brief period of ischemia induces a transient 
calcium overload which contributes to reperfusion stunning and arrhythmias and 
secondly, that elevated intracellular calcium levels during ischemia and early 
reperfusion may promote abnormal intracellular calcium transients which could 
exacerbate stunning and/or initiate and perpetuate arrhythmias (Opie, 1989, Opie 
1991 ). 
Other mechanisms 
In addition to oxygen free radicals and calcium influx, a number of mechanisms have 
been implicated in reperfusion injury, including activation of neutrophils and 
platelets, and development of microvascular injury with impaired blood flow 
(Olafsson, 1987). However, it must be remembered that the stage for reperfusion 
injury is set by the severity of the preceding ischemia (Veitch, 1990; Lucchesi, 1990): 
the more severe the ischemia (i.e. regional ischemia in evolving myocardial 
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infarction, poor myocardial protection stemming from failure to deliver cardioplegia 
beyond obstructions or failure to formulate a solution to meet specific needs), the 
more severe will be the ensuing reperfusion injury. 
Methods of myocardial protection 
Non-cardioplegic methods of myocardial protection 
During the past years a variety of different methods of protecting the myocardium 
during cardiac surgery have evolved (Hearse, 1981; Kirklin, 1993). Non-cardioplegic 
methods of myocardial protection are used infrequently today but are still 
occasionally applicable. More recently, techniques for performing coronary artery 
bypass surgery without cardiopulmonary bypass and cardioplegia have begun to 
emerge (Benetti, 1991; Borst, 1996). 
1. Continuous cardiac perfusion 
The myocardium is continuously perfused with oxygenated blood via the aortic root 
or during aortic valve surgery by direct cannulation of the coronary arteries. This can 
be performed at normothermia or moderate hypothermia (25° C - 32° C) and with or 
without electrical ventricular fibrillation. This method, however, does not produce 
ideal operative conditions. Although an empty beating heart has lower myocardial 
oxygen demands (Hottenrott, 197 4 ), altered compressive forces in ventricular 
geometry impede the distribution of intra-myocardial bloodflow resulting in sub-
endocardial ischemia (Miyamoto, 1978). 
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2. Intermittent cardiac ischemia 
The aorta is intermittently cross-clamped for short periods (less than 15 minutes) 
with subsequent 5 - 15 minutes' periods of reperfusion of the beating heart. This 
method can be used at normothermia (Moran, 1986; Van der Vusse, 1987) or at 
moderate cardiac hypothermia, with or without electrical fibrillation in order to obtain 
a still operative field (Bonchek, 1987). Interestingly, a low morbidity and mortality 
has been reported using this method for coronary revascularization procedures and 
it has been speculated that intermittent aorta cross-clamping might cause ischemic 
preconditioning and thereby make the heart more tolerant of ischemia (Abd-Elfattah, 
1995). There are clinical studies comparing intermittent aortic cross-clamping and 
hypothermic cardioplegic arrest which have shown equivalent outcomes (Baur, 1986; 
Moran, 1986). However, high-energy phosphates and cellular ultrastructure are 
better preserved in the cardioplegia group, although the use of cardioplegic 
solutions is also associated with an increased incidence of temporary post-operative 
rhythm disturbances (Flameng, 1984). Furthermore, a large number of experimental 
studies have shown cumulative damage as a result of intermittent aortic cross-
clamping when compared to hypothermic cardioplegic arrest (Follete, 1978; Hearse, 
1981; Levitsky, 1977, Wright, 1978). 
3. Prolonged ischemic cardiac arrest 
The aorta is simply cross-clamped for prolonged periods (15 - 60 minutes) at 
profound myocardial hypothermia (22° C). After 20 - 30 minutes the myocardium 
becomes electromechanically silent and still because of exhaustion of 
intramyocardial energy supplies. This method was pioneered successfully by 
Norman Shumway (Shumway, 1959), but it is now no longer used routinely. Aortic 
cross-clamp periods of up to 96 minutes were tolerated with acceptable clinical 
results, but prolonged cardiovascular support was necessary after these periods of 
anoxic rest and high-energy phosphate depletion (Griepp, 1973). 
Hypothermic ischemic arrest may still have a role today in pediatric cardiac surgery 
when combined with deep hypothermic circulatory arrest, as neonatal hearts react 
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differently to cardioplegic solutions compared to adult hearts (Anderson, 1994; 
Baker, 1988; Baker, 1990; Bove, 1986; Bove, 1988; Bull, 1984, Mangovern, 1988). 
Cardiop/egic methods of myocardial protection 
The principles of cardioplegic myocardial protection are summarized in table 1.7. 
Hypothermia 
Hypothermia reduces the metabolic rate of the heart: Enzymatic systems obey van' t 
Hoff's law: there is an exponential decrease in reaction rate with decreasing 
temperature. This relationship applies to oxygen consumption. Oxygen consumption 
decreases by a factor of 2.8 for each 10-degree fall in temperature. Hypothermia has 
a stabilizing effect on membranes and alters membrane fluidity (Frank, 1982). Low 
temperatures also protect the heart from the "calcium paradox" (Rich, 1982). 
Although preventing the development of the calcium paradox, hypothermia increases 
the sensitivity of the myocardium to exogenous calcium. However, the ability of 
hypothermia alone to prevent myocardial ischemic injury is limited. Additionally, the 
effects of temperature on the myocardium appear to be age dependent. In the 
neonatal heart, hypothermia alone may offer better protection than hypothermia plus 
cardioplegic solutions (Mangovern, 1988; Karck, 1995). 
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TABLE 1.7.: PRINCIPLES OF CARDIOPLEGIC PROTECTION 
Maximize energy conservation 
1. Stop electromechanical activity 
Chemical arrest of the heart in diastole 
Produce immediate arrest 
Must be easily maintained and reversed 
Must not cause myocardial damage 
2. Reduce metabolic rate 
Hypothermia 
Maintain intracellular homeostasis without energy-consuming 
membrane pumps 
Prevent unfavorable ischemia-induced changes 
1. Modify extracellular ionic environment 
Prevent calcium influx 





High energy phosphates? 
Remove end products of metabolism 
3. Counteract acidosis 
Modify pH 
Provide buffers 
4. Prevent edema 
Hyperosmolarity, lmpermeants 
Colloid oncotic pressure 
(Modified from Buckberg, 1987) 
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Several strategies have been developed to reduce myocardial temperatures safely. 
They include surface cooling, core cooling, topical cooling of the myocardium and 
perfusion cooling of the myocardium. 
Myocardial cooling is most effectively achieved by perfusing the coronary 
vasculature with iced (2-4°C} solution. Myocardial temperatures below 20°C are 
attained within minutes of the initiation of cold perfusion of the coronary arteries 
(Reitz, 1981 ). This rapid cooling can produce myocardial standstill, besides 
protecting the myocardium from ischemic damage during the period of aortic cross-
clamping. 
This technique may, however, predispose to later injury (Rebeyka, 1990) 
Temperatures of 6°C or below produce cardiac arrest (Hearse, 1975) but can result 
in tissue damage (Speicher, 1962). Cardioplegic solutions are used to induce 
cardiac arrest at higher temperatures. Other advantages of the use of cardioplegia 
include a more rapid and reliable onset of electromechanical silence. 
Since the introduction (Melrose, 1955) and development of cardioplegic solutions, 
there are now almost as many cardioplegic solutions as there are centers using 
them, but there is a more recent trend to greater uniformity and an increasing 
number of centers throughout the world are using properly formulated solutions 
which have been adequately tested under experimental conditions close to the 
clinical setting. Despite the variations in formulation, two broad types of cardioplegic 
solutions can be defined: blood cardioplegia and crystalloid cardioplegia (with or 
without the addition of a colloid substance). At present, there is no overwhelming 
evidence in favor of one type of cardioplegic solution for myocardial protection 
during intraoperative cardiac repair, but there is a general trend towards the use of 
blood cardioplegia in most countries, despite the more complex technical procedure 
and the higher costs. 
Crystal/aid cardioplegia 
Crystalloid cardioplegic solutions are formulated to resemble either intracellular 
(prototype: Bretschneider's solution) or extracellular (prototype: St. Thomas' Hospital 
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solution) fluid. The degree of myocardial protection afforded by a solution 
resembling intracellular fluid is affected by the rate and volume of infusion. 
Decreased protection was previously noted if high rates of infusion or large volumes 
were used (Jynge, 1978). However, more recent studies find better protection if high 
volumes are used (Preusse, 1987, Human, 1995). This is explained by the longer 
period required by intracellular solutions to equilibrate the interstitial space. For 
Bretschneider's solution (HTK 4) an infusion period of 7-8 minutes with a total 
volume of 3-4 liters per patient is suggested in order to use the full preservation 
potential of the solution. If a solution based on extracellular fluid is used, the degree 
of protection does not generally vary with the volume or rate of infusion of the 
cardioplegic solution (Jynge, 1978) although better protection was found in one 
study (Engelman, 1983) with higher infusion volumes for St. Thomas' Hospital 
solution. The authors concluded, however, that improved protection by the higher 
volumes was probably related to the lower temperatures achieved with larger 
volumes. However, not all solutions based on extracellular fluid afford the same 
protection. Only properly formulated crystalloid solutions are as effective as blood 
cardioplegia in preserving high-energy phosphate stores and preventing ischemic 
injury (Hearse, 1981 ). 
Blood cardioplegia 
The use of blood cardioplegia was initially based upon the assumption that the 
oxygen carried by the hemoglobin would provide extra protection against ischemic 
injury. This assumption has seemingly been both supported and refuted by 
experimental evidence (Magovern, 1982; Bing, 1982). The reasons for the 
discrepancy relate to the temperature of the cardioplegic solution infused 
(Magovern, 1982). The ability of hemoglobin to deliver oxygen to tissue decreases at 
lower temperatures. At 5°C, more oxygen is available to tissue from oxygenated 
crystalloid solution than from oxygenated blood cardioplegic solution. However, if the 
cardioplegic solution is delivered at higher temperatures, such as 20-27°C, then 
blood cardioplegic solutions will be able to deliver more oxygen to tissues than 
crystalloid cardioplegic solutions. 
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Blood contains many other components besides hemoglobin, including calcium, 
magnesium, protein, hormones, and cellular elements. Some studies claiming that 
blood cardioplegic solutions provided better myocardial protection than crystalloid 
cardioplegic solutions failed to add divalent cations to the crystalloid solutions used 
in the comparative studies. The omission of these cations from the crystalloid 
cardioplegic solutions may have played a significant role in the observed superiority 
of blood cardioplegia over the nonsanguineous cardioplegic solutions. If blood and 
crystalloid cardioplegic solutions have the same ionic constituents added (not that 
the concentrations of the ionic species are the same as in blood), there is little or no 
advantage in the use of blood cardioplegic solution in cases for which low infusion 
temperatures are used (Magovern, 1982). 
The rheologic properties of blood cardioplegia are worthy of note. The viscosity of 
blood increases as temperature falls. Because of higher viscosity, cold blood 
solutions require longer infusion times than does an nonsanguineous cardioplegic 
solution. Prolonged infusions may have a beneficial effect on distribution in non-
hypertrophied hearts. 
Distribution of the cardioplegic solution in a non-hypertrophied heart after multiple 
doses (Heitmiller, 1985) was found to be more uniform with blood than with 
crystalloid. This improvement in perfusion is observed even if the red blood cells 
have been rendered incapable of 02 transport. The presence of red blood cells or 
other microparticles allows perfusion of the entire capillary bed. No flow is seen in 
the true capillaries if they are perfused with nonparticulate solutions (colloid or 
crystalloid) (Zweifach, 1940). Despite this theoretical advantage, blood and calcium-
containing crystalloid cardioplegic solutions were found to have identical intracardiac 
distribution after three doses (40-minute aortic cross-clamp time). 
The use of blood cardioplegic solutions requires a delivery system. This is usually 
part of the cardiopulmonary bypass unit and includes a pump, heat exchanger and 
reservoir. A quantity of blood is removed from the bypass circuit and stored in the 
reservoir. Potassium is added to achieve the desired ~ concentration or 
alternatively a crystalloid concentrate is mixed with blood at a 4: 1 ratio (Buckberg, 
1989). The solution is infused by a pump into the aortic root using pressures ranging 
from 50 to 100 mm Hg. Care must be taken to avoid excessive intravascular pressure 
during infusion of the solution. Flows of 400-500 ml/min/m2 produce rapid arrest of 
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electromechanical activity and give effective myocardial cooling. The pressures 
needed to yield these flows depend on hematocrit, delivery temperature, coronary 
vessel patency, and vascular tone. Technical factors such as conduit, coronary or 
aortic cannula diameters also affect the required infusion pressure. Blood 
cardioplegic solution should be infused frequently during the cross-clamp period. It 
is most often used at delivery temperatures of 20°C or greater and consequently 
does not achieve the same degree of myocardial cooling. Excessive rewarming of 
the heart can occur if the solution is not reinfused at regular intervals ( approximately 
every 20 minutes). Factors that increase the likelihood of excessive myocardial 
rewarming are a high rate of bronchial return and systemic perfusion temperatures of 
27°C or greater (Rousou, 1988). 
Components of cardioplegic solutions 
The formulation of cardioplegic solutions remains a subject of lively debate. 
However, potassium, magnesium, calcium, sodium and buffers appear to be 
beneficial in preserving myocardial function. The osmolarity of cardioplegic solutions 
also merits comment. 
Potassium 
Melrose's original cardioplegic solution contained potassium citrate. The excessive 
potassium concentration, the chelating properties of citrate (magnesium and 
calcium) and the increased osmolarity contributed to the myocardial damage caused 
by clinical use of the Melrose solution. Excessively high potassium (I<) 
concentrations ( 40mM/L or greater) are potentially injurious to the myocardium and 
endothelium. Most clinically used solutions today employ K + concentrations of 15 -
40 mM/L. 
A 1970 study found that under conditions of hypothermia and ischemia, ATP and 
creatine phosphate levels are better maintained if electromechanical arrest is 
induced than in the absence of electromechanical arrest (Kubler, 1970). 
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In 1975, Hearse and co-workers (Hearse, 1975) demonstrated that hypothermia and 
hyperkalemia had additive effects on the preservation of myocardial ATP stores 
during ischemia. This finding was subsequently confirmed by other investigators. 
The major effect of potassium is the production of electromechanical arrest that 
results from depolarization of the sarcolemmal membrane. A state of diastole is 
maintained as long as there is increased extracellular potassium. The potassium 
concentration needed to produce diastolic arrest is a function of temperature; it 
decreases as temperature is decreased, (e.g., at 37°C, 20 mM/L of I< is required to 
produce arrest, and at 24°C , only 13 mM/L is needed) (Hearse, 1975). The benefit 
derived from electromechanical arrest is a function of temperature and potassium 
concentration. 
Potassium concentrations greater than 40 mM/L appear to alter the permeability of 
the myocyte to calcium (Rich, 197 4 ). Extracellular calcium may enter the cell and 
thereby increase energy consumption and calcium overload. The measured oxygen 
consumption of hearts exposed to very high potassium concentrations (170mM/L) is 
twice that measured in hearts exposed to lower concentrations (80 mM/L) of 
potassium (Bretschneider, 1975). The left ventricular diastolic pressure of isolated 
hypothermic (17°C) perfused neonatal rabbit hearts increases with the onset of 
potassium-induced arrest. The magnitude and duration of the increase in end-
diastolic pressure increased dramatically as potassium concentration exceeded 60 
mM/L. Rich and Brady ( 197 4) found that myocardial contracture, or "stoneheart," 
could be induced in hearts exposed to solutions containing more than 100 mM/L of 
potassium. 
There is not unanimous acceptance of hyperkalemic cardioplegic solutions. 
Laboratory and clinical studies (Del Nido, 1985; Ellis, 1978) found no improvement 
in postischemic recovery between groups of hearts treated with either high K \20-30 
mM/L) or low I< (4-10 mM/L) cardioplegic solutions. Data from one of the laboratory 
studies suggest that in the presence of a strong buffer, high K + concentrations (30 
mM/L or greater) are detrimental. Myocardial function was better preserved during 
the reperfusion period with a 10 mM/L I< buffered cold cardioplegic solution (Del 
Nido, 1985). The cardioplegic solutions used in this study had no calcium, low 
sodium (27 mM/L), and a high pH (7.8). The addition of buffer (histidine) and 30 
mM/L of I< resulted in extensive damage on reperfusion. The pattern of injury was 
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similar to that produced by massive Ca2+ influx. This suggests that there are complex 
interactions between ionic species that must be investigated before new cardioplegic 
formulations are used clinically. 
Magnesium and calcium 
Divalent cations have profound effects on membrane fluidity and stability (Trauble, 
1974). Perfusion of isolated interventricular septum with calcium-free medium results 
in membrane damage that is not entirely prevented by adding cadmium (a divalent 
cation with an ionic radius closer in size to Ca 2 + than to Mg 2+. Hypothermia (18°C) 
prevents the membrane damage seen with calcium depletion (Frank, 1982). 
Tolerance to calcium depletion diminishes with increasing temperature. At 18°C, 
nearly complete functional recovery is seen in hearts exposed to Ca 2+ -free medium 
for 30 minutes and then reperfused with Ca 2+ -containing medium. Recovery is only 
70% at 22°C and less than 20% at 28°C for the same duration of exposure to Ca 2+ -
free medium prior to reexposure to Ca 2+. The injury responsible for the decreased 
function is termed calcium paradox. Ca 2+ concentrations as low as 50 µM/L prevent 
the development of the calcium paradox (Rich, 1982). In a recent study of 
cardioplegic solutions containing one of three Mg 2+ concentrations (0, 1.2 and 15 
mM) in combination with one of three Ca 2+ concentrations (0.05, 1.5 and 4.5 mM}, 
Brown and co-workers (Brown, 1991) determined that optimal recovery from 
ischemia occurred at 0.05 mM Ca 2+ and 15 mM Mg 2+. Functional and metabolic 
recovery was reduced by decreasing [Mg 2+] or by increasing [Ca2+]. The decrement 
in recovery with increasing Ca2+ was more pronounced as the temperature 
decreased. 
The St. Thomas' Hospital solution has a [Mg 2+] of 15 mM/L and a [Ca2+] of 1.2 mM/L. 
This solution is optimal in adult hearts as demonstrated by multiple experiments. 
There is general agreement that inclusion of Mg2+ in cardioplegic solutions is 
beneficial. Magnesium is lost from the myocardium during ischemic arrest. This loss 
may result in impairment of cardiac recovery because Mg2+ is known to reduce the 
trans-sarcolemmal flux of Ca2+ and inhibit Na+ influx into the cell, among other effects 
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that are related to its function as a cofactor for many enzymatic reactions. 
Magnesium can produce cardioplegia in high concentrations. This observation was 
the basis for the "Kirsch" solution (Kirsch, 1970). Most clinically used solutions have 
a lower magnesium concentration than the Kirsch solution. Hearse and coworkers 
(Hearse, 1978) found a 15 mM/L concentration to be optimal. 
Nuclear magnetic resonance (NMR) spectroscopic studies have found that the 
addition of magnesium to cardioplegic solutions improved maintenance of high-
energy phosphate stores under conditions of hypothermic arrest (Pernot, 1983), yet 
these same investigators found that the addition of K + to a magnesium - based 
cardioplegic solution failed to protect ATP stores. This is at variance with the study 
of Hearse and coworkers (Hearse, 197 4 ), who found that additional protection was 
conferred by the addition of ~ to a Mg2+ solution. As in the case of comparisons 
between blood and crystalloid solutions, the temperature involved may be the 
important factor in the different conclusions. 
Sodium 
Intracellular sodium and calcium concentrations are interrelated. These two ions can 
be exchanged via a common channel termed the Na + -Ca2+ exchanger. Interventions 
that increase intracellular sodium activity may cause a dramatic increase in 
intracellular Ca2+ activity. In the absence of Ca2+ and Mg2+ , sodium may enter the 
cell through Ca2+ channels. 
The effects of changes in extracellular sodium concentrations are more complex 
than would be predicted by consideration of transcellular Na + - Ca2+ exchange 
alone. Perfusion of isolated hearts with low sodium perfusate causes calcium-
dependent increases in diastolic pressure, energy consumption, and dissociation of 
oxygen consumption from work. The effect is postulated to be mediated by 
alterations in SR calcium cycling (Renlund, 1985). 
Despite the theoretical considerations, a cardioplegic solution with decreased Na+, 
Bretschneider's "HTK" solution, is used clinically with success. This solution has 
essentially no Ca2+ (15-20 µM) and a high buffering capacity. Low Na+ 
concentrations can arrest the heart by inhibition of the "fast" inward current required 
for depolarization. If ~ is added, Na+ -pump activity is stimulated and intracellular 
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Na+ decreases in response. This effect reduces cell swelling and Ca2+ influx on 
reperfusion (Jynge, 1980). 
Hypertonic saline should be avoided because it increases intracellular sodium 
concentration with a subsequent increase in intracellular Ca2+ concentration. The 
"ideal" sodium concentration for standard cardioplegia is not firmly established, but 
is probably between 90 and 120 mM/L (Pernot, 1983; Stinner, 1989). The St. 
Thomas' solution contains 120 mM Na2+ (110 mM as NaCL and 10 mM as NaHC03). 
The action of Na+ ion is complex. Entry into the cell during ischemia is mediated via 
Na + -H + exchange. Thus, accumulation of H + within the cell can increase Na + 
during the early phases of reperfusion with a consequent rise in Ca2+. If the Na + -H + 
exchanger is blocked by amiloride, the increases in cell Na+ and Ca2+ seen on 
reperfusion are blocked (Meng, 1991 ). 
Buffer 
ATP consumption continues during ischemia. Hydrogen ion is generated as a 
consequence of ATP hydrolysis causing intracellular acidosis unless some provision 
is made for buffering. The cell has some limited buffering capacity. An important 
buffer is the amino acid histidine. Histidine has an imidazole group that can exist in a 
protonated or deprotonated state. The latter can be a proton acceptor and can 
thereby buffer intracellular pH changes: The cost of using histidine residues as 
buffer is high because the activity of enzymes is reduced or destroyed if histidine 
residues in active sites undergo protonation. 
If ATP stores decrease during ischemia, endogenous glycogen is converted to 
glucose for metabolism to ATP and lactate (Del Nido, 1985). If intracellular levels of 
ATP are maintained, exogenous glucose is used in preference to glycogen. The 
problem then is the maintenance of ATP levels during ischemia. 
These problems can be mitigated by the use of a buffer in the cardioplegic solution. 
The choice of buffer may be important. The bicarbonate ion is an inefficient buffer of 
intracellular pH change and has even been found to cause intracellular acidosis, 
whereas other species such as phosphate can buffer intracellular pH changes. 
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Adequate intracellular buffering is associated with better functional recovery 
(Hearse, 1976). 
Lange and colleagues (Lange, 1984) studied the effects of alkalinity and 
temperature on the effectiveness of multidose bicarbonate-buffered cardioplegic 
solutions. The use of 37°C, pH 8.2, bicarbonate-buffered cardioplegic solution failed 
to alter intracellular pH. The same solution when cooled to I0°C before infusion 
produced transient increases in intracellular pH. The increases in pH paralleled 
decreases in myocardial temperature. The magnitude of the intracellular pH change 
was equal to that pH change which could be predicted on the basis of the 
temperature change alone. There was no need to invoke buffering of intracellular H+ 
by the bicarbonate in the cardioplegic solution to explain the pH change. 
Tromethamine (THAM) and histidine are both effective in increasing intracellular pH 
if supplied in the perfusate (Preusse, 1982). Removal of reducing equivalents from 
the cytosol by a buffer prevents the inhibition of glycolysis by nicotine adenine 
dinucleotide hydrogen (NADH). However, THAM is toxic to certain tissues. 
Histidine has the desirable property of shifting its pKa into the alkaline range with 
decreasing temperature. The change is in the same direction and of the same 
magnitude as the change in pH of pure water with temperature (Reeves, 1976). It 
has been postulated that the pKa shift of the imidazole group of histidine residues of 
intracellular proteins accounts for the increase in intracellular pH with hypothermia. 
This pH change with temperature protects the activity of intracellular enzymes and 
maintains chemical neutrality. Histidine buffering maintains ATP levels during 
ischemia and prevents glycogenolysis by promoting utilization of exogenous glucose 
(Del Nido, 1985). Histidine appears theoretically to be the ideal buffer for use in 
cardioplegic solutions; however, in clinical practice, phosphate is very effective. 
Osmolarity 
Melrose's original cardioplegic solution had an osmolarity of greater than 500 
mOsm/L, which contributed to the myocardial damage it produced in clinical use. 
Severe myocardial damage is caused by solutions with osmolarities greater than 400 
mOsm/L. Hyperosmolar solutions cause myocardial injury by several mechanisms, 
one of which is intracellular water loss, which produces conformation changes in 
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protein structures within the cell. Another mechanism by which hypertonic 
cardioplegic solutions may cause damage is by raising intracellular sodium ion 
activity. Lado and co-workers (Lado, 1984) studied the effects of solutions of high 
osmolarity on intracellular sodium and calcium ion activity. The solutions were made 
hyperosmolar by the addition of sucrose while ion concentrations were kept 
constant. Segments of heart exposed to hypertonic (448 and 610 mOsm/L) solutions 
developed rapid increases in resting tension and dramatic decreases in contracted 
size. 
Intracellular calcium ion activity was increased beyond that expected on the basis of 
osmolar concentration effects due to osmotic water loss. The increase in calcium 
activity was thought to be a consequence of Na+ -Ca2+ exchange. The hyperosmolar 
solutions first induced a rise in intracellular sodium ion activity that resulted in a 
change in the Na+ electrochemical gradients across the cell membrane. Na+ -Ca2+ 
exchange reduces the intracellular Na+ load at the cost of increasing myoplasmic 
C 2+ a . 
The effects of hypo-osmolar solutions on intracellular ion activities are opposite to 
those seen with hyperosmolarity. Intracellular sodium ion activity is reduced to a 
level predicted on the basis of osmotic dilution. Calcium activity decreases much 
more than predicted on the same basis. This decrease in intracellular calcium 
activity is offset by increased cell swelling secondary to water gain. Experimentally, 
the optimum osmolarity for solutions designed for either cardioplegia or donor organ 
preservation is between 300 and 320 mOsm/L. 
Miscellaneous constituents 
Substrates 
At one time, glucose was thought to be a desirable component of cardioplegic 
solutions. In theory, glycolysis might be maintained and energy stores preserved 
(Opie, 1991 ). Von Oppel! (1991) was able to demonstrate a beneficial effect from 
glucose added to St. Thomas' Hospital cardioplegia in the isolated rat heart, but only 
in a concentration range between 7-11 mM, whereas higher concentrations 
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decreased recovery. However, this could not be confirmed by in vivo studies in a 
baboon model (Boehm, unpublished data). The possibilities that interspecies 
differences might be responsible for this discrepancy and that on the other hand the 
washout of end products of metabolism might have been relatively greater in the 
isolated rat heart model. 
However, because of the detrimental effects of ongoing glycolysis during 
hypothermic ischemic arrest, few clinically used cardioplegic solutions contain 
glucose. Provision of other substrates, i. e., those involved in purine synthesis, may 
provide better recovery of both myocardial energy stores and function. 
In studies of isolated hearts, continuous provision of adenosine in the pre- and 
postischemic periods improved post-ischemic function (Ely, 1985). Hypoxanthine 
and ribose provided independently also enhanced postischemic function (Lasley, 
1988; Pasque, 1982). All three substrates were included in a standard hyperkalemic 
(16 mM t\) crystalloid cardioplegic solution and administered prior to 1 hour of 
normothermic (37°C) global ischemia. The animals receiving the adenosine, 
hypoxanthine, and ribose-supplemented cardioplegic solution (AHR) exhibited 
significantly better postischemic recovery of both ATP stores and function as 
compared with a group receiving only the standard cardioplegic solution (Wyatt, 
1989). 
The mechanisms by which these substrates improve recovery are complex but 
include utilization of the salvage pathways in which adenosine is phosphorylated to 
adenosine monophosphate (AMP) and eventually to ATP. Hypoxanthine is 
phosphorylated in the presence of phosphoribosyl pyrophosphate (in the presence 
of ribose) to form inosine mono-phosphate and subsequently AMP. Additionally, 
provision of these compounds may retard loss of purine metabolites during ischemia 
and reperfusion. 
Steroids 
Although not universally accepted as being effective in improving myocardial 
preservation, steroids are another frequently added ingredient of cardioplegic 
solutions. However, an earlier study suggests that dexamethasone prevents 
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myocardial injury mediated by peroxidation stimulated by calcium load (Saxon, 
1985). Similar protection was provided by a-tocopherol (vitamin E) (Erin, 1983). 
Calcium entry blockers 
Calcium channel blockers have been tested as additives to cardioplegic solutions. 
Initial studies demonstrated that verapamil, diltiazem, and nifedipine protected the 
normothermic, globally ischemic heart (Nayler, 1980; Weishaar, 1980; Jolly, 1981 ). 
The mechanism of protection was not directly related to preservation of ATP stores 
but to limitation of mitochondrial Ca2+ uptake. The observed protective effect could 
be masked if the myocardial temperature was reduced to 25°C. (Nayler, 1981; 
Hearse, 1984). Following 60 minutes of ischemia at 25°C, there was no significant 
difference in postischemic recovery between hearts protected with hypothermia 
alone and those protected with hypothermia plus nifedipine. Nifedipine did, however 
confer additional protection if ischemia time was extended to 3 hours. Nifedipine also 
appears to protect the myocardium from the deleterious effects of profound cooling; 
i.e., temperatures of S°C. The mechanism of the protective effect is unknown. 
Diltiazem added to cardioplegic solution (150 mg/kg) improved recovery after 30 
minutes of cold 15-20°C) ischemia compared with standard cardioplegia; segmental 
shortening and dye indicators were used as measures of function and injury 
respectively (Rebeyka, 1990). 
In a clinical trial, patients receiving diltiazem cardioplegia remained asystolic during 
the reperfusion period and required pacing to be weaned from bypass (Christakis, 
1986). Nimodipine, one of the dihydropyridine calcium channel blockers, has been 
studied for its ability to reduce central nervous system (CNS) damage following 
ischemic injury. However, a clinical trial could not reveal a neuroprotective effect in 
the Nimodipine treated patient group. has also been found to improve post-
reperfusion cardiac function in patients aged 6 months to 20 years undergoing 
cardiac surgery when added to a cardioplegic solution in a concentration of 0.25 
mg/L (Mori, 1990). There were no differences between the nicardipine group and 
control group in age, bypass or cross-clamp time, temperature (23°C), or rate of 
spontaneous defibrillation (54-75%). Both groups had a 35-38% use of inotropes, 
but the nicardipine group had better cardiac indices and left ventricular stroke work 
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index (LVSWI) at lower wedge pressures than did the control group. The 
experimental group also had less evidence of myocardial injury as judged by MB-CK 
levels. Nicardipine is less likely than diltiazem or verapamil to cause decreased 
inotropy or conduction defects. It may be a useful adjunct to standard cardioplegic 
solutions. 
Reperfusion solutions 
Reperfusion solutions are useful for the purpose of replenishing lost intracellular 
substrates. Key metabolic intermediates lost during ischemia and reperfusion 
include purine nucleotides, succinate, and pyruvate (Taegtmeyer, 1978). NAO+ is 
converted to NAOH during anaerobic glycolysis. The cell has a limited ability to 
reconvert NAOH to NAO+ via cytosolic malate dehydrogenase. The net reaction is 
NAOH + malate. In an anaerobic environment, malate cannot be reconverted to 
oxaloacetate (OAA) by mitochondrial malate dehydrogenase. The result is the 
depletion of cytosolic OAA and accumulation of NAOH. 
The provision of glutamate during reperfusion accelerates restoration of normal 
intracellular levels of NAO+ and a-ketoglutarate. Glutamate and mitochondrial OAA 
can undergo transamination to yield ketoglutarate and aspartate. The mitochondrial 
membrane is freely permeable to aspartate. Aspartate can then be deaminated in 
the cytosol to yield OAA. Provision of glutamate allows NAOH+ to be converted to 
NAO\ with repletion of cytosolic OAA levels and regeneration of Krebs cycle 
intermediates. 
The five-carbon sugar ribose is an essential intermediate for both the de novo and 
the salvage pathway synthesis of purine nucleotides (Goldthwait, 1957). Ribose can 
also serve as a source of pyruvate for oxidative phosphorylation if the glycolytic 
pathway is blocked by metabolites produced during ischemia (Metzler, 1977). 
Provision of ribose during reperfusion can result in improved function by virtue of its 
roles in various biochemical pathways. The combination of ribose and glutamate in a 
potassium blood cardioplegic reperfusion solution is superior to unmodified pump 
blood, and other solutions, in restoring postischemic cardiac function in dogs (Haas, 
1984). 
54 
Depleted intracellular stores of ATP can be replenished providing ATP and 
magnesium chloride during the reperfusion period (McDonagh, 1984). The degree of 
functional recovery of the heart is sensitive to the amount of ATP provided. Hearts 
reperfused with excessive amounts of ATP have worse postischemic function than 
those reperfused with control solution. If ATP and magnesium chloride was provided 
at a low rate (0.13 mg/kg/min) for the first 30 minutes of reperfusion, nearly 100% 
recovery of left ventricular ejection function was attained. However, myocardial 
compliance remained depressed, as did oxygen extraction. The depressed oxygen 
extraction probably reflected the diminished availability of mitochondrial substrate for 
oxidative phosphorylation. The alternative explanation is mitochondrial injury. 
A nonsanguineous reperfusion solution has been used clinically with apparent 
benefit (Menasche, 1984). The solution was designed to maintain electrical silence, 
reintroduce Ca2+ in physiologic concentration, and provide glutamate, buffering, and 
moderate hyperosmolarity (by adding mannitol). The addition of mannitol protects 
against free radical damage and reduces cellular edema. This reperfusate was 
infused via the aortic root just before removal of the cross-clamp. A total of 1000 ml 
was given at a rate of 200-300 ml/min. Patients receiving this solution had 
significantly better indices of myocardial function than did those not receiving it. Of 
patients undergoing mitral valve replacement, those receiving the nonsanguineous 
reperfusion required less inotropic support than the control group. The same 
phenomenon was not observed in the group of patients undergoing aortic valve 
surgery. 
Much research is being directed toward prevention of reperfusion injury. Recognition 
of the involvement of blood elements in this process has led to new areas of 
investigation (Lucchesi, 1989). A very interesting area of research is the use of 
neutrophil antibodies as a means of reducing postischemic injury. Endothelial injury, 
which is postulated as a result of ischemia and reperfusion, promotes neutrophil 
adhesion and subsequent inflammatory damage. The endothelial injury can be 
prevented experimentally using antibodies against the neutrophil surface 
glycoprotein CD18. In a dog model of regional ischemia (at 37°C), the use of the 
neutrophil antibody anti-Mal reduced the infarcted area (as a percentage of at-risk 
area) by 46% after 6 hours of reperfusion. If the anti-Mal treatment is continued for 
48 hours postischemia, a reduction in infarcted area is noted at 72 hours of 
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reperfusion. (Takahashi, 1990). Inhibition of neutrophil adhesion to the vascular 
endothelium in at-risk areas represents a new and potentially promising area in the 
field of myocardial preservation. 
Donor heart preservation 
The routine repair of cardiac defects does not test the limits of myocardial 
preservation as does organ preservation for transplantation. The donor heart must 
be stored for transport in such a way that it will not be damaged by preservation 
techniques and will function effectively after 4 hours of storage. There are, however, 
major differences between in-vivo cardioplegic protection and ex-vivo storage 
preservation, which are summarized in Table 1.8. Recent studies have found that 
hearts protected with an "intracellular" (University of Wisconsin, UW)-type solution 
were more likely to regain full function after transplant than hearts protected with an 
"extracellular" solution (Stanford vs St. Thomas II) (Wicomb, 1989; Ledingham, 
1990). For a given solution, the infusion conditions are extremely important. For the 
St. Thomas' solution, if initial arrest is produced at 37°C, followed by infusion of cold 
(7,5°C) solution, postischemic function is better than if initial cold infusion is used 
(Takahashi, 1990). The opposite is true for the UW solution. If initially infused at 
20°C with subsequent cooling of the heart to 4°C, function decreases as compared 
with hearts receiving the initial infusion of UW-solution at 4°C (Ledingham, 1990). 
The UW solution used in these studies did not contain Ca2+. Recent studies by the 
University of Wisconsin group indicate that the addition of 0.5 mM Ca2+ greatly 
enhances the posttransplant survival of kidneys (up to 5-day preservation with 
continuous perfusion) (McAnultry, 1989). 
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TABLE 1.8.: DIFFERENCES BETWEEN CARDIOPLEGIC AND STORAGE 
PRESERVATION 
CardiopleQia Storage 
Site in-vivo ex-vivo 
Frequency multiple doses single dose 
Temperature 15°C - 20° C 4°c 
Flow collateral flow no flow 
Time short ischemia long ischemia 
Precondition predamaged heart healthy heart 
Na+ - ~ pump partial inactivation complete inactivation 
~ -concentration excludes excessive K+ high K+ used 
Membrane potential polarized or depolarized depolarized 
Tissue edema importance of importance of 
colloids impermeants 
Legend: Major differences exist between in-vivo cardioplegic protection and storage preservation for 
transplantation. 
As in the case of cardioplegic solutions, the optimum solution, technique, and mode 
of organ preservation for transplantation is yet to be developed. However, the 
current UW solution has been found to protect rabbit hearts for up to 8 hours at 4 °C 
with no decrease in function (Takahashi, 1990). The period during which the heart is 
removed from the cold environment and placed in the body and prior to reperfusion 
must of necessity be minimized to reduce the likelihood of loss of myocardial 
function. It is during this period that technical factors can either help or hinder the 
effectiveness of the preservation technique employed at organ harvest. 
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Failure of myocardial preservation 
The following concepts should guide both present and future myocardial 
preservation techniques: 
1. Preservation of ATP levels does not ensure adequate functional recovery, much 
less optimum functional recovery. 
2. The optimum Ca2+ concentration in cardioplegic solutions varies with age of the 
myocardium. 
3. The interactions between Mg2+, Ca2+, and Na+ are complex and temperature 
dependent. 
4. Extracellular buffering alone is not enough; buffers that protect against 
intracellular acidosis (which HC03- does not) are preferred. 
5. Prevention of reperfusion injury by means of antioxidants, free radical scavengers, 
or other means improves functional recovery. Preservation of vascular endothelial 
function must be optimized. 
Even the most well-formulated cardioplegic solution may fail to provide protection 
from myocardial injury. 
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TABLE.1.9.: REASONS FOR FAILURE OF MYOCARDIAL PRESERVATION* 
Preexisting myocardial injury 
Technical factors 
Premature cardiac rewarming 
Myocardial distention 
Prolonged fibrillation 
Premature return of electromechanical activity 
Infrequent use of cardioplegic solution 
Coronary air emboli 
Free radical damage 
Myocardial substrate depletion 
Calcium influx 
Legend * As manifested by poor myocardial performance on completion 
of rewarming, necessitating use of inotropes or continued 
support on bypass. 
There are multiple reasons for this failure during open heart surgery and after 
storage preservation, and the majority of them are technical (Table 1.9.). 
Cunningham and co-workers ( 1979) found that technical errors during aortic cross-
clamping led to inadequate myocardial protection. These errors were failure to re-
inject the cardioplegic solution frequently enough, allowing electrocardiographic 
activity to return and myocardial temperatures to exceed 28°C. The surgeon and 
anesthesiologist must be aware of the time intervals between injections of 
cardioplegic solution. Ideally, the solution should be reinfused every 20 minutes and 
generally should not be allowed to exceed 30 minutes unless deep hypothermic 
arrest is used. If cardiac electrical activity is noted, immediate reinfusion of 
cardioplegic solution is necessary. Despite all precautions, there appears to be a 
limit to the ischemia time during the surgical repair of lesions. This time limit was 85 
minutes in work by Bull and colleagues (Bull, 1984 ). After longer times, 
postoperative mortality increased. 
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Myocardial rewarming can be a difficult problem. There are multiple contributing 
factors such as room temperature, heat generated by operating room lights, systemic 
perfusion temperature, and noncoronary collateral flow. The right atrium appears 
most susceptible to rapid rewarming to the systemic perfusion temperature. This 
phenomenon has been blamed for atrial arrhythmias during the postischemic period 
(Chen, 1985). Noncoronary collateral flow can defeat the best myocardial 
preservation efforts. It contributes to myocardial distention, rewarming, and washout 
of cardioplegic solution. Washout is helpful in eliminating poorly formulated 
cardioplegic solutions but more often prematurely terminates the beneficial effects of 
well-designed solutions (Buckberg, 1981 ). High rates of noncoronary collateral flow 
are seen in patients with well-developed bronchial vessels or high grade coronary 
stenoses. Noncoronary collateral flow is related to the systemic perfusion index. Low 
indices reduce the return to the left heart through these channels, thus reducing 
myocardial distention and rewarming. Adequate left ventricular venting is necessary 
to prevent cavity distention and premature subendocardial rewarming. The rate of 
left ventricular subendocardial rewarming can be slowed by the use of low (20°C) 
systemic perfusion temperature. Even the most carefully conducted procedure 
cannot prevent all the biochemical events that lead to ischemic and reperfusion 
injury. 
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Comparison of cardioplegic solutions used clinically 
Large numbers of different cardioplegic solutions have been formulated and are 
used clinically today. However, the formulation of cardioplegic solutions remains a 
subject of lively debate. Many conclusions regarding cardioplegic solutions are 
based on studies carried out in isolated heart preparations. The experience with 
solutions found to be beneficial in the laboratory may be disappointing in the clinical 
area because of poorly controlled factors such as non-collateral coronary flow. 
Conversely, solutions that are less than optimal in the isolated heart may perform 
well in a clinical setting. Therefore, cardioplegic solutions must be evaluated in 
models comparable to the clinical settings in which they are used before clinical use. 
Three different types of cardioplegic solutions are in use today (Table 1.10): 
1. Crystalloid cardioplegic solutions 
2. Colloid cardioplegic solutions 
3. Blood cardioplegia. 
The cardioplegic techniques used today are summarized in Table 1.11. 
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TABLE 1.10.: COMPOSITION OF CARDIOPLEGIC SOLUTIONS 
COMPOSITION OF CARDIOPLEGIC SOLUTIONS 
CRYSTALLOID COMPOSITION COLLOID COMPOSITION 
EXTRACELLULAR INTRACELLULAR ALBUMIN BLOOD 
St. Thomas' No.1 +2 Bretschneider HTK Hamburg Buckberg 
Kirklin No.1 Stanford Kirklin No. 2 
Sabax 
Legend: Cardioplegic solutions can be divided into crystalloid and colloid solutions. Crystalloid 
solutions resemble either extracellular or intracellular ionic composition. Colloid solutions 
are either albumin-containing crystalloid solutions, or blood-based solutions with additional 
oxygen carrying capacity. 
TABLE 1.11.: CARDIOPLEGIC TECHNIQUES 
1. Composition of the cardioplegic solution 
crystalloid: extracellular/ intracellular electrolyte content 
colloid: addition of oncotic agents to crystalloid solution 
blood: mixed 1 :4 with crystalloid concentrate 
2. Temperature a) of the myocardium: - normothermic 
- mild hypothermia 
- deep hypothermia 
b) of the body - normothermic 
- mild hypothermia 
- deep hypothermia 
3. Application a) site - antegrade (aortic root, ostia) 
- retrograde (coronary sinus) 
- combined (alternating or simultaneously) 
b) volume: - normal volume (15 ml/kg/BW*) 
- high volume (50 ml/kg/BW*) 
c) pressure - low pressure 
- high pressure 





Legend: Different cardioplegic techniques in clinical use according to composition, temperature, and 
application. 
*BW: body weight 
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1. Crystalloid cardioplegic solutions 
These solutions have frequently a normal or slightly supranormal osmolarity but no 
oncotic or colloid osmotic active substances. This means that the forces binding 
water are produced only by the low-molecular electrolytes and not via membrane 
impermeable high-molecular colloid substances. That implies that pressure control 
during perfusion is extremely important. Amongst many solutions, the most important 
crystalloid solutions used today are Bretschneider's solution (Table 1.12.), St. 
Thomas' Hospital solution No. 1 and No. 2 (Table 1.13.), Stanford cardioplegia 
(Table 1.14.), and Kirklin cardioplegia (Table 1.15). The common principle of all 
these solutions is to reduce myocardial metabolism mainly via inactivation of the 
contractile apparatus. 
TABLE 1.12.: BRETSCHNEIDER'S CARDIOPLEGIC SOLUTION (HTK4) 
NaCl 15 mM/L 
KCI 9 mM/L 
MgCl2 4 mM/L 
Histidine 180 mM/L 
Tryptophan 18 mM/L 
Mannitol 2 mM/L 
a.-Ketoglutarate 20 mM/L 
pH 7.1 
osmolarity 280-300 mosm/1 
TABLE 1.13.: ST. THOMAS HOSPITAL CARDIOPLEGIA N0.1 AND 2 
No. 1 (Maccarthy) No. 2 (Plegisol) 
NaCl 144 mM/L 110 mM/L 
KCI 20 mM/L 16 mM/L 
MqCl2 16 mM/L 16 mM/L 
CaCl2 2.4 mM/L 1.2 mM/L 
NaHC03 --- 10 mM/L 
Procaine-HCL 1.0 mM/L ---
pH 5.5-7.0 7.8 
osmolarity 300-320 mosm/1 285-300 mosm/1 
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TABLE 1.14.: STANFORD CARDIOPLEGIA 
Na+ 25 mM/L 
c1- 30 mM/L 
~ 30 mM/L 




osmolarity 450 mosm/1 
TABLE 1.15.: KIRKLIN CARDIOPLEGIA (UAB = UNIVERSITY OF 
ALABAMA/BIRMINGHAM) 
with Albumin without Albumin 
Na+ 100 mM/L 110 mM/L 
K+ 30 mM/L 30 mM/L 
Cl- 84 mM/L 85 mM/L 
HC03- 28 mM/L 27 mM/L 
Ca2+ 1.4 mM/L 1.0 mM/L 
Glucose 5 g/L 5 g/L 
Mannitol 5 g/L 9.9 g/L 
Albumin 50 g/L ---
2. Colloidal cardioplegic solutions 
These solutions contain water-binding oncotic or colloid-osmotic substances. These 
substances may be albumin, mannitol or high molecular weight polyglycoses such as 
hydroxyethyl starch. Important colloid cardioplegic solutions are the Hamburg 
cardioplegia (Table 1.16.) or the modified Kirklin cardioplegia containing albumin 
(Table 1.15. ). 
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TABLE 1.16.: HAMBURG CARDIOPLEGIA 
KCI 5 mM/L 
CaCb 0.5 mM/L 
NaHC03 25 mM/L 
MQ-aspartate 2 mM/L 
Procaine-HCI 4 mM/L 
Glucose 10 mM/L 
Mannitol 200 mM/L 
Hydroxyethyl starch 6% 
Methylprednisolon 250 mg/L 
total Na+ 50 mM/L 
osmolarity 320 mosm/L 
colloid osmotic pressure 46 cmH20 
pH 7.4 
P02 600mmHg 
3. Blood cardioplegia 
In the years 1978 and 1979, Buckberg in Los Angeles and Barner in St. Louis 
introduced the procedure of blood potassium cardioplegia into clinical practice. The 
blood from the oxygenator of the heart-lung machine was used not only as the 
vehicle for potassium cardioplegia, but also for oxygen transport and as substrate 
carrier. However, as indicated in the previous chapter, oxygen delivery to the 
myocardium is limited at low temperatures. Buckberg additionally advocated 
application of a modified blood cardioplegic solution as reperfusion solution (Table 
1.17.b) before opening the aortic cross-clamp. Other advantages of blood 
cardioplegia are improved buffering capacity via endogenous buffering substances. 
Furthermore, blood contains endogenous oxygen-free radical scavengers which 
potentially can protect the myocardium from reperfusion-related damage (Table 
1.17.). 
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TABLE 1.17a.: CONCENTRATE FOR 4:1 BLOOD CARDIOPLEGIA 
(ACCORDING TO BUCKBERG, 1989) 
WARM INDUCTION 
Additive Volume (ml) Delivered concentration 
THAM (300 mM/L) 225 pH + 7.6 
CPD 225 Ca2+ + 0.15 mM/L 
50% D/W 40 Osm +400 mOsm/kgH20 
5% D/W 220 Glucose + 70 mM/L 
KCI (2 mM/L) 40 ~ 20-25 mM/L 
Glutamate (7.32%) 125 Glutamate 13 mM/L 
Aspartate (7.32%) 125 Aspartate 13 mM/L 
Legend: Infused at 37°C at a rate of 250 - 350 ml/min till arrest, then at 150 ml/min for a total of 5 
min. Thereafter standard cold (4°C - 8°C) cardioplegia is given for approximately 3 min. 
CPD: Citrate phosphate dextrose, D/W: Dextrose/Water; 4:1 ratio for blood: crystalloid 
concentrate. 
TABLE 1.17b.: CONCENTRATE FOR 4: 1 BLOOD CARDIOPLEGIA 
(ACCORDING TO BUCKBERG, 1989) 
REPERFUSION SOLUTION 
Additive Volume (ml) Delivered concentration 
THAM (300 mM/L) 225 pH + 7.6 
CPD 225 CaL+ + 0.15 mM/L 
50% D/W 40 Osm +400 mOsm/kqH20 
5%D/W 220 Glucose ±: 70 mM/L 
KCI (2 mM/L) 15 ~ 8-10 mM/L 
Glutamate (7.32%) 125 Glutamate 13 mM/L 
Aspartate (7.32%) 125 Aspartate 13 mM/L 
Legend: Infused at 37°C, at a rate of 150 ml/min antegrade for 1.5min, retrograde for 1.5 min. 
Systemic rewarming commenced 3-4 min before delivery. CPD: Citrate phosphate dextrose, 
D/W: Dextrose/Water; 4:1 ratio for blood: crystalloid concentrate. 
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Effect of cardioplegia on operative mortality 
The fact that myocardial protection and cardioplegia can influence operative 
outcome has been demonstrated in large studies (see also chapter 1.2. : 
Cardioplegia at Groote Schuur Hospital). The CASS-Study comprising 6652 CABG-
patients between 1975 and 1978 in 15 US hospitals reported an operative mortality 
varying between 1.4 and 4.5% depending on the subgroup of patients studied, with 
an average risk of operative death of 2.9% (Table 1.18), (Kennedy, 1980). 
Amongst other factors, hospital mortality was related to the myocardial protection 
regimen which was used. Berger, also from the CASS-study, had a high operative 
mortality of 6.8% if normothermia was used (Berger,1981) (Table 1.19.). 
Hypothermia and topical cooling lowered operative mortality to 5.3%, whereas if cold 
cardioplegia was used operative mortality was only 1.9% (Table 1.19.). The rate of 
perioperative myocardial infarction correlated with the decrease in mortality (Table 
1.19.), showing a rate of perioperative myocardial infarction of 7.5% for the 
normothermic group and of 8. 9% for the hypothermic group, where only topical 
cooling was applied, whereas the subgroup of patients treated with cold cardioplegia 
had the lowest rate of perioperative myocardial infarction with only 3.8%. 
TABLE 1.18.: OPERATIVE MORTALITY IN THE CASS STUDY 
Number of patients Description Mortality% 
6652 all patients 2.9 
6176 only CABG patients 2.3 
4913 elective CABG-patients 1.7 
1263 emergency CABG-patients 4.4 
4303 CABG-patients<60y 1.4 
1873 CABG-patients>60y 4.2 
5197 male CABG-patients 1.8 
979 female CABG-patients 4.5 
Legend: Operative mortality of 6652 CABG-patients who were operated upon in US hospitals 
between August 1975 and December 1978 (modified from Kennedy, 1980) 
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TABLE 1.19.: INFLUENCE OF MYOCARDIAL PROTECTION 
Operative mortality Rate of perioperative Ml 
n % n % 
Normothermia 44 6.8 40 7.5 
Hypothermia 150 5.3 135 8.9 
Cold cardiop/egia 745 1.9 677 3.8 
Legend: Myocardial protection regimen in relation to operative mortality and rate of perioperative 
myocardial infarction (modified from Berger, 1981) 
1.2. Cardioplegia at Groote Schuur Hospital 
Hypothermic cardioplegic cardiac arrest was used routinely at Groote Schuur 
Hospital from approximately 1978; initially a modified Bretschneider intracellular type 
solution was used. However, major modifications especially in calcium content and 
other important components made the composition quite different from 
Bretschneider's original formulation; therefore it will be called Groote Schuur 
Hospital solution from now on. Hospital mortality decreased from 7.2% in the 
precardioplegic period (1975 - 1977) to 4.5% in the period from 1978 -1980 
(p ~ 0.01) (Figure 1.2). After our initial experiments, which are part of this thesis, we 
were able to show better myocardial protection with St. Thomas' Hospital 
cardioplegia No. 2. This solution was subsequently introduced into clinical practice 
at Groote Schuur Hospital and in most cardiac surgery units throughout South Africa. 
Although overall mortality did not decrease, being 4.2% in the period from 1985 to 
1987 compared to 4.3% in the period from 1989 to 1991 (Figure 1.2), there was a 
decrease in mortality from 16.7% (1985 - 1987) to 5,6% (1989 - 1991) (p ~ 0.01), in 
the higher risk procedures (CABG + valve replacement) (Figure 1.3). Furthermore, 
post cardiopulmonary bypass usage of the intraaortic balloon pump decreased from 
3.0% (1985 -1986) to 1.0% (1990 - 1991) (p ~ 0,01) (Figure 1.4). 
These data reflect the fact that improved cardioplegic myocardial preservation is at 
least one factor that has helped to increase the safety of open heart surgery. 
Naturally, also improved surgical technique and further improvements in 
cardiopulmonary bypass technique have probably contributed to this decreased 
68 
mortality and morbidity, but on the other hand the complexity and extent of cardiac 
surgical repair has increased considerably during the same time period. 
FIGURE 1.2.: HOSPITAL MORTALITY FOR ADULT CARDIAC SURGERY AT 
GROOTE SCHUUR HOSPITAL DURING FOUR DIFFERENT 
PERIODS 
10 
Hospital Mortality [%] 






Legend: 1975 - 77: precardioplegic period 
1978 - 80: Groote Schuur Hospital cardioplegia 
1985 - 87: Modified Bretschneider solution 
1989 - 91: St. Thomas' Hospital solution No. 2 
* = p < 0.01 vs 1975 - 1977 
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FIGURE 1.3.: HOSPITAL MORTALITY FOR HIGH RISK PROCEDURES (CABG + 
VALVE REPLACEMENT) AT GROOTE SCHUUR HOSPITAL 







Legend: 1985-87: Modified Bretschneider's solution 
1989-91: St. Thomas' Hospital solution No. 2 




FIGURE 1.4.: POSTOPERATIVE USAGE OF THE INTRAAORTIC BALLOON 













1985 - 1986 1990 -1991 
Legend: 1985-87: Modified Bretschneider's solution 
1989-91: St. Thomas' Hospital solution No. 2 
* = p < 0.01 
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1.3. Adenosine 
Adenosine, a physiologic purine compound nucleoside, has stimulated renewed 
interest in the context of induced or spontaneous myocardial ischemia. It has been 
called the natural cardioprotector (Van Belle, 1990) owing to its ability to attenuate 
ischemia induced damage. It has further been called the 'signal of life' for 
intercellular responses by indicating cell viability to inflammatory cells (Engler, 1991) 
and it has been associated with the attribute autacoid, meaning anti-injury hormone, 
that links ATP catabolism to inhibition of granulocyte adherence, microvascular 
obstruction and superoxide anion formation (Gruber, 1989). There is in fact a whole 
new class of pharmacological agents that augment adenosine release from ATP-
catabolism, called adenosine promoter agents. 
Physiological roles 
Precursor of high energy phosphates and regulator of coronary flow 
The potential physiologic roles of adenosine are summarized in Table 1.20. 
Adenosine is a purine nucleoside compound of fundamental importance for the 
structure of nucleic acids and as a backbone for energy storage and use by living 
cells (ATP-system). It is also a regulator of biological functions as it controls 
coronary flow especially under ischemic conditions (Berne and Rubio hypothesis) 
(Rubio, 1969): 
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TABLE 1.20.: POTENTIAL ROLES OF ADENOSINE 
Potential roles of Adenosine 
Cardiogrotection 
>sur,ml~ <demand 
coronary vascular resistance adrenergic stimulation (pre-
postsynaptic) 
renin release Orconsumption 
endothelin release antilipolytic effects 
platelet activation membrane stabilization 
leucocyte activation Ca++ I i< homeostasis 
no reflow phenomenon 
glucose utilization 
high energy phosphates 
mediator of ischemic preconditioning 
reduction of myocardial stunning 






Legend: Potential roles of adenosine in improving the supply/demand ratio of the myocardium 
* systemic vascular resistance 




Periods of increased metabolic needs of the myocardium result in increased ATP 
catabolism and subsequent adenosine release, which in turn acts via purinergic A2 
receptors (P 1-receptor subtype) on the small coronary resistance arterioles thereby 
self-regulating coronary blood flow and metabolic needs. Although the adenosine 
hypothesis is widely accepted in coronary vasodilatation arising during hypoxia or 
ischemia, there is evidence that it plays no major role during physiologic exercise 
(Bache, 1988) and coronary vasodilatation in response to acute hypoxia is not 
uniquely dependent on adenosine (Gerwitz, 1987). Normal serum levels (in man) of 
adenosine range between 0.1 and 0,3µmol/L (Sollevi A, 1987) and any excess 
adenosine is rapidly broken down by adenosine deaminase. 
Reduction of superoxide anion production from neutrophils 
Cronstein (Cronstein, 1983) described adenosine as a physiologic modulator of 
superoxide anion generation by human neutrophils, but found no effect on either 
degranulation or aggregation. In a second study in 1986 (Cronstein, 1986) he 
confirmed the role of adenosine as an endogenous inhibitor of neutrophil- mediated 
injury to endothelial cells in an in vitro model. He concluded that the engagement of 
adenosine receptors prevents both the adhesion of neutrophils and the injury they 
cause to endothelial cells. More recently investigators from the University of Munich 
(Thiel, 1992) showed that the inhibition of oxygen radical production via adenosine 
results from receptor-mediated inhibition of stimulus-induced increases in 
intracellular calcium. 
In an attempt to reduce ischemic injury in a coronary microembolization model with 
three antioxidant agents (superoxide dismutase, allopurinol, CV3611 ), Hori found 
less edema, increased numbers of microspheres required for complete stoppage of 
flow, less dysfunction during progressive embolization and increased adenosine 
release when these antioxidants were used (Hori, 1991 ). When the adenosine 
receptor antagonist 8-phenyltheophylline was used the beneficial effects of 
superoxide dismutase were blocked, indicating that augmented adenosine was a 
mechanism of this free radical scavenger. 
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This raises the possibility that increased local adenosine levels are the common 
pathway of protection from reactive oxygen species during ischemia and reperfusion 
(Engler, 1991 ). Is there an additional deleterious effect by which free radicals lower 
effective adenosine levels and thereby defeat a microvascular protective mechanism 
(Engler, 1991 )? Originally it was thought that the principal source of superoxide 
production was the metabolism of hypoxanthine to uric acid via endothelial xanthine 
oxidase (McCord, 1985). Recent studies have confirmed that xanthine oxidase 
inhibition by allopurinol or oxypurinol may be protective, but the conclusions are 
controversial (Werns, 1986; Lasley, 1988). Even more recently a non-purine based 
agent that also inhibits xanthine oxidase failed to limit reperfusion injury, whereas 
oxypurinol reduced injury under identical circumstances. This raises the question of 
the role of xanthine oxidase inhibition in the mechanism of protection; perhaps 
oxypurinol and allopurinol have additional mechanisms of protection. The release of 
adenosine as the mechanism by which viable cells are recognized by cell-mediated 
inflammation has prompted Engler to call adenosine the signal of life (Engler, 1987), 
a marker that indicates cell viability to inflammatory cells. Cells that are no longer 
capable of ATP catabolism no longer excrete adenosine and can be recognized as 
necrotic debris for disposal by phagocytic cells. 
Inhibition of platelet aggregation 
Endogenous adenosine has been shown to inhibit platelet aggregation during 
myocardial ischemia (Kitakaze, 1991 ). During low flow ischemia in open-chest dogs, 
treatment with 8-phenyltheophylline, an adenosine receptor antagonist, reduced 
coronary flow and led to thromboembolization in the small coronary arteries. The 
authors demonstrated that this thromboembolization during lack of adenosine activity 
is triggered by stimulation of A2-adrenoreceptors by release of norepinephrine 
during ischemia. 
Sollevi (Sollevi, 1985) demonstrated in 1985 in a clinical study that adenosine 
spared platelets during cardiopulmonary bypass without causing systemic 
vasodilatation. However, the study failed to show any reduction in postoperative 
blood loss when adenosine was infused. 
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Inhibition of adrenergic stimulation and calcium antagonistic properties 
Adenosine inhibits the myocardial effects of catecholamine stimulation (Schrader, 
1977). Adenosine inhibited the contractile response to catecholamine stimulation by 
inhibiting isoproterenol-induced rise in cyclic 3' 5' -AMP levels. Summarizing the 
electrophysiological effects of adenosine on cardiac tissues, Rubio pointed out that 
the negative inotropic effect of adenosine on atrial muscle, associated with a 
shortened action potential, the decrease of AV-conduction and a negative inotropic 
effect, are probably caused by a depression of calcium influx (Rubio, 1979). Kato 
confirmed in 1990 that adenosine decreases Ca2+ current under ~-adrenergic 
stimulation mainly by reducing channel availability (Kato, 1990). Since adenosine 
also opens the ~TP channel, it can also reduce net calcium influx as has been 
demonstrated for ~TP channel openers (Behling, 1995). 
Stimulation of glycolytic flux 
Wyatt published a study in 1989 in which he could demonstrated increased 
glycolytic flux via exogenous adenosine in the isolated rat heart (Wyatt, 1989). 
Adenosine stimulated glycolytic flux in the normoxic as well as in the hypoxic 
myocardium and the effect was mediated by interaction with A1- adenosine 
receptors. However Dale conducted a study on isolated rat myocytes in which 
adenosine failed to alter glycolytic rates (Dale, 1991 ). Rather it was found that PIA 
(N6-(L-2-phenylisopropyl) adenosine, a nonmetabolizable adenosine analogue, 
inhibited glucose utilization with glucose as the sole exogenous substrate, as it 
inhibited glucose transport by binding to the glucose transport molecule. These 
discrepancies are difficult to explain by differences in methodology in estimating 
glycolysis or different perfusion systems alone and further studies will be required to 
clarify this issue. 
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Clinical roles 
Diagnosis and treatment of supraventricular arrhythmias 
Adenosine has a depressant effect on the SA node and impairs impulse conduction 
through the AV node, but has little effect on impulse generation and conduction in 
ventricular myocardium. These effects are mediated at the cellular level by an 
increase in potassium and a decrease in calcium conductance and are not 
antagonized by atropine. The effects of adenosine are rapid in onset (5-30 sec) and 
transient because the half life is 10-30 seconds only, because of a rapid uptake and 
breakdown by adenosine deaminase in erythrocytes and endothelial cells. These 
differing regional cardiac effects and short half life have led to the use of adenosine 
in the treatment of cardiac arrhythmias (Belardinelli, 1990) 
Adenosine can terminate supraventricular arrhythmias in 86-100% of cases if the AV 
node is involved and forms one of the limbs of the re-entrant circuit, such as atria-
ventricular reciprocating tachycardia and atrioventricular nodal re-entry. Adenosine 
effectively terminates these types of supraventricular arrythmias by transiently 
interrupting impulse propagation through the AV node. However, the arrhythmias 
may reoccur quickly in up to one third of cases after the effects of adenosine 
dissipate. Adenosine will nearly always terminate tachyarrhythmias of atrial origin. 
Adenosine may be of diagnostic value because it slows the ventricular rate by 
causing block at the AV node level and reveals the unaffected atrial arrhythmia, as in 
automatic atrial tachycardia, atrial flutter and atrial fibrillation. Although adenosine is 
not effective in terminating ventricular tachycardia it has been safely and effectively 
used to help differentiate ventricular tachycardia from supraventricular tachycardia 
with a wide ORS complex. It seems to be safer for this procedure than verapamil 
which often has deleterious hemodynamic effects in patients with ventricular 
tachycardia. 
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Measurement of maximal coronary vasodilator reserve 
More recently adenosine has been used successfully to measure maximal coronary 
vasodilatation (Wilson, 1990) in humans. lntracoronary bolus injection (16 µg), 
intracoronary infusion (>80 µg/min) and intravenous infusion (140 µg/kg/min) caused 
coronary hyperemia similar to that caused by papaverine. The duration of coronary 
vasodilatation was much shorter after adenosine bolus injection than after 
papaverine administration; no side effects were recorded apart from a brief decrease 
in arterial pressure similar to that caused by papaverine. In particular, there was no 
alteration in heart rate and cardiac conduction in the dosage used. One clear 
advantage over papaverine is the short half life of adenosine, whereas the total dose 
of papaverine that can be given is limited by its relatively slow systemic excretion 
(half life 3-6 hours). Consequently intravenous or prolonged intracoronary infusion 
lead to systemic hypotension. In addition intracoronary papaverine prolongs the QT 
interval and can cause polymorphous ventricular tachycardia. Intravenous 
dipyridamole, another drug which has been used and which acts via inhibition of 
adenosine deaminase, has the disadvantage of prolonged action (>30 minutes) and 
therefore precludes repeated measurements in the same study. Adenosine was 
therefore found to be a safer, more practical agent for measuring maximal coronary 
vasodilator reserve.(Wilson, 1990) 
Induced hypotension 
Recently adenosine has also been introduced as an agent to induce controlled 
hypotension during anesthesia in patients undergoing cerebral aneurysm surgery 
and in patients with peripheral vascular disease (Sollevi, 1984; Oewall 1987). 
Intravenous infusion at a rate of 90 µg/kg/min lowered mean arterial blood pressure 
by approximately 20%. Whereas systemic and pulmonary vascular resistance 
indices decreased by 36 and 32% respectively, cardiac index increased by 18%. 
Heart rate, ventricular filling pressures and whole body oxygen consumption were 
not affected (Oewall, 1988). Coronary sinus flow increased by 128% in parallel with 
a 96% increase in coronary sinus oxygen content. Signs of myocardial ischemia 
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were demonstrated in one patient while myocardial lactate uptake was unchanged in 
all subjects. However, more recently Zaell reported a significant depression of the 
ST segment in six out of fourteen patients after coronary bypass surgery with 
intravenous infusion rates of 30-120 µg/kg/min (Zaell, 1991 ). The authors therefore 
concluded that adenosine, while inducing systemic, pulmonary and coronary 
vasodilatation, increased the intrapulmonary shunt fraction and may cause or 
aggravate myocardial ischemia via coronary steal phenomena. Unfavorable 
coronary redistribution is therefore an undesirable side effect which needs further 
elucidation in controlled clinical trials before adenosine can be recommended for 
routine use to induce controlled hypotension. 
Experimental roles 
Mediation of ischemic preconditioning: 
It is now well established that the extent of any myocardial infarction depends on the 
duration and the severity of the ischemic insult, the presence and degree of any 
collateral circulation, the rate of oxygen consumption, and the area of myocardium at 
risk (Walker, 1992). However the exact biochemical mechanism of cell death 
remains unclear. At present most theories relate to either the loss of high energy 
metabolites such as ATP and phosphocreatinine or the accumulation of catabolites 
such as lactate, H+-ions and inorganic phosphate. 
In experiments to separate the effects of high energy phosphate depletion from 
those of catabolite accumulation, Reimer et al. found that brief periods of ischemia 
and reperfusion were able to protect the heart through a longer sustained ischemic 
insult (Reimer, 1986). Induction of ischemic tolerance in this way has been termed 
ischemic preconditioning. 
Global ischemic preconditioning as a protective mechanism in the clinical setting, 
especially in the field of cardiac surgery, has been extensively studied by Yellon et 
al. (Jenkins, 1995; Alkhulaifi, 1994; Speechly-Dick, 1995; Yellon, 1993). According 
to a recent survey 28% of British cardiac surgeons still use intermittent aortic cross 
clamping and ventricular fibrillation instead of cardioplegic arrest and yet have 
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acceptable clinical results (lzzat, 1994). Yellen (Yellen, 1994) found significant 
preservation of high energy phosphate content in preconditioned hearts of patients 
undergoing CABG surgery. Walker and Yellen (Walker, 1993) had already 
postulated in 1993 that global ischemic preconditioning might account for the 
successful use of cross-clamp fibrillation during cardiac surgery. Abd-Elfattah and 
Wechsler (Abd-Elfattah, 1995) confirmed that intermittent aortic cross clamping 
prevents cumulative adenosine triphosphate depletion, postischemic ventricular 
fibrillation and ventricular dysfunction, and represents a form of preconditioning. 
Adenosine has subsequently evolved as the most likely candidate as an 
endogenous mediator of this phenomenon (Walker, 1995). Being released from 
ischemic myocytes, adenosine is thought to act as a local regulator of the cell via a 
feedback mechanism. Probably the adenosine which accumulates during ischemia 
acts on myocardial A1 receptors which in turn trigger biochemical changes in the 
heart that confer lasting protection against a subsequent ischemic insult. Most likely, 
these protective changes could be stimulation of glycolysis and opening of ATP 
regulated K+ channels (Walker, 1992). Kiener and Yellen (Kiener, 1994) conclude 
that in the future preconditioning or "preconditioning mimetic" agents have the 
potential to be applied to a wide array of cardiovascular disorders and might result in 
better preservation of the heart in the settings of cardiopulmonary bypass, heart 
transplantation, angina and myocardial infarction'. 
However, no consensus has been reached about the exact mechanism of 
preconditioning and although the role of adenosine has been well studied it does not 
seem to play a role in the rat (Cave, 1993) and can therefore not be the universal 
mediator. Several other mechanisms have been proposed including limitation of 
glycolysis, maintenance of high energy compounds and increased activity of the 
inhibitory G protein and increased activity of protein kinase C activity (King, 1996; 
Lawson, 1993). 
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Amelioration of myocardial stunning 
Myocardial stunning is defined as transient postischemic contractile dysfunction of 
myocytes that have not undergone irreversible cell injury (Braunwald, 1985, Belli, 
1988). The most likely mechanisms for the development of stunning are free radical 
formation and intracellular calcium overload. Depletion of high energy phosphate 
stores and impairment of regional blood flow may play an additional role. Forman 
speculated that adenosine could accelerate the recovery of contractile function 
through a number of mechanisms (Forman, 1991 ). Adenosine may enhance 
intracellular ATP levels via the salvage pathway while conserving utilization through 
its negative inotropic effect in the presence of catecholamine stimulation. Adenosine 
could also reduce free radical mediated injury by inhibiting superoxide anion release 
from neutrophils (Cronstein, 1986) and decreasing catecholamine release and lipid 
peroxidation. Adenosine also blocks calcium dependent channels and therefore may 
restore intracellular calcium homeostasis. Finally adenosine may enhance oxygen 
delivery and washout of "toxic" metabolites through arteriolar vasodilatation and 
antiplatelet and antineutrophil effects (Forman, 1991 ). 
Adenosine during ischemia and reperfusion 
In view of the cardioprotective properties of adenosine during ischemia and 
reperfusion numerous experimental models have been used to investigate the 
potential benefits of adenosine during these periods. 
Reibel and Ravetto showed 1979 that postischemic perfusion of the isolated rat 
heart with adenosine for 5 hours could restore ATP values to control levels (Reibel, 
1979). At this stage the main effect of adenosine was thought to be restoration of 
high energy phosphates via precursor availability. These initial findings were 
emphasized by Sollevi in 1987 (Sollevi, 1987) in a clinical study, who showed that 
considerable amounts of purines are washed out of the myocardium during 
reperfusion, impeding restoration of the normal energy state and return of 
myocardial function. 
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Starting from the theory that catabolism of high energy phosphate precursors is the 
limiting factor for their regeneration during reperfusion, Faker found in 1980 that 
pretreatment with EHNA, an adenosine deaminase inhibitor, together with adenosine 
infusion during ischemia increased myocardial blood flow and ATP content at 
reperfusion in dogs (Faker, 1980). However, adenosine infusion alone, while altering 
myocardial blood flow similarly, did not alter subsequent ATP levels. 
Using a similar approach Humphrey showed in 1982 (Humphrey 1982) that 
suppression of adenosine catabolism by adenosine deaminase inhibitors (EHNA) 
improved the functional recovery of ischemic myocardium. EHNA alone or EHNA 
together with adenosine prior to ischemia resulted in 100% recovery of aortic output 
after 30 minutes of global ischemia in the isolated rat heart. However, as in the 
previous study, only the combination of adenosine and EHNA was able to improve 
postischemic ATP levels significantly. 
Ely from Virginia, USA demonstrated in 1985 improved functional recovery in an 
isolated rat heart model of global ischemia with adenosine infusion prior to ischemia 
and at reperfusion (Ely, 1985). In these experiments, in contradiction to the 
previously mentioned studies, adenosine treatment alone enhanced metabolic 
recovery as evidenced by better preserved ATP levels. Furthermore, adenosine 
(100 µmol) increased the time to onset of ischemic contracture by 50%. Ely 
concluded from his study that adenosine enhanced myocardial preservation by 
reducing the net degradation of ATP during ischemia and facilitated repletion of ATP 
levels during reperfusion. 
Starting in 1989, Bolling published several studies showing improved postischemic 
recovery when adenosine was added during ischemia in the isolated rat heart 
(Bolling, 1989). He found improvement of ventricular function which was maximal 
with adenosine 400 µM including better preservation of diastolic function. He noted 
no differences in postischemic coronary flow and attributed the improved recovery to 
an enhanced repletion of high energy phosphates with adenosine, although his 
study did not include measurements of high energy phosphates. The same author 
published a second study where he found improved recovery with adenosine or 2-
deoxycoformycin, a non-competitive inhibitor of adenosine deaminase 
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(Bolling, 1990). Combination of these two drugs enhanced recovery even further. 
This time he measured ATP levels and found elevated levels at reperfusion in the 
drug treated hearts, although ATP levels declined equally during ischemia in the 
control and treatment groups. Confirming his results he found in 1991 inferior 
recovery in a third study in animals treated with adenosine deaminase (Bolling 
1991 ). Postischemic functional recovery closely paralleled the availability of 
myocardial adenosine and he concluded that myocardial adenosine levels at the end 
of ischemia and at early reperfusion are important determinants of functional 
recovery after global ischemia. 
Adenosine releasing agents 
A relatively new approach with an old drug is the enhancement of endogenous 
adenosine release via adenosine-releasing agents. AICA riboside (5-amino-4-
imidazole carboxamide riboside), described as long ago as 1952 (Greenberg, 1952), 
augments adenosine release only from energy deprived cells with net ATP 
catabolism (Gruber, 1989). Gruber found AICA riboside pretreatment of myocardium 
reduced granulocyte accumulation and improved collateral flow in the ischemic area. 
In addition the episodes of ventricular arrhythmias during coronary artery ligation 
were significantly reduced in AICA riboside pretreated hearts. The study also 
confirmed that adenosine inhibits granulocyte superoxide anion production in vitro, 
as already demonstrated by Cronstein (Cronstein 1983, 1986) . 
Conclusion 
A review of all these experimental investigations shows numerous potential 
cardioprotective qualities of adenosine. However, it is difficult to attribute these 
protective qualities to one single mechanism. It seems more likely that these 
properties act together via synergistic mechanisms. However, it would be interesting 
to separate the vascular effects (A2 receptor-mediated) from the myocardial effects 
(A1 receptor-mediated). This would be possible with currently available selective 
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agonists for one receptor subtype. Whereas isolated heart models allow rapid 
screening tests in large numbers and control of pre- and afterload conditions, they 
often lack clinical relevance and the species tested is often distant from man. In-vivo 
models, while more closely simulating the clinical situation, allow less control of 
loading conditions for assessment of myocardial function (Bretschneider 1980). It 
also seems that the initially postulated ATP repletion via adenosine as precursor is 
not the main mechanism involved. Especially during ischemia there seems to be no 
significant regeneration of ATP even when high concentrations of adenosine are 
present. However, during reperfusion, the presence of adenosine probably 
enhances fast restoration of high energy phosphates. On the other hand there 
seems to be no close correlation between high energy phosphate content and 
mechanical recovery and Hohlfeld and Hearse (Hohlfeld 1989) have questioned 
whether elevation of high energy phosphate levels postischemia is important. They 
concluded that total tissue ATP is not necessarily a good indicator of functional 
capabilities under conditions of normothermic ischemia and reperfusion in the 
isolated rat heart, but they did not question the uncontradicted value of ATP as a 
parameter of ischemia related tissue damage. Probably different adenine nucleotide 
compartments characterized by different specific activities with varying contributions 
during normoxia and hypoxia preclude total tissue ATP as a reliable marker of 
mechanical function postischemia (Schrader, 1976). 
Two other questions remain: Is the presence of adenosine essential before or during 
ischemia or during the reperfusion phase? The answer is not yet established, but 
most probably adenosine will be beneficial in all three phases. 
The other question is whether supplementation via exogenous adenosine, inhibition 
of adenosine breakdown via adenosine deaminase or adenosine transport inhibition 
via nucleoside transport inhibitors is the most successful way to ensure high local 
myocardial levels of adenosine. Again the answer is not yet established, but the 
combination of those three approaches seems likely to offer most promise. There is 
sufficient experimental evidence to support the effectiveness of either method. 
Different experimental setups and animal species have to be taken into 
consideration. 
More recently adenosine releasing substances (ARA) stimulating endogenous 
adenosine release have become available. This is perhaps the most effective 
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approach especially as the undesirable side effects of high and prolonged 
adenosine administration such as generalized receptor activation (Van Belle, 1990), 
renal vasoconstriction (Osswald, 1978; Spielman, 1987) and bronchospasm 
(Holgate, 1987) can be avoided. 
Adenosine has been called the natural cardioprotector (Van Belle, 1990) and has 
been termed autacoid, meaning anti-injury hormone, that links ATP catabolism to 
inhibition of granulocyte adherence, microvascular obstruction and superoxide anion 
formation (Gruber, 1989). In view of the experimental evidence discussed above it 
appears that adenosine is in fact an anti-injury hormone with multiple sites of action. 
Apart from its role of enhancing coronary flow during ischemic stress associated with 
ATP catabolism in order to meet metabolic needs, it also slows heart rate and AV-
conduction resulting in preservation of energy and decreased 0 2 consumption. The 
antiadrenergic effects act additionally to counteract the systemic hormonal 
stimulation during these periods. Whereas the potential of stimulating glycolytic flux 
has been disputed it could, once proven, act to ensure the functioning of metabolic 
pathways during ischemic periods. The Ca2+ _ antagonistic properties could prevent 
ca2+ accumulation during ischemia and reperfusion with all its adverse 
consequences. Inhibition of leukocyte adherence and superoxide anion generation 
together with diminishing platelet aggregation act together to maintain adequate flow 
during reperfusion and to reduce the deleterious consequences of the reintroduction 
of oxygen. All these multiple sites of action aim in the same direction of ameliorating 
ischemia and reperfusion induced damage. 
While further experimental results elucidating the various protective mechanisms are 
necessary the time has come to start clinical trials with this promising substance. To 
my knowledge the only commercially available solution employing adenosine is UW-
solution for heart storage prior to transplantation, although it was originally designed 
for storage of intraabdominal organs, such as liver and kidney. Cardioplegic and 
reperfusion solutions for local and global myocardial ischemia could be substantially 
enhanced by addition of adenosine. For blood-based solutions a combination with 
adenosine deaminase inhibitors or nucleotide transport inhibitors would be 
necessary to prevent rapid degradation. 
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CHAPTER 2 
MODELS USED TO STUDY MYOCARDIAL PROTECTION 
Cardioplegic solutions need to be developed and evaluated in animal models prior to 
human use. Thereafter, multivariate clinical trials of experimentally investigated 
solutions are valuable and necessary. However, the multitude of uncontrolled 
variables, as a result of the varied diseases necessitating cardiac surgery, makes 
evaluation of cardioplegic solutions difficult in the clinical situation. 
In animal studies, it is important to undertake evaluations in more than one species 
because of interspecies differences. Hearse DJ, Jynge P and co-workers evaluated 
the St. Thomas' Hospital No 2 cardioplegic solution in both rats and dogs 
(Jynge, 1981 ). However, the ideal species for evaluating solutions intended for 
human use is possibly the baboon, as it is one of the closest species to man. In this 
thesis two models and species were used to assess the efficacy of cardioplegic 
solutions used in South Africa, and experimental modifications of the St. Thomas' 
Hospital cardioplegic solution. 
All experimental animals used in our laboratory received care in accordance with the 
,,Principles of laboratory animal care" of the National Society for Medical Research 
and the ,,Guide for the care and use of laboratory animals" prepared by the National 
Academy of Sciences (NIH Publication No 80 - 23, revised 1978). In addition, 
experimental protocols were reviewed and authorized by the Animal Research 
Review Committee of the University of Cape Town. 
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2.1. ISOLATED RAT HEART MODEL 
The isolated perfused rat heart was used as the experimental model for the majority 
of studies in this thesis. This model has two components; the Langendorff 
preparation and the working heart model. 
Langendorff preparation 
The Langendorff model was originally described in 1895 (Langendorff, 1895) and 
since then has been used extensively to study cardiac metabolism in a number of 
different animals (Hearse, 1981 ). Male rats of the Sprague-Dawley strain maintained 
on a standard diet were used for our experiments. 
The rat was anesthetized with diethyl ether, heparinized with 200 U heparin injected 
into the exposed femoral vein, and the heart was then carefully but rapidly excised 
and placed into cold (4 °C - 10 °C) Krebs-Henseleit buffer (Table 2.1 ). The low 
temperature arrests the heart and thus provides some protection to the myocardium 
during this initial ischemic period. The aorta was then cannulated and the heart 
mounted on the perfusion apparatus (Fig. 2.1 ), within one minute of excision. 
Normothermic (37 °C}, Krebs-Henseleit buffer oxygenated with 95 % 0 2 and 
5 % CO2 (p02 greater than 600 mm Hg) was filtered through a cellulose filter (0.8 µm 
size pores; Millipore Corporation, Bedford, Massachusetts, USA) and then allowed to 
flow retrograde into the aorta at a constant pressure of 100 cm H20 (75 mm Hg}, 
thus establishing coronary perfusion. Normal sinus rhythm recommenced 
immediately. The pulmonary artery was then incised to ensure adequate drainage of 
coronary effluent, and the heart was maintained at 37 °C in a water-jacketed 
chamber. This model thus allows the perfused heart to continue beating in a 
nonworking mode, and was used to stabilize the experimental hearts prior to 
conversion to the working model. In addition, this mode of perfusion was also used 
for the initial reperfusion of the postischemic heart. 
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Working heart model 
In order to allow the heart to perform external work so that mechanical performance 
could be monitored, the Langendorff model was then converted to the working model 
originally described by Neely and colleagues (Neely, 1967). The left atrium was 
cannulated through the pulmonary veins, and filled with oxygenated Krebs-Henseleit 
buffer at a constant pressure of 20 cm H20 (15 mm Hg). The left ventricle then 
spontaneously ejects the perfusate against a hydrostatic pressure of 100 cm H20 (75 
mm Hg), and the coronary flow was collected and recirculated. Aortic pressure, 
aortic flow, coronary flow, and heart rate were then recorded in the control working 
period, prior to the ischemic period, and also in the postischemic recovery period. 
Cardioplegic solutions were infused into the aorta at a pressure of 80 cm H20 (60 
mm Hg) prior to the ischemic period, by simultaneously closing the aortic and atrial 
cannulae (Fig. 2.1 ), and infusing the cardioplegic solution through a side arm of the 
aortic cannula. Constant hypothermia ( 1 O °C) was maintained throughout the 
ischemic period by another separate cold (10 °C) water-jacketed chamber. 
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FIGURE 2.1. ISOLATED WORKING RAT HEART 
Working Heart Circuit Langendorff 
reservoir 
20cm 
• ' •• 








Legend: Three way taps (T) allow easy conversion to either Langendorff mode, the working heart 
circuit or infusion of cardioplegic solutions. Reprinted from J Thorac Cardiothorac Surg 
1991; 102; 405-412 (with permission Mosby Year Book Inc.) 
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TABLE 2.1.: KREBS-HENSELEIT BUFFER 
Compound mM/L gm/L Electrolyte mM/L 
NaCl 118 6.9 Na+ 143 
NaHC03 25 2.1 I< 6 
KCI 4.8 0.36 Ca2+ 1.25 
KH2P04 1.2 0.16 Mg2+ 1.2 
CaCb • 2H20 1.25 0.18 er 125.3 
MgS04 • 7H20 1.2 0.3 PO/ 1.2 
D-Glucose • H20 11.1 2.2 Glucose 11.1 
Legend: Modified Krebs-Henseleit buffer used in our laboratory 
Experimental protocols 
All hearts were stabilized for 10 minutes in the Langendorff mode, prior to changing 
to the working model. Pre-ischemic control hemodynamic parameters were 
measured at 2,5 and 10 minutes during this working period. Any heart that was 
unstable during this period was rejected. The 10-minute values were then recorded 
as the preischemic controls for future comparisons. 
Cardioplegic arrest was induced by infusing 10 ml of cold (10 °C) cardioplegic 
solution into the aorta. 
At the end of the ischemic period each heart was reperfused in the Langendorff 
mode with standard oxygenated Krebs-Henseleit buffer (37 °C) for 10 - 20 min at a 
pressure of 80 - 100 cm H20 (60 - 75 mm Hg) according to individual experimental 
protocols. The hearts were then converted to the working model for a further 1 O 
minutes, at which time the postischemic hemodynamic parameters were recorded. 
The coronary sinus effluent was collected during the ischemic period when multidose 
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cardioplegia was administered, as well as during the postischemic Langendorff 
reperfusion period. At the end of the experiments the hearts were freeze-clamped 
with Wollenburg tongs to determine their high-energy phosphate content. 
Exclusion criteria: 
In the preischemic control period the following values were used to discard hearts: 
Aortic output< 30 ml/min 
Coronary flow > 22 ml/min 
Heart rate < 200 beats/min, or irregular rhythm 
In the postischemic period any heart whose coronary flow increased significantly by 
more than 50 % - suggesting a left atrial leak - was excluded. 
Parameters of recovery 
To evaluate the efficacy of myocardial protection both mechanical, metabolic and 
morphological parameters may be measured (Hearse, 1981 ). However, ultimately 
the most important parameter is mechanical recovery, which was measured under 
controlled conditions (both preload and afterload), in this isolated rat heart model. 
Hemodynamic parameters 
Cardiac output (CO) in this preparation is the sum of aortic flow (AO) and coronary 
flow. Stroke volume (SV) was then calculated using the following formula: 
SV = CO/ HR (ml/beat) 
Values obtained during the postischemic working period were expressed as a 
percentage of their individual preischemic control values. Results were then 
presented as percentage means and standard errors of percentage means. 
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Metabolic parameters 
Loss of myocardial high energy phosphate stores is an integral component of 
ischemia, and Bretschneider and co-workers predicted poor recovery if ATP levels 
fell below 4 µmol/gm wet weight (Bretschneider, 1985). ATP levels have been used 
in clinical studies and correlate with postoperative outcome (Hammon, 1987). 
However, other studies have demonstrated that postischemic levels of ATP of less 
than 2 µmol/gm wet weight neither predict recovery of contractile function nor 
irreversible damage (Vary, 1979). Thus, although newer 'on line' nuclear magnetic 
resonance techniques for measuring ATP may provide valuable information, one 
cannot predict functional recovery from these values (Rosenkranz, 1986; Saks, 
1989). High energy phosphates were measured in the studies in this thesis by 
freeze-clamping the hearts with Wollenberg tongs and freeze drying the samples. 
The levels were then determined by the method of Lamprecht and Trautschold, 
expressed as µmol/gm wet weight (Lamprecht, 1974). Preischemic control values for 
ATP and CP were derived from hearts subjected to the same initial experimental 
protocol, i.e. 10 min Langendorff and 10 min working heart modes, but thereafter 
immediately freeze clamped. Tissue ATP and CP levels were then also measured at 
the end of the ischemic period in some of the studies, by freeze clamping a second 
set of hearts prior to reperfusion. In addition, high energy phosphate levels were 
also measured in most of the studies after reperfusion, at the end of the 
experimental protocol. 
Analysis of data 
Extreme observations or ,,outliers" were tested for by Dixon's criteria (Snedecor, 
1980), in order to exclude major experimental errors, and if found those hearts were 
then excluded from further analyses. 
The statistical tests used to compare differences between groups were the Anova 
one-way, two-way or three-way analyses of variance. However, the Anova depends 
upon an assumption of common variance amongst observations within each 
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treatment group. Therefore, if variance was not consistent necessary adjustments for 
the violation of common variance were made. If statistical significance was obtained 
with ANOVA then pairwise comparisons of means were performed using either t-
statistics with a nominal level of significance set at 5 %, or by the f-test. Appropriate 
tables were then used to determine p-values for comparisons of interest. Statistical 
significance was assumed when the p-value was less than 0. 05. Bonferroni 
correction was performed for multiple comparisons. 
2.2 In vivo primate model 
Juvenile and adult Chacma baboons (Papio ursinus) were used in the primate 
experiments in this thesis. An in vivo model using cardiopulmonary bypass to 
simulate the clinical situation as close as possible was used. 
Animal preparation 
The baboons were fed on a standard diet which was withheld the day prior to 
surgery. 
The animals were premedicated with intramuscular ketamine hydrochloride (10 
mg/kg body weight). An endotracheal tube was then inserted, which was stabilized 
and secured with a cardboard ring and Elastoplast. A narcotic analgesic morphine 
sulfate (0.25 mg/kg), an antisialogogue, atropine sulfate (0.5 mg) and a 
neuromuscular blocker, pancuronium bromide (0.1 mg/kg) were administered 
intravenously. Anesthesia was maintained with a mixture of nitrous oxide (7 Umin), 
oxygen (3 Umin), and 0.5 % halothane, administered via a Bird Mark 8 respirator 
(Bird Corporation, Palm Springs, California, USA) at a respiratory rate of 10 - 20 
breaths/min. Tidal volume was adjusted according to animal size, ventilator 
pressures were kept at 15 - 20 cm H20, and blood gases were monitored throughout 
the experiment and ventilation adjusted accordingly. The animals were also 
monitored for signs of insufficient anesthesia (hypertension, bradycardia, 
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tachycardia, pupillary dilatation, lacrimation, salivation and muscular tension), and 
the level of anesthesia was appropriately adjusted. Intra-arterial and central venous 
lines were inserted into the femoral vessels. 
Immediately prior to performing the median sternotomy a second dose of morphine 
sulfate was given. After full heparinization (500 U/kg) the heart was cannulated in 
preparation for cardiopulmonary bypass. Venous blood was drained via a single 
venous cannula inserted into the right atrium, oxygenated by a bubble oxygenator 
(Polystan Venotherm Oxygenator, low prime adult / pediatric Cat 012500, or infant 
Cat 011200; Polystan A/S, Vaerlose, Denmark), temperature controlled with a heat 
exchanger incorporated in the oxygenator, and the blood was then returned by the 
cardiopulmonary bypass machine (Polystan A/S; Vaerlose, Denmark), via a cannula 
inserted into the ascending aorta. A Swan-Ganz thermodilution catheter (American 
Edwards 7F; American Edwards Laboratory, American Hospital Supply corporation, 
Santa Ana, California, USA) was inserted through the superior vena cava and 
positioned in the pulmonary artery for the measurement of cardiac output. Cannulae 
were also inserted into the left atrium and left ventricle and a thermistor probe 
(Microprobe thermometer Model BAT-12; Physitemp, Clifton, New Jersey, USA) was 
positioned in the ventricular septum. 
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FIGURE 2. 2.: SITUS OF THE ANIMAL PREPARATION INTHE PRIIMATE MODEL 
Legend: Situs of the animal preparation in the baboon. CPB is connected via cannulae in the right atrium and ascending aorta. A Swan-Ganz thermodilution catheter is inserted via the SVC. Additional monitoring lines are inserted in the left atrium and left ventricle. A thermistor probe is inserted in the interventricular septum. 
Experimental protocol 
Systemic temperature was lowered and maintained at 26 °C after commencing 
cardiopulmonary bypass. The aorta was then cross-clamped and cardioplegic 
solution (15 ml/kg) infused via a separate cannula inserted into the ascending aorta, 
at a constant pressure of 80 mm Hg. In addition, the pericardia! cavity was irrigated 
with iced saline during each infusion of cardioplegic solution. Multidose maintenance 
cardioplegia ( 100 ml/dose) was re infused every 30 minutes throughout the 180-
minute cross-clamp period. Systemic rewarming was commenced 30 minutes before 
the release of the aortic cross-clamp, and continued throughout the 15-minute 
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reperfusion period until normothermia was attained. The left ventricle was vented 
during the cross-clamp period and initial reperfusion period to ensure left ventricular 
decompression, by a cannula inserted via the right superior pulmonary vein. The 
animal was then weaned from cardiopulmonary bypass without the use of any 
inotropes. 
The animals were killed while still under full anesthesia by the intravenous infusion 
of a strong solution of potassium chloride, thereby effecting immediate cardiac arrest 
at the completion of each experiment. 
FIGURE 2.3.: EXPERIMENTAL PROTOCOL OF THE IN-VIVO BABOON MODEL 
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Legend: CPB was commenced after positioning of all cannulae and after prior hemodynamic measurements and obtaining a left ventricular biopsy specimen with a Truecut needle. Subsequently the aorta was crossclamped and the heart was perfused with cardioplegic solution at 80 mmHg controlled via a pressure regulating feedback device. During 180 minutes of global hypothermic ischemia the hearts were perfused in 30 minutes intervals with maintenance cardioplegia and additional cooling with topical cold saline was provided. Prior to release of the aortic cross clamp at the end of the ischemic interval a further myocardial biopsy was taken and subsequently the animals were weaned from CPS. After 5 and 30 minutes after termination of CPB hemodynamic measurements were performed and a myocardial biopsy specimen was obtained. 
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Parameters of recovery 
Myocardial temperature and hemodynamic parameters - heart rate, arterial blood 
pressure, right and left atrial pressure, first derivative of left ventricular developed 
pressure (LV dP/dt), and cardiac output (by thermodilution) were recorded with a 
Honeywell AR-6 Simultrace Recorder (Electronics for Medicine, Honeywell Inc, 
Pleasantville, New York, USA). Preischemic hemodynamic parameters were 
recorded after the positioning of all cannulae before starting cardiopulmonary 
bypass. A left ventricular function curve was plotted by recording these parameters 
at increasing left atrial filling pressures (5, 10, 15, 20 mm Hg), obtained by infusing 
cardiopulmonary bypass prime into the animal. In addition, two left ventricular 
transmural needle biopsy specimen were taken from the apex of the left ventricle for 
determination of high-energy phosphates and transmission electron microscopic 
assessment in some experiments. 
Postischemic hemodynamic and biochemical parameters were again taken at 5 and 
30 minutes after termination of cardiopulmonary bypass, (a postischemic LV function 
curve was only obtained at the 30 minute postischemic period). 
Analysis of data 
Values were expressed as an index, to exclude the influence of animal size. The 
following formulae were used to derive cardiac index (Cl), stroke volume index (SVI), 
and left ventricular stroke work index (SWI). 
BSA (cm2) = Weight 0·425 (kg) X Height 0·725 (cm) X 71.84 (Du Bois, 1916) 
Cl (L/min/m2) = CO (Umin)/ (BSA X 10-4 m2/cm2) 
SVI (ml/beat/m2) = (Cl X 1000 ml/L) / HR (beats/min) 
SWI (gm • m/beat/m2) = SVI X (LV systolic pressure (mm Hg) - LVEDP (mm Hg) X 
0.014348 (Saksena, 1983) 
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Postischemic values were then expressed as a percentage of each individual 
preischemic control, and the same statistical tests as previously described in this 
section were used. 
For statistical comparisons of SWI left ventricular function curves, the SWI at each 
left atrial filling pressure was expressed as a percentage of the stroke work achieved 
in the preischemic control curve for each individual animal. Mean percentages and 
standard errors of mean percentages were then compared by ANOV A. However, for 
display purposes an average preischemic control left ventricular function curve was 
derived by pooling the data from all control function curves. Postischemic function 
curves for each group were then normalized to the average preischemic curve; by 
multiplying the mean percentage recoveries and their standard errors for each 
group, at each left atrial filling pressure from O - 20 cm H20, by the average control 
SWI at the corresponding pressure. 
The volume of cardioplegic solution administered to each animal (15 ml/kg) was 




HYPOTHESIS UNDER TEST 
3.1. Adenosine in intraoperative myocardial protection 
Because of its ability to attenuate ischemia induced damage, adenosine - a 
physiologic purine compound nucleoside - has stimulated renewed interest in the 
context of induced or spontaneous myocardial ischemia. 
The initial idea was to use adenosine as an alternative cardioplegic agent or as an 
adjunct to high potassium cardioplegic solutions in order to achieve fast arrest and 
improved postischemic myocardial function. During pilot studies we had found that 
adenosine in high concentration was able to achieve fast electromechanical cardiac 
arrest in the isolated rat heart. At that time there were only a few studies using 
adenosine as adjunct to high potassium, showing an improvement in postischemic 
recovery. However, no study had used adenosine for induction of cardioplegic 
arrest. 
3.2. Aim of the study 
The objective of the present study was to test the anti-ischemic properties of 
adenosine in intraoperative myocardial protection. Two animal models were 
developed: 
1. The isolated rat heart model as a preclinical screening model to test the 
hypothesis, and 
2. A large animal model in the in-vivo primate as a clinically orientated model to 
verify the findings in the expectation of clinical application. 
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In both models the two potentially important factors for intraoperative myocardial 
preservation were to be investigated. 
1. Is adenosine a cardioplegic agent on its own without high potassium, by virtue of 
its inhibition of the SA and AV nodes? 
2. Can adenosine on its own or in conjunction with high potassium improve 
myocardial preservation during global, hypothermic ischemia as measured by 
hemodynamic, biochemical and ultrastructural recovery? 
A further aim was to elucidate at least some of the mechanisms by which adenosine 
would achieve this aim, although this was not the primary intention of the study. In 
order to achieve this aim adenosine was tested as a cardioplegic agent and as an 
adjunct to high potassium in the isolated rat heart during 30 and 90 minutes of global 
ischemia. 
The in vivo-baboon model was used to first compare different crystalloid cardioplegic 
solutions used clinically in South Africa. The solution giving the best recovery should 
be used as control solution to test the effects of an intervention with adenosine. 
End points of the study were the hemodynamic recovery of the postischemic hearts, 
the biochemical status as measured with ATP and CP levels of the myocardium and 
in some experiments the ultrastructural changes during ischemia and reperfusion. 
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CHAPTER4 
STUDIES IN THE ISOLATED RAT HEART 
4.1. Adenosine vs high potassium to induce cardiac arrest: 
Langendorff and working heart mode 
Rationale 
Adenosine, an endogenous nucleoside, formed mainly as a degradation product of 
ATP, is an intermediate metabolite in many important biochemical pathways and has 
been shown to play an important role in the regulation of a number of physiologic 
processes (Arch, 1987; Drury, 1929; Sparks, 1986). Among its various effects 
adenosine was found to produce bradycardia and atrioventricular block 
(Bellardinelli, 1983; Dobson, 1987). These electrophysiologic properties of adenosine 
have led to its use as potent antiarrhythmic agent for the management of paroxysmal 
supraventricular tachycardias (Belhassen, 1984; Di Marco, 1985; Pelleg, 1986). 
Recent studies showed the beneficial effects of calcium channel blockers on the 
functional recovery of ischemic myocardium (Christakis, 1986; Nayler 1980). As the 
effects of adenosine involve the depression of sinus node automaticity and of 
calcium-mediated slow channel conduction, we investigated the feasibility of 
preserving myocardial function during induced global ischemia by a high dose 
adenosine cardioplegia. The adenosine cardioplegia was compared with potassium 
as well as with a mixture of potassium and adenosine cardioplegia. 
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Experimental procedures, materials and methods 
The experimental procedures, materials and methods used are described in detail in 
chapter 2. 1. 
Perfusion technique 
All experiments were performed on male Sprague-Dawley rats, weighing 250 to 
350 g. The techniques used are described in detail in chapter 2.1. 
Perfusion time sequence 
For hemodynamic stabilization all hearts were perfused by the Langendorff mode for 
10 minutes at first. Afterwards the hearts were converted to the working mode for 
another 10 minutes. Coronary and aortic flow rates were measured by collecting the 
perfusate draining from the hearts. Aortic pressure and ECG were monitored 
continuously by the mean readings from a two channel recorder (Mx 2P-148). 
In the initial pilot study, after infusion of 10 ml of cold (4°C) cardioplegic solution at a 
rate of 2 ml/min, infused over 5 minutes, time for complete electromechanical arrest 
was recorded as well as the number of arrest- and escape beats via the two channel 
recorder. Two sets of experiments were performed: the first set was performed in the 
Langendorff mode, the second in the working heart mode. 
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Perfusion solutions 
Six perfusion solutions were used: [1] standard Krebs-Henseleit buffer (KHB}, [2] 
KHB supplemented with 1 mM/L of adenosine (Boehringer lngelheim), [3] KHB 
supplemented with 10 mM/L of adenosine, [4] KHB containing 20 mM/L potassium, 
[5] KHB supplemented with 20 mM/L potassium and 1 mM/L of adenosine, [6] KHB 
supplemented with 20 mM/L potassium and 10 mM/L of adenosine. 
Tissue analysis 
At the end of the experiments all hearts were freeze-clamped and stored in liquid 
nitrogen. LOH was controlled to exclude myocardial damage prior to ischemia. 
Myocardial contents of adenosintriphosphate (ATP) and phosphocreatine (CP) were 
quantified by high pressure liquid chromatography, using the technique described 
elsewhere (Sollevold, 1986). One further set of hearts was freeze-clamped just prior 




Compared with potassium cardioplegia, adenosine was found to arrest the hearts 
more rapidly. While potassium cardioplegia arrested the hearts within 52 seconds, a 
high dose of adenosine caused arrest within 2.1 (adenosine 1 mM/L) or 1.6 
(adenosine 10 mM/L) seconds (p < 0,001 ). The number of arrest beats were 6 and 7 
for the adenosine versus 168 for the potassium cardioplegia. Escape beats, i.e. 
ventricular contractions after complete cardiac arrest, were not noted with potassium 
cardioplegia but occurred during adenosine arrest. With 10 mM/L adenosine escape 
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beats were fewer compared with 1 mM/L in both groups, with and without potassium 
(Table 4.1.). 
Working heart mode 
In the working heart mode the time of arrest and the number of arrest beats were still 
significantly different between high potassium and adenosine (10 mM/L) 
cardioplegia. Using 10 mM/L of adenosine contractile myocardial function stopped 
within 7 seconds, while in experiments using potassium cardioplegia 63 seconds 
elapsed before complete cardiac arrest. The number of arrest beats was 15 in the 
adenosine versus 125 in the potassium trials (Table 4.2). In the control group cold 
Krebs-Henseleit-Buffer was used as control cardioplegia by virtue of hypothermia 
only. 
TABLE 4.1.: CARDIAC ARREST IN LANGENDORFF PERFUSION 
Cardioplegia Time to arrest Arrest beats Escape beats 
(n = 7) (seconds) 
Adenosine 1 mM 2.1 ± 0.6* 6 ± 1* 11 ± 2* 
Adenosine 1 O mM 1.6 ± 0.3* 7 ± 1* 3 ± 1* 
~20mM 52.0 ± 2.0 168 ± 9 0 
~ 20 mM + Ado 1 mM 9.0 ± 5.0* 16 ± 8* 15 ± 7* 
~20 mM + Ado 10 mM 1.9±0.2* 9 ±2* 4 ± 1* 
Legend: Time to cardiac arrest, arrest and escape beats recorded in the different 
treatment groups in the Langendorff mode 
* p < 0.001, modified t-test, compared to K+ 20 mM 
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TABLE 4.2. CARDIAC ARREST IN WORKING HEART PERFUSION 
Cardioplegia Time to arrest Arrest beats Escape beats 
(n = 7) (seconds) 
Krebs (control) 446 ± 39 640 ± 107 38 ±9 
Adenosine 10 mM 7 ± 1* 15 ± 2* 31 ± 7* 
I< 20 mM 63 ± 12 125 ±27 37 ±24 
Legend: Time to cardiac arrest, arrest and escape beats recorded in three different 
treatment groups in the working heart mode 
* p < 0.05, t-test, compared to K+ 20 mM 
4.2. Short-term global ischemia 
Adenosine as cardioplegic agent and as cardioplegic additive 
Rationale 
As the first study showed significantly shorter times for cardiac arrest induction in the 
adenosine treated hearts, we wanted to test the effect of this accelerated 
electromechanical arrest on hemodynamic recovery after short term global ischemia. 
Experimental procedures, materials and methods 
The experimental procedure used is already described in chapter 2.1 and 4.1. 
Additionally, following infusion of cold (10°C) cardioplegia at 2 ml/min for 3 minutes, 
the cardioplegic solution was washed out with Krebs-Henseleit solution at 2 ml/min 
for 3 minutes, in the groups indicated. Subsequently, a period of 30 min of global 
ischemia at 10°C was started. Reperfusion was initiated with the Langendorff-
perfusion for a 1 O minutes equilibration period followed by 10 minutes in the working 
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heart mode. Functional recovery was assessed by the recovery of aortic flow and the 
heart rate-systolic (mean) pressure-product expressed as a percentage of the 
preischemic value. 
Recovery 
30 min of ischemia at 10 °C 
During the initial experiments adenosine cardioplegic solution (10 mM) was infused 
prior to ischemia in the usual way. These hearts did not improve their recovery 
significantly. Therefore, the adenosine was washed out immediately after infusion 
during the following experiments with an equal amount of Krebs-Henseleit buffer. 
Using this technique two out of three parameters determined for cardiac recovery 
after ischemia showed a maximum in the adenosine group (10 mM). The aortic 
output was 91.1 % while the heart rate-systolic pressure-product exceeded 100 %. 
Recovery in potassium treated hearts was always less compared to adenosine, but 
the differences did not reach significance. The mixture of potassium and adenosine 
showed no constant relation to either group. While the aortic output showed a 
paramount value (93.4 %), the heart rate-systolic pressure-product was only 86.6 % 
(Table 4.3.). 
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TABLE 4.3.: RECOVERY AFTER 30 MIN OF ISCHEMIA AT 10 °C 
Group Aortic output HR X syst. P. HR x mean P. 
(n = 7) % % % 
Krebs 49.4 ± 14.2 72.6 ± 18.8 45.0 ± 11.2 
Adenosine 1 O mM 64.6 ± 15.9 72.7 ± 17.1 71.4 ± 16.3 
Krebs+ 84.6 ± 3.0 * 95.7 ± 3.2* 87,6 ± 5.4 
Ado 10 mM+ 91.1 ± 4.6* 103.0 ± 4.4* 98.0 ± 8.4 
~ 20 mM+ 89.0 ± 5.8 97.1 ±6.8 93.5 ± 15.5 
Ado 10 + ~ 20+ 93.4 ± 2.7 86.6 ±4.3 96.1 ± 9.2 
Legend: Hemodynamic recovery in percent of preischemic values after 30 min of global hypothermic 
ischemia in the different treatment groups with and without washout of adenosine. 
• Cardioplegia wash-out right after infusion with Krebs Henseleit buffer 
* p < 0.01, t-test, compared non-washout to washout 
Energy status 
After cardioplegia, before ischemia 
The comparison of ATP stores showed no significant difference. All mean values 
ranged within the interval of 3.8 and 4.5 µmol/g wet weight, which is nearly identical 
with the pre-ischemic ATP energy storage of 4.1 ± 0.2 µmol/g wet weight. 
Phosphocreatine levels showed higher nucleoside contents for 1 and 10 mM 
adenosine (7.5 ± 0.7/7.1 ± 0.2 µmol/g wet weight) compared with the pre-ischemic 
energy status of 6.6 ± 0.3 µmol/g wet weight, whereas energy stores after potassium 
cardioplegia were depressed to 6.0 ± 0.3 µmol/g wet weight (Table 4.4.). 
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TABLE 4.4. ENERGY STATUS IMMEDIATELY AFTER CARDIOPLEGIA 
INFUSION IN LANGENDORFF EXPERIMENTS PRIOR TO 
ISCHEMIA 
Group ATP PCr 
(n = 7) 
Pre-cardioplegia 4.1 ± 0.2 6.6 ±0.3 
Adenosine 1 O mM 4.0 ± 0.1 7.1 ± 0.2* 
Adenosine 1 mM 4.5 ±0.2 7.5 ± 0.7* 
t< 20 mM 4.2 ± 0.1 6.0 ± 0.3 
Ado. 10 mM + t< 20 mM 3.8 ± 0.4 6.5 ±0.2 
Legend: High energy phosphate content of the myocardium at control stage 
(pre-cardioplegia) and immediately after infusion of cardioplegia. 
Units: µmol/g wet weight 
* p < 0.05, mod. t-test, compared to K+ 20 mM 
30 minutes of ischemia and 20 minutes of reperfusion 
Out of all cardioplegic groups adenosine (10 mM) cardioplegia showed maximal high 
energy phosphates. ATP stores were 4.2 ± 0.1 µmol/g wet weight for adenosine; this 
is better than for potassium (3.8 ± 0.2 µmol/g wet weight). The potassium 
cardioplegia supplemented with adenosine showed even less ATP compared with 
potassium alone (3.3 ± 0.2 µmol/g wet weight) (Table 4.5.). 
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TABLE 4.5.: ENERGY STATUS AFTER 30 MINUTES OF ISCHEMIA AND 20 
MINUTES OF REPERFUSION 
Group ATP PCr 
(n = 7) 
Krebs (KHB) 3.1 ±0.2 4.1 ± 0.4 
Adenosine 10 mM 3.3 ±0.2 5.6 ±0.5 
Krebs+ 4.2 ± 0.1* 5.0 ± 0.4* 
Ado 10 mM+ 4.2 ± 0.1* 5.4 ± 0.2 
I< 20 mM+ 3.8 ±0.2 4.6 ± 0.7** 
Ado 10 + I< 20 mM+ 3.3 ±0.2 4.0 ± 0.3** 
Legend: High energy phosphate content after 30 min of global hypothermic ischemia 
and 20 min of reperfusion in the different treatment groups. 
• Cardioplegia wash-out immediately after infusion with 10 ml of Krebs buffer 
Units: µmol/g wet weight 
* p < 0.05, mod. t-test, compared to KHB 
- p < 0.05, mod. t-test, compared to KHB + washout 
The same findings were observed for phosphocreatine levels. Maximal stores were 
identified for the adenosine group (5.4 ± 0.2 µmol/g wet weight), while potassium 
cardioplegia (4.6 ± 0.7 µmol/g wet weight) was superior to the admixture of 
adenosine and potassium (4.0 ± 0.3 µmol/g wet weight). 
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4.3. Medium-term global ischemia 
Adenosine as cardioplegic agent and as cardioplegic additive 
Rationale 
Since we could only show a trend for improved recovery in the adenosine treated 
hearts after 30 minutes of global ischemia, we extended the time period of ischemia 
to 90 minutes in order to worsen the ischemic insult. 
Experimental procedures, materials and methods 
The experimental procedure has been described in the previous chapter. The only 
modification was the extension of the global ischemic period up to 90 minutes in this 
set of experiments. 
Results 
90 min of ischemia at 10 °C 
As in the experiments comprising 30 minutes of ischemia, adenosine (10 mM) 
cardioplegia showed superior recovery. The heart rate-systolic pressure product was 
calculated as 92. 7 % for the adenosine group while the same parameters for the 
potassium and the potassium-adenosine mixture were 88.0 % and 88. 7 % 
respectively. Aortic output was evaluated as 83.9 % for the adenosine cardioplegia 
while all other groups hardly reached the 75 % recovery level (Table 4.6.). 
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TABLE 4.6.: RECOVERY AFTER 90 MIN OF ISCHEMIA AT 10 °C 
Group Aortic output HR X syst. P. HR x mean P. 
(n = 7) % % % 
Krebs+ 48.0 ± 1.4 * 78.3 ±4.2* 68.8 ± 7.2 
Ado 10 mM+ 83.9 ± 1.3* 92.7 ±2.5- 85.5 ± 4.1 ** 
t< 20 mM+ 75.1 ± 2.5 88.0 ± 4.4 84.2 ± 6.1 
Ado 10 + t<20 mM+ 70.6 ± 3.9 88.7 ± 3.0 79.0 ± 4.7 
Legend: Hemodynamic recovery in % of preischemic values after 90 min of global hypothermic 
ischemia in the different treatment groups. 
+ Cardioplegia wash-out immediately after infusion with of Krebs Henseleit buffer 
* p < 0.05, mod. t-test, compared to K+ 20 mM 
** p < 0.05, mod. t-test, compared to KHB 
Summary of findings 
Adenosine is an intermediate metabolite in many important biochemical pathways. 
This study was designed to investigate the feasibility of preserving myocardial 
function by the cardioprotective properties of adenosine. 
Male Sprague-Dawley rats, weighing 250 to 350 g, were isolated and attached to a 
Langendorff perfusion system. After conversion to the working heart mode various 
cardioplegic agents (adenosine 1 and 10 mM, potassium 20 mM, combination of 
both) were infused. Following 30/90 min of hypothermic (10°C) global ischemia, 
Langendorff and working heart perfusion were started again and hemodynamic 
recovery as well as tissue analyses of ATP and phosphocreatine (PCr) were 
determined. 
Compared with potassium cardioplegia, adenosine was found to arrest the hearts 
more rapidly, i.e. ventricular function stopped within a few seconds. Hemodynamic 
parameters after ischemia (30/90 min) at 10 °C showed superior recovery for 
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adenosine 10 mM. The mixture of potassium (20 mM) and adenosine (10 mM) 
demonstrated no improvement in hemodynamic recovery. Tissue analysis prior to 
ischemia showed no increase of ATP contents, but of PCr levels in the adenosine 
groups (1 and 10 mM). After 30 min of ischemia at 10°C ATP and PCr were best 
preserved in the adenosine group, compared with potassium cardioplegia, but these 
values did not reach statistical significance. 
We conclude that adenosine cardioplegia (10 mM) is suitable and safe for 
preserving myocardial function during induced global ischemia. However, wash out 
of adenosine was necessary to demonstrate this effect. The combination of 
potassium and adenosine however, is less effective than expected. 
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CHAPTERS 
STUDIES IN THE IN-VIVO BABOON MODEL 
5.1. Comparison of cardioplegic solutions used in South Africa 
Rationale 
The primary function of a cardioplegic solution is to halt all myocardial 
electromechanical activity and thereby conserve energy (Hearse, 1983; Lell, 1983). 
This is achieved by manipulating the extracellular concentrations of the major 
cations (sodium, potassium, magnesium, calcium). Myocardial hypothermia, attained 
by infusing the solution into the coronary arteries at a temperature of 4°C, lowers 
energy demands still further (Lell, 1983). Since the use of a hyperkalemic 
cardioplegic solution by Melrose in 1955 (Melrose, 1955), ever increasing numbers 
of formulations are being used experimentally and clinically, thus complicating the 
objective comparison of solutions and reportedly beneficial additives. A vast amount 
of basic research has, however, shown the complex interrelationship of all 
components in a cardioplegic solution and highlighted the need for careful 
experimental assessment before any alterations are made to existing solutions. 
In 1988 a questionnaire was sent to all perfusion technologists registered with the 
South African Society of Cardiovascular Perfusion Technology regarding the 
cardioplegic solution used by their unit. Eighty percent of the questionnaires were 
returned, and this revealed that three hospitals performing cardiac surgery in South 
Africa were using a form of blood cardioplegia whilst a further seven employed 
various formulations of crystalloid cardioplegia. The solution prepared by SABAX 
(SABAX Ltd., Samuel Evans Road, Aeraton, Johannesburg) was used by three units, 
a basic solution of Plasmalyte B plus 30mmol potassium chloride with various 
additives was employed by a further three, and only Groote Schuur Hospital was at 
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that time using a modified Bretschneider solution made up by the hospital 
dispensary (GSH). The composition of each of these solutions is tabulated in Table 
5.1. In principle the St. Thomas' Hospital solution No. 2 relies on a high potassium, 
high magnesium system; the GSH solution on a high potassium, low sodium system 
and the SABAX solution on a high potassium composition. 
Most of these clinically used cardioplegic solutions have, however, never been 
adequately or objectively evaluated, either experimentally or clinically. This study 
was therefore undertaken to compare the efficacy of two crystalloid cardioplegic 
solutions used in this country with an internationally accepted and extensively 
investigated solution, viz. St. Thomas' Hospital cardioplegic solution No. 2 {ST2} 
(Jynge, 1980; Jynge, 1981; Robinson, 1984; Ledingham, 1987). Additionally, a 
solution containing normal extracellular concentrations of the major cations, and 
therefore unable to induce chemical cardiac arrest, was employed as a control in 
order to highlight the effects of cardioplegic solutions as opposed to the beneficial 
effects of hypothermia. The physiologic saline solution, Krebs-Henseleit buffer 
(KHB}, was selected as the control non-cardioplegic solution (Table 5.1). 
The ST2 cardioplegic solution used in this study is the improved St. Thomas' 
Hospital solution No. 2 (Plegisol: Abbott Laboratories, North Chicago, Illinois) and 
not the original St. Thomas' Hospital solution No. 1 (Mac earthy) (Ledingham, 1987). 
This solution has previously been shown in the rat heart to be superior to other 
solutions such as Ringer-lactate solution with added potassium and balanced saline 
solution with glucose and potassium (Robinson, 1984). 
In contrast, SABAX cardioplegia, although used clinically in South Africa, has neither 
been reported to have been experimentally evaluated nor clinically compared to 
other attested solutions. 
The GSH cardioplegic solution was originally based on the initial Bretschneider's 
solution which was formulated with an "intracellular" concentration of electrolytes, 
specifically sodium (Jynge, 1978). Over the years our GSH solution was altered 
without any reported experimental or clinical trials, resulting in the composition 
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indicated in Table 5.1. The Bretschneider's HTK-4 solution in clinical use in Europe 
today differs greatly from both our GSH solution and the original Bretschneider 
solution. 
Experimental procedures, materials and methods 
Materials and methods used are described in detail in chapter 2.2. 
Crystal/aid cardiop/egic solutions tested 
The composition of the tested solutions is given in table 5.1. The ST2 cardioplegic 
solution and the control non-cardioplegic solution KHB were prepared in the 
laboratory and filtered through a 0,8 µm filter to remove any bacteria and particulate 
matter. The SABAX solution was kindly donated by SABAX Ltd., South Africa. The 
GSH solution was the standard solution made by the hospital pharmacy at Groote 
Schuur Hospital. 
Groups : Four different solutions were tested : Group ST2: St. Thomas' Hospital 
solution No.2 (n=8) , SBX: Sabax cardioplegic solution (n=?), GSH: Groote Schuur 
Hospital cardioplegic solution (n=?), KHB: control group treated with Krebs-
Henseleit-buffer solution (n=?). Plasmalyte B was not evaluated in this study. 
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TABLE 5.1: CRYSTALLOID CARDIOPLEGIC SOLUTIONS USED IN SOUTH 
AFRICA (mM/L) 
Na K Ca Mg HC03 Glucose Mannitol Osmolarity 
ST2 120 16 1.2 16 10 +300 
SA8AX 141 24/12** 0.9 1.5 38 51 68 - ** ±,450/432 
GSH 15 20 1.0 12 15 240 14 ±_350 
Pl 8(1) 140 34 1.5 37 56 ±_400 
Pl 8(2) 130 34/14* ±,0.4* 1.5 27 ±.4* ±_330 
Pl 8(3) 130 34 1.5 27 ±_370 
KH8-buffer 143 5.9 1.25 1.2 25 11 +300 
Legend: ST2 - St. Thomas' Hospital cardioplegic solution No. 2 
Results 
SABAX - Cardioplegic solution available from SABAX Limited, Aeroton, Johannesburg 
GSH - Cardioplegic solution previously used at Groote Schuur Hospital, Cape Town 
Pl B - Cardioplegic solution made up by the addition of 30 mM KCI, and additional 
sodium bicarbonate to 1 liter of Plasmalyte B solution in Pl 8(1) 
KHB - Krebs-Henseleit physiological buffer solution used as a non-cardioplegic control 
solution 
* - The maintenance cardioplegia has only 10 mM KCI added in addition to 200 ml 
pump blood per 800 ml crystalloid solution. This would thus change the solution 
from a calcium-free solution to one with an approximate calcium content of 
0.4 mM/L and approximate glucose concentration of 4 mM/L. 
** - In the maintenance cardioplegia the potassium concentration is diminished to 
12 mM/L. 
The myocardial hypothermia produced by the above experimental protocol was 
uniform in all animals. Ventricular septa I temperature consistently fell to 10°c with 
each infusion of cardioplegic solution. The myocardium then rewarmed to 
approximately 20°C in the 30 minutes between each reinfusion. 
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Hemodynamic recovery 
Since there were no differences between hemodynamic recovery at 5 minutes and at 
30 minutes, as determined by two-way analysis of variances, only the functional 
recovery at 30 minutes is presented in Table 5.2. 
Functional recovery as assessed by SVI in the ST2 group was 113.9% ± 8.3, which 
was superior to all the other solutions: SABAX 81.4% ± 7.8 (p ~ 0.05); GSH 80.2% ± 
6.0 (p ~ 0.05) and KHB buffer 55.6% ± 10.0 (p ~ 0.01 ). The recovery of Cl and SWI 
of the ST2 treated animals, 95% ± 5.8 and 97.1 % ± 12. 7 respectively, was 
significantly improved when compared to GSH (73.6% ± 3.0, 51.9% ± 2.5) (p < 0.05) 
and KHB (59.9% ± 9.9 (p < 0.05), 34.9% ± 9.2, (p < 0.01 )). However, Cl and SWI for 
ST2, although higher than SABAX treated animals (84.3% ± 5.8, 71. 7% ± 14.0), was 
not statistically different. 
However, when comparing the functional recovery (SVI, Cl, SWI) of SABAX to GSH 
cardioplegia or KHB buffer, hearts treated with SABAX cardioplegia were not 
superior to either the KHB control solution or the hearts perfused with the GSH 
cardioplegic solution. 
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TABLE 5.2: HEMODYNAMIC RECOVERY (PERCENTAGE OF PRE-ISCHEMIC 
CONTROL) OF BABOON HEARTS AT 30 MINUTES AFTER 
RELEASE OF AORTIC CROSS-CLAMP 
n Cl SVI SWI LVdP/Dt 
ST2 8 94.75 5.81 113.95 + 8.30 97.14 ±12.68 87.00 ±12.39 
SBX 7 84.30 ± 5.79 81.35 ± 7.84 * 71.67 ±14.03 83.96 ±10.22 
GSH 7 73.58 ± 3.01 * 80.21 ± 6.02 * 51.91 ± 2.52 * 71.43 + 6.49 
KHB 
Legend: 
7 59.86 + 9.93 * 55.61 +1 o.oo** 34.98 ± 9.24 ** 54.72 + 6.82 
ST2 - St. Thomas' Hospital cardioplegic solution No. 2 
SBX - Cardioplegic solution obtainable from SABAX Limited (Aeroton, Johannesburg) 
GSH - Cardioplegic solution previously used at Groote Schuur Hospital, Cape Town 
KHB - Krebs-Henseleit non-cardioplegic physiological solution 
The percentage recovery of Cardiac Index (Cl}, Stroke Volume Index (SVI), first derivative 
of left ventricular developed pressure (LV dp/dt) and Stroke Work Index (SWI) compared to 
the pre-ischemic control, were obtained at 30 minutes after termination of cardiopulmonary 
bypass at a left atrial pressure of SmmHg, following a 3-hour ischemic period. The hearts 
were protected with the different solutions delivered every 30 minutes at 4°C during this 
period in addition to topical cold saline. 
* p s 0.05 vs ST2 
** p s 0.01 vs ST2 
Left ventricular (LV) function curves were determined at the end of the experimental 
protocol in some animals. The SWI was measured at different preloads by varying 
the left atrial pressure between 5 mm Hg and 20 mm Hg (Figure 5.1. ). The post-
ischemic L V function curve of hearts perfused with ST2 cardioplegia approximated to 
the basal pre-ischemic LV function curve measured in some animals prior to the 
3-hour ischemic period. This finding was in contrast to the depressed post-ischemic 
curve for hearts protected with GSH cardioplegia or KHB buffer. This technique was 
not available for the animals treated with SABAX-solution due to technical reasons. 
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Legend: Post-ischemic LV function of hearts protected during a 3-hour ischemic period with St. 
Thomas Hospital cardioplegic solution No. 2 (-0-), Groote Schuur Hospital cardioplegia 
(-A-), or Krebs-Henseleit non-cardioplegic physiological buffer (-•:•-) compared with a pre-
ischemic control LV function curve(-•-). LV function assessed as stroke work index (SWI) 
was measured at 30 minutes after termination of cardiopulmonary bypass at a varying left 
atrial pressure (LAP). For hearts treated with SABAX solution (-0-) SWI was only measured 
at LAP of 5 mmHg. Values are expressed as means (g/min/m2/beat) and standard error of 
the means. 
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Recovery of high energy phosphates 
The ATP and CP content of all hearts decreased during the 3-hour ischemic period 
despite maintenance doses of cardioplegic solution (Table 5.3). This loss of ATP 
was not different between the various groups. However, after releasing the aortic 
cross clamp there was a marked post-ischemic recovery of high energy phosphate 
levels. The ATP content 5 minutes post-cardiopulmonary bypass for hearts treated 
with ST2 was slightly better at 3.09 ± 0.45 (µmol/g wet weight) in comparison to 
those perfused with SABAX (2.58 ± 0.5), GSH (2.77 ± 0.5) and KHB (2.23 ± 0.34), 
but not statistically different. Also at 30 minutes post-bypass there was no difference 
in the ATP content between any of the solutions (Table 5.3a.). 
The CP levels at 5 minutes and 30 minutes post-bypass were similar in all groups. 
Levels in the ST2 treated hearts (6.8 ± 0.8 (5min) / 6.1 ± 4.0 (30 min) (µmol/g)) 
showed no statistical difference compared to hearts perfused with SABAX 
(4.9 ± 0.7 / 3.9 ± 0.7) and GSH solution (4.6 ± 1.0 I 5.2 ± 1.0). In addition, at 5 and 
30 minutes, the CP content of the non-cardioplegic KHB-treated hearts was not 
lower than with any of the cardioplegic solutions (Table 5.3b.). 
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TABLE 5.3. HIGH ENERGY PHOSPHATE PRESERVATION 
TABLE 5.Ja.: ATP (µMOL/G WET WEIGHT) 
Control ACC 5' 30' 
ST2 4.08 .±. 0.49 2.68 .±. 0.23 3.09 .±. 0.45 2.57 + 0.33 
(5) (5) (5) (5) 
SBX 3. 78 .±. 0.50 2.98 .±. 0.45 2.58 .±. 0.51 2.40 .±. 0.20 
(5) (5) (5) (5) 
GSH 3. 75 .±. 0.35 3.24 .±. 0.45 2. 77 .±. 0.49 2.86 + 0.53 
(7) (7) (7) (4) 
KHB 3.89 .±. 0.28 1.92 + 0.21 2.23 .±. 0.34 2.11 :!."_0.54 
(7) (5) (7) (7) 
TABLE 5.Jb.: CP (µMOL/G WET WEIGHT) 
Control ACC 5' 30' 
ST2 6.59 .±. 0.97 1.98 .±. 0.53 6. 78 .±. 0.80 6.10 .±. 0.36 
(5) (5) (5) (3) 
SBX 7.32 .±. 0.84 2.50 .±. 0.74 4.88 .±. 0.67 3.90 + 0.74 
(5) (5) (5) (5) 
GSH 7.18 .±. 0.65 1.43 .±. 0.44 4.61 .±. 0.96 5.21 .±. 0.96 
(7) (7) (7) (4) 
KHB 6.81 .±. 0.46 0.49 .±. 0.27 5.69 .±. 0.88 5.76 + 0.52 
(7) (5) (7) (7) 
Legend: Adenosine Triphosphate (ATP)(Table-5.3a.) and Creatine Phosphate (CP) (Table-5.3b.) 
content expressed as a mean µmoles/g wet weight of myocardial tissue and standard error 
of the mean. Measurements were taken prior to commencement of cardiopulmonary bypass 
(control), prior to the release of the aortic cross clamp (ACC) after a 3-hour ischemic period, 
at 5 minutes and at 30 minutes after termination of cardiopulmonary bypass. The number of hearts (n) for each mean is given in parentheses. 
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Ultrastructure 
Only a limited number of samples have been assessed so far. All groups showed 
mild to moderate changes in the subendocardial region after 3 hours of ischemia 
(Figure 5.2a.); these were partially reversible after reperfusion (Table 5.4.). An 
example of the changes at the end of ischemia is shown in Figure 5.2a. and the 
ultrastructural appearance after one hour of reperfusion in Figure 5.2b .. 
TABLE 5.4.: ULTRASTRUCTURAL PRESERVATION OF MYOCARDIUM 
BEFORE AND AFTER PROTECTION WITH CARDIOPLEGIC 
SOLUTIONS USED IN SOUTH AFRICA 
Time Group Cristae Dense Glycogen 
granules Loss 
PRI ST2 (n=2) 0 0 0 
0 0 0 
PRI GSH (n=2) 0 1 0 
0 0 1 
PRI SBX (n=2) 0 1 0 
0 0 0 
EOI ST2 (n=2) 2 1 3 
1 1 0 
EOI GSH (n=2) 2 2 1 
1 1 0 
EOI SBX (n=2) 3 1 0 
1 1 0 
RPS ST2 (n=2) 1 1 0 
1 1 0 
RPS GSH (n=2) 0 1 0 
1 0 0 
RPS SBX (n=2) 0 2 0 
0 1 0 
Legend: The myocardial biopsy samples from the left ventricular apical area were 
scored according to a semiquantitative scoring system: 0 = normal, 1 = 
mild abnormality, 2 = moderate abnormality, 3 = severe abnormality. 
PRI: Preischemia, EOI: End of ischemia (180 min), RPS: After 1 hour of 
reperfusion. 
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Figure 5.2.a Ultramicroscopical appearance of portion of a myocyte from a baboon heart after 
perfusion with Sabax-CP solution following an ischemic crossclamp period of 180 
minutes. There is evidence of swelling of the mitochondria with an abnormal crystal 
arrangement and intracytoplasmic edema. 
(Electron photomicrograph x 51000). 
Figure 5.2.b Relatively normal appearance of mitochondria is evident in this myocyte from a baboon 
heart which has undergone 3 hours cardiac arrest and perfusion with Sabax-CP 
solution followed by 1 hour reperfusion with blood . 
(Electron photomicrograph x 51000). 
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Comparison of time to induce cardiac arrest and ref unction time 
Comparison of the time intervals taken by each solution to induce complete cardiac 
arrest revealed no statistical difference, and all solutions stopped electromechanical 
activity within 8-11 seconds (ST2: 8.3 ± 1.4 seconds, SABAX: 10. 7 ± 2.5 seconds 
and GSH: 7.9 ± 1.9 seconds) (N.S.) (Figure 5.3.).The average time to wean the 
animals off CPB, which is also referred to as "refunction time" and which is 
considered to be an index of myocardial protection (Sondergaard, 1967), was 
longest for GSH with 9.4 ± 3.9 minutes. Animals in the SABAX group had a mean 
refunction time of 6.9 ± 1.8 minutes compared to 4.6 ± 1.3 minutes in the ST2 group 
(Figure 5.4.). 
Defibrillation energy 
Additionally the average energy required to cardiovert the hearts back to sinus 
rhythm post-ischemia (defibrillation energy) was highest in the SABAX group 
(85.7 ± 23.8 joules) (p :s: 0.05 vs ST2), whereas animals in the GSH and ST2 groups 
required 34.3 ± 15.9 and 38.8 ± 6.7 joules respectively (Figure 5.5.). 
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FIGURE 5.5.: COMPARISON OF DEFIBRILLATION ENERGY 
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Legend: ST2: St. Thomas' Hospital solution No. 2 (n=8) 
SBX: Sabax cardioplegic solution (n=7) 
GSH: Groote Schuur Hospital solution (n=7) 
Electrocardiographic criteria 
a): p ~ 0,05 vs ST2 
[J]: Joules 
Transient ST-segment elevations in the post-ischemic ECG recordings were 
observed in all groups (4/7 cases for the GSH solution, 4/7 cases for the SBX 
solution and 4/8 cases for the ST2 solution). New Q waves were not discernible in 
any of the cardioplegic groups. All animals of the SBX treated group recovered in 
normal sinus rhythm after defibrillation. Of the hearts treated with GSH solution, one 
remained in atrial fibrillation, whereas in the group treated with ST2, one heart 
recovered with multiple unifocal ventricular extrasystoles for several minutes 
(Table 5.5.). 
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TABLE 5.5.: ECG CRITERIA POST ISCHEMIA 
GSH (n=?) SBX {n=?) ST2 (n=8) 
ST-elevation 4 4 4 
New Q-wave 0 0 0 
NSR 4 7 6 
Atrial Fibrillation 1 0 0 
AV-Block 0 0 1 
Ventricular ectopics 1 0 1 
Legend: GSH: Groote Schuur Hospital solution; SBX: SABAX solution; ST2: St. Thomas' Hospital 
solution No. 2. NSR: Normal sinus rhythm. ST-segment elevation was transient in all 
animals and disappeared during the 30 minutes reperfusion phase. Atrial fibrillation 
observed in one animal in the GSH group was successfully cardioverted via direct 
countershock treatment. AV-block of 3rd degree recorded in one animal was gradually 
improved during reperfusion; at the end of 30 minutes reperfusion only 1st degree AV-block 
was present. Ventricular ectopics recorded in two animals were unifocal and subsided during 
the first ten minutes of reperfusion. Serum potassium concentrations were in the normal 
range. 
Summary of findings 
Cardioplegic solutions are routinely used to arrest and protect the myocardium 
during open heart surgery. Most of the hospitals performing cardiac surgery in South 
Africa employ various crystalloid cardioplegic solutions as opposed to blood 
cardioplegia. In this report we compare the locally manufactured cardioplegic 
solution (obtainable from Sabax Ltd.) and a modified Bretschneider's solution 
previously employed at Groote Schuur Hospital with the current international 
standard, the St. Thomas' Hospital cardioplegic solution No.2. 
Chacma baboon hearts were subjected to a 3-hour in vivo ischemic period during 
which the myocardium was protected with each of these cardioplegic solutions. In 
this model, the post-ischemic functional recovery of hearts protected with the 
St. Thomas' Hospital cardioplegic solution No.2 was superior. There was a trend 
towards better maintenance of high energy phosphates in the hearts treated with St. 
Thomas' Hospital cardioplegic solution No. 2. 
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5.2. Adenosine as adiunct to a non-cardioplegic solution 
Rationale 
Cardioplegic solutions are routinely used to arrest and protect the myocardium 
during open-heart surgery. The common component of most cardioplegic solutions is 
a high concentration of potassium, which is intended to induce fast 
electromechanical arrest by depolarization of membranes (Buckberg, 1987). 
Membrane depolarization during ischemia has disadvantageous effects on energy 
metabolism and increases calcium influx. More recently, Ferguson (Ferguson, 1986) 
reported continuing low amplitude electrical activity during potassium cardioplegia. 
We therefore tested the hypothesis that adenosine, a high energy phosphate 
precursor which has been shown to induce fast cardiac arrest and to improve post-
ischemic hemodynamic recovery in an isolated rat heart model (chapter 4) 
(Schubert, 1989; De Jong, 1990), might 
1. act as cardioplegic agent by hyperpolarization of membranes. 
2. improve post-ischemic hemodynamic recovery. 
We employed an in vivo baboon model, closely resembling the clinical situation, to 
test this hypothesis. 
Experimental procedures, materials and methods 
Materials and methods are described in detail in chapter 2.2. 
In order to determine the hemodynamic and high energy phosphate recovery after a 
prolonged period of global cardiac ischemia, Chacma baboons weighing 13-28 kg 
were subjected to three hours of cardiac arrest protected by three different solutions 
(Table 5.6.). 
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Group I (n=8) received St. Thomas Hospital solution No. 2 {ST2), Group II (n=?) 
Krebs-Henseleit Buffer (KHB) and Group Ill (n=8) was treated with 10 mM adenosine 
in KHB for induction and plain KHB for maintenance. Adenosine was dissolved in 
KHB for this purpose. 
TABLE 5.6.: COMPOSITION OF SOLUTIONS TESTED. 
mMI/L ST2 ADO KHB 
Glucose 11.1 11.1 
Adenosine 10 
+ 
Na 120 133 133 
+ 
K 16 6 6 
Ca 
2+ 
1.2 1.25 1.25 
2+ 
16 1.2 1.2 Mg 
HC03- 10 25 25 
Legend: ST2: St. Thomas' Hospital Solution No. 2 
ADO: Adenosine (1 OmM) in Krebs-Henseleit Buffer 
KHB: Krebs-Henseleit Buffer 
Results 
Comparison of time to induce cardiac arrest, refunction time and total defibrillation 
energy: 
Comparison of the time intervals taken by each solution to induce complete arrest 
showed a shorter period for ST2 (8.3 ± 1.4 sec) when compared to ADO (55.0 ± 5.6 
sec) (p s 0.001) and KHB (80.0 ± 5.4 sec) (p s 0.001) (Figure 5. 7. ). 
The average time to wean the animals off CPB, which is also referred to as 
refunction time and which is considered to be an index of myocardial protection, was 
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longest for KHB treated animals (13.2 ± 3.7 min) in comparison to ST2 (4.6 ± 1.3 
min) (p < 0.05) and ADO (5.1 ± 1. 7 min) (N.S.) (Figure 5.8.). 
Defibrillation energy required to reverse the hearts back to sinus rhythm 
postischemia was lowest for the ST2 treated groups (50,0 ± 15,0 joules) compared 
to KHB (250,0 ± 45,0 joules) (p.:: 0.001). ADO treated hearts required 140,07 ± 67,3 
joules (Figure 5.9.). 
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Legend: ST2: St. Thomas' Hospital solution No 2 (n=8) 
ADO: Adenosine 10 mM in ST2 (n=8) 
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FIGURE 5.8.: COMPARISON OF REFUNCTION TIME 
30 -
..... 20 -
C ·-E .... 
10 -
I 
:x C) xx J()( 
>Ox >O ~~~ ~S<'. X 
'V 'Y 00 0 
ST2 ADO 
Legend: ST2: St. Thomas' Hospital solution No 2 (n=8) 
ADO: Adenosine 10 mM in ST2 (n=8) 
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FIGURE 5.9.: COMPARISON OF DEFIBRILLATION ENERGY 
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Legend: ST2: St. Thomas' Hospital solution No 2 (n=8) 
ADO: Adenosine 10 mM in ST2 (n=8) 






p ~ 0,001 vs ST2 
Joules 
FIGURE 5.10.: ECG RECORDING OF INDUCTION OF CARDIAC ARREST FOR 
THE THREE DIFFERENT TREATMENT GROUPS 
~·~ ... --,--+l~l --:-t-f'-1 ~.......;.-+i""'I, 
I 
Legend: ADO: adenosine 10 mM in KHB; KHB: Krebs Henseleit buffer ; ST2: St. Thomas' Hospital cardioplegia No. 2. Vertical arrows indicate the start of cardioplegic infusion; bold vertical lines indicate 1 second intervals. Fast electrical arrest is recorded with adenosine cardioplegia within 1.5 seconds with only two arrest beats. However, there are several escape beats in this recording and soon after termination of the registration the hearts regularly started with ventricular fibrillation . In the recording of an KHB treated animal unmodified electrical activity is seen until hypothermia causes arrest. High potassium solutions as ST2 cause fast arrest, within 6 seconds in this recording. After two normal beats, two deformed complexes are recorded and for about two seconds ongoing atrial electrical activity is present until complete arrest is achieved. No ventricular escape beats and no ventricular fibrillation are seen in hearts treated with ST2. 
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Hemodynamics 
No differences between hemodynamic recovery at 5 and at 30 minutes within each 
group after termination of cardiopulmonary bypass were discernible by two way 
analysis of variance. Therefore, only the functional recovery at 30 minutes is 
presented (Table 5.6.). 
Functional recovery 30 minutes after termination of CPS as assessed by Cl and SVI 
was significantly better for the ST2 and ADO treated hearts than in the KHS control 
(Table 5.6). Left ventricular dP/dt was best for ST2 (87.0 ± 12.4 %) and ADO (73.1 ± 
9.9 %) in comparison to KHS (54.7 ± 6.8 %) although this did not reach statistical 
significance (Table 5.6.). 
High energy phosphate recovery 
The ATP and CP content of all hearts decreased during the three hour ischemic 
period despite maintenance doses of cardioplegic solution. ATP was well preserved 
in the ADO group (103.5 % ± 21.1) in comparison to KHS (48.5 % ± 8.7) and ST2 
(67.9 % ± 9.3), but not statistically different 30 minutes after termination of CPS 
(Table 5.6.). CP recovery was also not different between the three treatment groups 



































































































































































































































































































































































































Initial analysis of cardiac ultrastructure showed mild to moderate changes in 
mitochondrial structure in all treatment groups at the end of ischemia. After 
reperfusion, only adenosine-treated hearts showed a normal ultrastructural 
appearance, whereas residual changes remained in the other groups (Table 5.7.). 
TABLE 5.7.: ULTRASTRUCTURAL PRESERVATION OF MYOCARDIUM 
BEFORE AND AFTER PROTECTION WITH THREE DIFFERENT 
CARDIOPLEGIC SOLUTIONS 
Time Group Cristae Dense Glycogen 
granules Loss 
PRI ST2 (n=2) 0 0 0 
0 0 0 
PRI ADO (n=2) 0 1 0 
0 0 0 
PRI KHB (n=2) 0 1 1 
0 0 0 
EOI ST2 (n=2) 2 1 3 
1 1 0 
EOI ADO (n=2) 0 0 0 
0 1 0 
EOI KHB (n=2) 2 0 0 
3 0 0 
RPS ST2 (n=2) 1 1 0 
1 1 0 
RPS ADO (n=2) 0 0 0 
0 1 0 
RPS KHB (n=2) 0 0 0 
3 2 0 
Legend: The myocardial biopsy samples from the left ventricular apical area were 
scored according to a semiquantitative scoring system: 0 = normal, 1 = mild 
abnormality, 2 = moderate abnormality, 3 = severe abnormality. PRI: 
Preischemia, EOI: End of ischemia (180 min), RPS: After 1 hour of 
re perfusion. 
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Summary of findings 
Hyperkalemia-induced hypopolarization of the sarcolemmal membrane during 
standard crystalloid cardioplegic arrest potentiates calcium influx during ischemia 
and reperfusion and is associated with depletion of high energy phosphate reserves. 
Adenosine has been shown to induce rapid cardiac arrest whilst preserving 
membrane hyperpolarization in an isolated rat heart model (Schubert, 1989). In this 
study we compared the efficacy of adenosine, both as an arresting agent and as an 
ultrastructural, hemodynamic and high energy phosphate preserving agent, in an in 
situ global ischemia model in the baboon with St. Thomas' Hospital No. 2 solution 
(ST2)(n=8) and with Krebs-Henseleit buffer (KHB)(n=7). The addition of 10 mM/L 
adenosine to the non-cardioplegic KHB (ADO)(n=8) improved hemodynamic 
recovery significantly in terms of cardiac index (91.6% ± 7.2 vs 59.9% ± 9.9) and 
stroke volume index (101.6% ± 8.9 vs 55.6% ± 10.0) and was not statistically 
distinguishable from the ST2 with regard to cardiac index (91.6% ± 7.2 vs 94.8% ± 
5.8), stroke volume index (101.6% ± 8.9 vs 114.0% ± 8.3) or left ventricular dP/dt 
(73.1% ± 9.9 vs 87.0% ± 12.4). However adenosine did not induce rapid complete 
electromechanical arrest in this model. Comparison of the time intervals taken by 
each solution to induce complete arrest showed a shorter period for ST2 (8.3 ± 
1.4 sec) when compared to ADO (55.0 ± 5.6 sec) (p :::; 0.001) and KHB (80.0 ± 
5.4 sec) (p:::; 0.001). ATP was best preserved with ADO (103.5% ± 21.1 vs 67.9% ± 
9.3 and 48.5% ± 8.7) although this was not statistically significant. This suggests 
therefore that the mechanism of cardioprotection by adenosine depends on factors 
other than its role as high energy phosphate precursor or fast arresting agent. 
136 
5.3. Adenosine as adjunct to St. Thomas Hospital solution 
Rationale 
There are several studies in experimental models of myocardial ischemia showing 
the effect of exogenous adenosine on prevention of endogenous breakdown and on 
the preservation of ATP, but reports on functional recovery are few (Bolling, 1989; 
Bolling, 1990). This is especially important since recent evidence suggests no direct 
correlation between high energy phosphate content at the end of ischemia and 
functional recovery during reperfusion (Hohlfeld, 1989). Furthermore there has been 
only one report in an isolated rabbit heart model concerning the optimal 
concentration of adenosine (Bolling, 1990). Obviously the optimal dose will be 
important because in suboptimal concentration adenosine will be unable to exert its 
beneficial properties, whereas in an excessive concentration unwanted side effects, 
such as negative chronotropy or renal vasoconstriction will be more predominant 
(Belhassen, 1984; Spielman, 1987). 
All the above mentioned properties might render adenosine an ideal cardioplegic 
substance, but as we have previously shown ( see chapter: Adenosine as adjunct to 
a non-cardioplegic solution), it does not act as a cardioplegic agent in an in-vivo 
baboon model via its inhibitory action on SA and AV conduction. This finding is at 
variance with an experimental study in the isolated rat heart (Schubert, 1989). But 
even while it failed to inhibit ventricular fibrillation, with adenosine as adjunct to a 
non-cardioplegic solution such as Krebs-Henseleit-Buffer (KHB) myocardial 
protection was significantly improved and was as effective as the protection 
achieved with St. Thomas' Hospital Cardioplegia No 2, whereas recovery with KHB 
alone was poor. We have previously shown ( see chapter: Comparison of 
cardioplegic solutions used in South Africa), that compared with various crystalloid 
cardioplegic solutions St. Thomas' Hospital No.2 cardioplegia resulted in the best 
recovery in the same model. 
137 
The objective of the present study was to assess the potential benefits of adenosine 
on functional and metabolic recovery as an adjunct to a high potassium cardioplegic 
formulation such as the St. Thomas' solution No 2 and to optimize the dose. We 
employed an in-vivo baboon model closely resembling the clinical setting in hearts 
undergoing an extended period of hypothermic global ischemia. 
Experimental procedures, materials and methods 
Materials and methods are described in detail in chapter 2.2. 
Treatment Groups 
Group I (n=7) received St. Thomas' solution No. 2 (ST2}, Group II (n=6) ST2 with 
adenosine 0.1 mM/L, Group Ill (n=9) ST2 with adenosine 1.0 mM/L and Group IV 
(n=4) ST2 with adenosine 10 mM/L. 
Adenosine was added for induction cardioplegia as well as for maintenance 




Mean hemodynamic recovery, as expressed by cardiac index, stroke volume index, 
stroke work index and minute work index, was best in hearts perfused with 
St. Thomas' Hospital cardioplegic solution No.2 modified with 1 mM adenosine 
(Group Ill) (Table 5.8.). Recovery of these parameters was 100% or more in this 
group, whereas recovery was not so good in the remaining groups: Recovery of 
cardiac index was 115.6% ± 8.6% in Group Ill vs 87.5% ± 8.2% in Group I, 89.9% ± 
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8.75% in Group II and 62.9% ± 7.25% in Group IV. There was a similar distribution 
of recovery for the derived parameters stroke volume index (SVI) and stroke work 
index (SWI) (Table 5.8.). There were no changes in the above parameters when 
measured at 30 minutes compared to the 5 minute measurement (Cl: 80.3% ± 5.7% 
(Group I), 77.4% ± 7.6% (Group II), 106.5% ± 10.5% (Group Ill) and 61.7% ± 9.3% 
(Group IV) (Table 5.8.). 
Left ventricular dP/dUDP recovery at 5 minutes was 111.4% ± 4.6% for group I, 
101.0% ± 4. 7% for group II, 100.4% ± 3.9% for group Ill and 95.8% ± 6.5% for group 
IV (p< 0.05 vs group I) (Table 5.8.). 
Left ventricular function assessed by volume loading at 30 minutes revealed 
adequate recoveries for 1 mM Ado and ST2 compared to depressed function 
obtained for 1 OmM/L Ado, whereas the hearts treated with ST2 and ST2 + 0.1 mM/L 
Ado showed intermediate recovery (Figure 5.11 ). 
FIGURE 5.11.: LEFT VENTRICULAR FUNCTION CURVES FOR THE 
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Legend: Normalized percentage recovery to an integrated preischemic control of 
the four different treatment groups (as described in chapter 2.2.). The 
group treated with 1 mM adenosine approximates the preischemic control 
best. Inferior recovery is calculated for the group treated with 1 OmM 
adenosine, whereas the groups with OmM and 0, 1 mM adenosine show 
intermediate recovery of ventricular function. 
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Calculated systemic vascular resistance indices (SVRI) showed statistical 
differences between group I and Ill at 5 minutes reperfusion : 112.0% ± 15% for 
group I compared to 73.0% ± 6.2% for group Ill (p< 0.05) (Table 5.8.). 
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OmM 0.1 mM 1 mM 10 mM 
3.15 3.08 2.17 2.96 N.S. 
±0.50 ±0.29 ±0.17 ±0.30 
n=7 n=6 n=9 n=4 
87.50 89.92 115.63 62.90 a,b,c 
±8.18 ±8.75 ±8.57 ±7.25 
n=6 n=6 n=9 n=4 
80.34 77.42 106.49 61.69 d,e 
±5.68 ±7.58 ±10.52 ±9.34 


























27.19 29.14 20.10 28.22 N.S. 
±4.38 ±3.42 ±1.93 ±3.38 
n=7 n=6 n=9 n=4 
86.65 79.89 102.23 68.65 C 
±9.00 ±4.70 ±6.72 ±7.78 
n=6 n=6 n=9 n=4 
86.96 77.58 107.12 69.16 d,e 
±9.76 ±5.18 ±11.38 ±16.50 
n=7 n=6 n=9 n=4 
40.07 49.29 29.51 39.99 N.S. 
±7.42 ±7.14 ±4.29 ±10.99 
n=7 n=6 n=9 n=4 
80.16 67.16 99.87 50.89 C 
±7.95 ±6.21 ±15.05 ±10.64 
n=6 n=6 n=9 n=4 
83.05 62.08 105.40 54.45 c,d 
±6.81 ±4.60 ±17.09 ±17.04 
n=7 n=6 n=9 n=4 
9.42 9.97 9.96 8.98 N.S. 
±0.32 ±0.58 ±0.43 ±0.48 
n=7 n=6 n=9 n=4 
111.37 100.97 100.39 95.76 f 
±4.58 ±4.65 ±3.88 ±6.45 
n=6 n=6 n=9 n=4 
104.35 94.09 98.85 96.29 N.S. 
±4.18 ±4.11 ±3.80 ±11.95 






117.36 108.62 110.67 105.75 N.S. 
±5.19 ±8.63 ±6.14 ±3.25 
n=7 n=6 n=9 n=4 
102.42 112.46 113.76 92.35 C 
±5.99 ±7.79 ±5.26 ±6.48 
n=6 n=6 n=9 n=4 
% Recovery 30 min 96.01 100.00 101.03 96.24 N.S . 
................................................................................................................. ±6.27 .................. ± 7.05 .................. ±4.55 ............... ±1?.,.1~ ....................... . 
Systemic Vascular Control 2514.31 2650.86 
Resistance index ±534.45 ±303.35 
(Dynes.sec-1) n=7 n=6 
% Recovery 5 min 112.01 89.70 
±15.13 ±7.40 
n=6 n=6 
% Recovery 30 min 119.35 107.82 
±9.48 ±10.30 
n=7 n=5 
Legend: a: p<0.05; OmM vs 1 mM c: p<0.05; 1 mM vs 1 OmM 
b: p<0.05; 0.1 mM vs 1 OmM d: p<0.05; 0, 1 mM vs 1 mM 
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3142.61 2740.42 N.S. 
±125.96 ±138.03 
n=8 n=4 
72.98 80.22 C 
±6.23 ±10.06 
n=8 n=4 
89.35 99.92 N.S. 
±7.62 ±25.21 
n=8 n=4 
e: p<0.01; 1 mM vs 1 OmM 
f: p<0.05; OmM vs 1 OmM 
Time to induce cardiac arrest: 
Comparison of the time intervals taken by each solution to induce complete 
electromechanical arrest showed no differences between the various groups: 10.2 
sec± 2.6 sec in group I, 9.7sec ± 1.3 sec in group II, 7.1 sec± 1.3 sec in group Ill 
and 10.0 sec± 1.9 sec in group IV (N.S.). 
Cardioplegic infusion times: 
The measurement of time intervals required for infusion of maintenance cardioplegia 
represent an indirect measurement of coronary vasodilator tone as the delivery 
pressure was maintained at 80 mmHg. All measurements per group were pooled and 
averaged. The infusion times for each application of maintenance cardioplegia of 
100ml on average were significantly shorter for the groups treated with 1 mM and 
1 OmM adenosine concentration (9.95 .± 0.32 sec and 10.07 .± 0.50 sec respectively) 
compared to plain ST2 and ST2 plus 0.1 mM adenosine (12.8 .± 0.52 sec and 11.87 .± 
0.62 sec respectively) (Figure 5.12. ). 
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FIGURE 5.12.: MEAN INFUSION TIMES OF MAINTENANCE CARDIOPLEGIA IN 



















Legend: a: p ~ 0.05 vs O mM b: p ~ 0.01 vs 0.1 mM c: p ~ 0.05 vs O mM 
FIGURE 5.13.: MEAN POST-ISCHEMIC DEFIBRILLATION COUNT PER ANIMAL 
IN THE DIFFERENT TREATMENT GROUPS TO REVERT THE 
HEARTS BACK TO SINUS RYTHM 
2.0 
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Legend: a: p ~ 0.05 vs 0, 0.1, 1 O mM 
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Defibrillation requirement: 
Defibrillation requirement as expressed by the defibrillation count per animal was 
high for the hearts treated with St. Thomas' Hospital solution modified with 10 mM 
adenosine (Group IV, 1.5 ± 0. 7) and low in hearts treated with St. Thomas' Hospital 
solution modified with 1mM adenosine (Group Ill, 0.2 ± 0.2, p< 0.05 vs group I: 0.71 
± 0,3} (Figure 5.13). 
Metabolic recovery: 
Tissue adenosine triphosphate (ATP) levels were lowered in all groups at the end of 
the ischemic period. (Table 5.9.). However, there was a trend towards better 
maintenance of ATP-levels in all hearts treated with adenosine. Five minutes after 
termination of cardiopulmonary bypass ATP-levels were 3.54 ± 0.34 µmol/g for group 
Ill compared to 2.53 ± 0.42 µmol/g for group I, 2.12 ± 0.27 µmol/g for group II (p ~ 
0.05 vs group Ill) and 2.78 ± 0.25 µmol/g for group IV. (Table 5.9.). At 30 minutes 
reperfusion there were no statistical differences. 
Tissue creatine phosphate (CP) levels were reduced in all groups at the end of 
ischemia with no statistical differences between the different groups. Five minutes 
after discontinuation of cardiopulmonary bypass, CP levels were better preserved in 
group Ill (7.78 ± 1.23 µmol/g) compared to group II (3.42 ± 0.88 µmol/g, p ~ 0.05 vs 
group Ill). At thirty minutes of reperfusion there were no differences in GP-content 
between the groups (Table 5.9.). 
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TABLE 5.9.: HIGH ENERGY PHOSPHATES 
Parameter Time OmM 0.1 mM 1 mM 10 mM 
Adenosine Control 3.20 3.31 4.00 3.24 N.S. 
triphosphate ±0.52 ±0.42 ±0.20 ±0.65 
(µmol.g·1 n=6 n=6 n=4 n=3 
wet weight) End 1.93 2.39 2.98 2.37 N.S. 
ischemia ±0.35 ±0.26 ±0.21 ±0.57 
n=6 n=6 n=4 n=4 
5min 2.53 2.12 3.54 2.78 a 
±0.42 ±0.27 ±0.34 ±0.25 
n=5 n=6 n=5 n=4 
30 min 2.23 3.13 2.92 2.52 N.S. 
±0.30 ±0.40 ±0.36 ±0.76 









Legend: a: p ~ 0.05; 0.1 mM vs 1 mM 














5.28 7.17 5.04 N.S. 
±0.84 ±1.10 ±0.90 
n=5 n=3 n=3 
1.32 1.74 3.61 N.S. 
±0.32 ±0.56 ±1.73 
n=6 n=4 n=4 
3.42 7.78 5.15 b 
±0.88 ±1.23 ±0.77 
n=6 n=5 n=4 
5.78 5.85 4.16 N.S. 
±0.85 ±1.44 ±1.02 
n=6 n=5 n=3 
Ultrastructural studies have so far been performed on only two animals per group. 
The limited number of results show no differences in mitochondrial preservation or 
glycogen loss between the groups (Table 5.10.). 
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TABLE 5.10.: ULTRASTRUCTURAL PRESERVATION OF MYOCARDIUM 
BEFORE AND AFTER PROTECTION WITH ADENOSINE 
SUPPLEMENTED ST. THOMAS' HOSPITAL CARDIOPLEGIA NO. 2 
Time Group Cristae Dense Glycogen 
granules Loss 
PRI ADO 0.1mM 1.5 0 0.5 
(n=2) 0 0 0 
PRI ADO 1mM 0 1 1.5 
(n=2) 0 0 0 
PRI ADO 10mM 0 0 1 
(n=2) 0.5 0 0 
EOI ADO 0.1mM 0.5 0 0.5 
(n=2) 0.5 0 0 
EOI ADO 1mM 1.5 0 1.5 
(n=2) 0 0 0 
EOI ADO 10mM 1.5 0 1 
(n=2) 0.5 0 0 
RPS ADO 0.1mM 0 0 1.5 
(n=2) 0 0 0 
RPS AD01mM 0 1 1.5 
(n=2) 1 0 0 
RPS ADO 10mM 1 0 1 
(n=2) 0.5 0 0 
Legend: The myocardial biopsy samples from the left ventricular apical area 
were scored according to a semiquantitative scoring system: O = 
normal, 1 = mild abnormality, 2 = moderate abnormality, 3 = severe 
abnormality. PRI: Preischemia, EOI: End of ischemia (180 min), 
RPS: After 1 hour of reperfusion. 
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Summary of findings 
Adenosine has numerous protective properties in the ischemic myocardium. We 
have previously shown that adenosine added to Krebs-Henseleit buffer for induction 
cardioplegia improved hemodynamic recovery, as measured by cardiac output and 
dP/dt in an in-vivo baboon model. The aim of this study was to test the hypothesis 
that adenosine added to St. Thomas' Hospital solution No.2 (ST2) for induction and 
maintenance cardioplegia would improve hemodynamic recovery in a dose-
dependent manner. Four different treatment groups were studied in an in-vivo 
baboon model closely resembling the clinical setting: Group I: ST2 (control), Group 
II: ST2 + 0.1 mM/L adenosine, Group Ill: ST2 + 1 mM/L adenosine and Group IV: ST2 
+ 1 OmM/L. After three hours of cardiac arrest hemodynamic recovery as measured 
by cardiac index (Cl) was 115.6 ± 8.6% for group Ill (p _s 0.05 vs group I), 87.5 ± 
8.2% for group I, 89.9 ± 8.8% for group II and 62.9 ± 7.3% for group IV (p _s 0.05 vs 
group Ill). Reperfusion left ventricular function curves for group Ill best approximated 
to the preischemic control curves, while all other groups showed depressed 
postischemic function, which was most pronounced in group IV. However, systemic 
vascular resistance index (SVRI) at 20 minutes reperfusion was significantly lower in 
group Ill compared to group I, indicating systemic vasodilatation induced by higher 
concentrations of adenosine, resulting in improved cardiac output. Postischemic 
defibrillation requirements to revert the hearts back to sinus rhythm were reduced in 
group Ill compared to group I (0.2 ± 0.2 counts/animal vs 0.7 ± 0.3 counts/animal 
respectively). In groups Ill and IV coronary vasodilatation was induced as indirectly 
measured with the time intervals required for infusion of maintenance cardioplegia at 
a defined perfusion pressure of 80 mmHg. ATP-levels were best preserved in group 
Ill at early reperfusion. In summary, adenosine 1 mM/L added to ST2 improved 
hemodynamic recovery , which was mediated by a drop in SVRI, as dP/dt values 
were not different between the various groups. However, further benefits of 





6.1. Adenosine deaminase (ADA) concentration in various species 
Rationale 
Like inosine, adenosine is a catabolite of adenine nucleotide metabolism. In contrast 
to inosine, which has a relatively long half-life in blood, adenosine exists in blood 
plasma for less than one second (Moeser, 1989). In the circulation ist life may be 
even shorter because of the high activity of adenosine deaminase in endothelial 
cells ( de Jong, 1990). Consequently the adenosine concentration in blood is very 
low (ca. 0.01 µM) (Dawicki, 1988) and difficult to quantitate. In coronary effluent from 
the normoxic isolated rat heart, the adenosine concentration is about 0.1 µM (Huizer, 
1987). Adenosine is rapidly broken down by adenosine deaminase and after cell 
entry mainly phosphorylated to AMP (Doloretta, 1988) in the erythrocytes and in the 
capillary endothelium (Gerlach, 1985). It is doubtful whether its incorporation into 
myocytes is also rapid, since the adenosine transport across the membrane, which is 
a carrier-mediated process, is the rate-limiting step (Bodwitch, 1985; Dow, 1987). 
As we found differences in the rat heart model and in the baboon model with regard 
to induction of cardiac arrest, we tried to determine whether there are species 
differences in blood adenosine deaminase. At the time of the study there were no 
comparative data on blood purine catabolism in various species. 
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Experimental procedures, materials and methods 
We compared adenosine breakdown in whole blood (diluted 10x with water: 
hemolysate) of baboons, pigs and rats with that in man. Fresh blood from these 
species and from healthy volunteers was taken and immediately processed. A 
volume of 0.1 ml of the sample was mixed with 50mM Na-phosphate buffer (pH 7.4) 
and 45 µM adenosine, adding up to a final volume of 3.0 ml. The 11 absorption at 265 
nm was measured for 15-30 seconds at 20°c. 
Results 
TABLE 6.1.: ADENOSINE DEAMINASE ACTIVITY (units/I) 
SPECIES n PLASMA HEMOLYSATE 
MAN 4 7.3 ± 2.0 74± 7 
BABOON 4 6.7 ± 0.7 231 ± 16* 
PIG 4 7.5 ± 1.8 158 ± 17* 
RAT 7 11.3 ± 2.8 172 ± 43 
Legend: mean + SE, * p<0.005 vs man (modified t-test); 
Summary of findings 
Adenosine deaminase found in erythrocytes is relatively inactive in human blood. To 
avoid overdosing, care must be exercised if clinical trials are planned, using animal 
data on cardioprotection by adenosine. 
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CHAPTER 7 
DISCUSSION, SUMMARY AND CONCLUSIONS 
7.1. Limitations of the animal models used 
The isolated rat heart model several limitations. The most important are that a non-
blood perfusate and small mammalian "normal" hearts are used. 
Species 
Small mammalian hearts, especially the rat's, guinea pig's and rabbit's have been 
widely used to study the effect of cardioplegic solutions, because of low cost, ease 
of handling, and the possibility of studying large numbers (Hearse, 1981 ). However, 
physiological differences clearly exist between species (Blank, 1989; Galinanes, 
1990; Hearse, 1976) and tolerance to normothermic ischemia varies between 
species (Galinanes, 1990). Furthermore, cardioplegic protection may be beneficial in 
one species (rat), but provide no protection in others (ferret and guinea pig) 
(Galinanes, 1990), and susceptibility to reperfusion damage also differs (Hearse, 
1976). 
Major physiological differences also exist between these smaller mammals and 
larger animals (pig, dog, primate); e.g. smaller animals have high resting heart rates 
(rat - 355 beats/min, guinea pig - 273 beats/min), and the oxidative capacity of the 
myocardium of smaller animals is significantly higher, although the glycolytic 
potential of mammalian myocardium seems to be fairly uniform (Blank, 1989). 
Smaller animals also have higher levels of basal metabolism and oxygen 
consumption (Hudson, 1971 ), and may have considerably different 
electrophysiological properties (Bretschneider, 1980). This might be phylogenetically 
related to the much higher heart rate and includes a considerably shorter plateau of 
the action potential, a different relationship of the fast sodium to the slow calcium 
and sodium channels of the external membrane, and probably a quantitatively 
different source of calcium- producing electromechanical coupling (Bretschneider, 
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1980). Therefore, before extrapolating from the results found in small animals, these 
results need to be confirmed in large animals or preferably in species more closely 
related to man. 
Amongst larger animals there are also differences; the pig has extremely limited 
collateral flow between different regions of the myocardium and develops cardiac 
edema rapidly. The calf heart exhibits considerably higher resistance to ischemia 
than the dog heart; in canine hearts resistance is somewhat less than in a healthy 
human heart (Bretschneider, 1980). The canine heart is less tolerant to 
cardiopulmonary bypass and develops myocardial edema more predictably and 
frequently than the human heart (Ravetto, 1973). 
In addition, differences in susceptibility to ischemic injury also depend upon the 
maturity of the animal (Pridjian, 1987), and cardioplegic solutions used in adult 
hearts may not have equivalent efficacy in neonatal hearts (Baker, 1988; Baker, 
1990). 
The baboon has a close evolutionary relationship to man, and is therefore probably 
the closest available experimental model to man for evaluating the efficacy of 
cardioplegic solutions. Nevertheless, direct extrapolation of animal experiments to 
the human clinical situation requires caution, especially as we have shown that 
adenosine deaminase activity is five times higher in baboon erythrocytes than in 
human samples. 
Ex vivo models 
Experimental conditions can be rigidly controlled in ex vivo models (Hearse, 1981 ). 
However, the "unphysiological" crystalloid perfusates used in the majority of these 
models allow only limited recovery after ischemic contracture, and also increase 
compliance and cause slow deterioration of the heart with time (Galinanes, 1990; 
Neely, 1967). Furthermore, bubble oxygenation of the crystalloid perfusate 
denatures added proteins and may cause microemboli. Trace amounts of heavy 
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metals in the reagents of the perfusate can also affect the stability of the model 
(Neely, 1967), and Neely et al added Ca-EDTA 0.5 mM/L to the Krebs-Henseleit 
perfusate to improve the stability of their model. Thus, alternative paracorporeal and 
in vivo models using blood perfusates are more physiological, although more 
complex and expensive (Warnecke, 1980). 
In vivo models, in contrast to ex vivo models, maintain the involvement of metabolic, 
nervous, hormonal and other factors such as noncoronary collateral flow. However, 
metabolic, hormonal, biochemical factors such as ionized calcium concentration 
(Drop, 1980) and hematological parameters (hematocrit) in these paracorporeal 
models can also effect myocardial function and therefore outcome. Cardiac output 
can also be altered by heart rate, preload and afterload in the in vivo model. 
Although the former two variables can be kept constant, afterload can be difficult to 
keep stable and can thus affect the results. Therefore, isovolumic measurements of 
contractility may be more relevant in this model, and a more sensitive indicator of 
ischemic damage may be postischemic oxygen utilization (Krukenkamp, 1986). 
Nevertheless, the clinical situation of cardiopulmonary bypass, with its associated 
damaging effects, can be closely simulated with in vivo models. 
Experimental protocol 
The experimental protocol used to evaluate the efficacy of cardioplegic solutions is 
extremely important. Cardioplegic solutions should be evaluated in models that 
simulate the clinical situation, and two fundamental aspects are the temperature 
during the ischemic period and the energy state of the experimental heart. 
Hypothermia alters the physiological environment; ,,fluidity" of proteins and lipids, 
activity of enzymes (Pullmann, 1960), calcium homeostasis (Kean, 1988; Shattock, 
1983), coronary autoregulation (Chitwood, 1979; Mendler, 1984), and the neutral pH 
of water (White, 1981 ). Therefore, one should critically question the validity of 
normothermic evaluations of cardioplegic solutions, destined to be used in 
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hypothermic conditions (Jynge, 1978; Kempsford, 1988). Nevertheless, it is 
important to also be aware of the efficacy of cardioplegic solutions at different 
temperatures (Jynge, 1978), as temperatures may vary during open-heart 
procedures. In all studies in this thesis, the cardioplegic solutions were evaluated at 
hypothermia (10 °C). 
The majority of experimental animals have "normal hearts", whereas in the clinical 
situation operations are performed on diseased hearts. Thus models simulating 
coronary stenoses to study cardioplegic distribution (Gundry, 1984; Lazar, 1988), or 
models using energy depleted hearts (by adding an initial ischemic insult) 
(Rosenkranz, 1982), for instance via preischemic ventricular fibrillation 
(Boehm, 1993) or using hypertrophied hearts (Blandergroen, 1990), and cyanotic 
hearts (Fujiwara, 1988) are extremely relevant and important (Buckberg, 1990). 
However, when studying the effects of cardioplegic solution composition on 
functional recovery, an initial ischemic insult may impose an additional reperfusion 
injury which itself induces additional physiological changes. Nevertheless, because 
of the excellent performance of better formulated cardioplegic solutions, an initial 
normothermic ischemic insult may be necessary. 
Other experimental variables 
The preparation of the cardioplegic solution itself can introduce experimental 
variables. For example, particle-induced coronary vasoconstriction must be 
prevented (Hearse, 1985; Robinson, 1984), and therefore all experimental 
cardioplegic solutions should be filtered through an 0.8 µm sized cellulose filter 
(Millipore corporation; Bedford, Massachusetts, USA). 
Oxygen content of cardioplegic solutions 
Most of the solutions prepared in the laboratory are routinely gassed with 95 % 0 2 5 
% CO2 during their preparation, in order to prevent precipitation of calcium salts. 
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Thereafter, depending upon how these solutions are stored and the length of 
elapsed time prior to use, the oxygen content can vary significantly. Thus "non-
oxygenated" cardioplegic solutions may contain significant quantities of dissolved 
oxygen if equilibration to atmospheric pressure has not yet occurred. Furthermore, 
some commercial cardioplegic solutions (Bretschneider's HTK 4) are stored in 
vacuum in glass bottles, and are therefore anoxic if infused immediately upon 
opening the container. Hence, the amount of oxygen dissolved in ,,non-oxygenated" 
solutions can result in experimental variations. Oxygenation of crystalloid 
cardioplegic solutions has been shown to improve myocardial protection via the 
amount of physically dissolved oxygen in several models ( de Wit, 1988; Ledingham, 
1988; von Oppell, 1991 ). 
Processing of samples for electron microscopy 
Morphological studies have consistently been in broad agreement with both 
enzymatic and functional assessments (Hearse, 1981) . Characteristic mitochondrial 
changes correlate well with functional recovery and adequacy of myocardial 
preservation (Sjostrand, 1986) . However, processing of tissue for transmission 
electron microscopy is critical, as fixation techniques may alter structural findings 
(Sjostrand, 1986; Van Winkle, 1989). Fixation of tissue samples in these studies was 
with 5 % buffered glutaraldehyde and processing was by routine techniques 
employed in our laboratory ( osmic acid and dehydration in graded alcohols and 
embedding in Araldite) (Rose, 1972). 
Extrapolation of results to the clinical situation 
Extrapolation of experimental results obtained in animal models should be done with 
care for the reasons mentioned. This is underlined by the fact that we could not 
confirm the induction of cardiac arrest with a high dose of adenosine in the baboon 
compared to the isolated rat heart. This finding stresses the fact, that before 
extrapolating from animal models distant from man, results must be confirmed in 
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animal species closer to man. Nevertheless, while adenosine failed to induce 
electromechanical arrest in the in vivo study it did improve hemodynamic recovery 
and electropysiologic and ultrastructural preservation significantly when added to a 
normokalemic solution (KHB). However, improvement of hemodynamic parameters is 
limited in the isolated rat heart model to adenosine as adjunct to a non-cardioplegic 
(normokalemic) solution. 
Likewise, in the baboon model hemodynamic recovery, as measured and calculated 
with ejection phase parameters, is only evident when adenosine is added to a non-
cardioplegic (normokalemic) solution. The improvement in postischemic 
hemodynamic recovery found in the dose response study, where adenosine was 
added to St. Thomas Hospital solution No. 2, was mainly mediated via a reduction of 
systemic vascular resistance. Improvement of postischemic electrophysiological 
stability, however, could still be demonstrated in this study. 
Therefore, if extrapolating from the experimental to the clinical setting, the full 
potential benefit of adenosine in the context of cardioplegia is only to be anticipated 
if adenosine is used as adjunct to normokalemic solutions. This would, however, 
require additional measures to achieve electromechanical arrest such as high 
magnesium, low sodium or calcium depletion. 
Nevertheless, supplementation of high potassium cardioplegic solutions with 
adenosine is beneficial in the baboon. In a recent study performed in a canine model 
adenosine-supplemented blood cardioplegia was compared to standard cardioplegia 
(Hudspeth, 1994). The authors found no change in dP/dt recorded before and after 
ischemia and between the two different groups. However, enddiastolic pressure 
volume relations as measured via impedance catheter technique were improved in 
the adenosine-supplemented group, indicating that more sensitive parameters of 
cardiac performance, especially of diastolic function, might be necessary to detect 
improvements when adenosine is used as adjunct to high potassium solutions. A 
study published in 1996 (Alekseev, 1996) employing the perforated patch clamp 
method applied to single guinea-pig ventricular myocytes revealed that adenosine 
1 mM did not significantly reduce the magnitude of ~ induced membrane 
depolarization. Yet adenosine significantly slowed the rate of membrane 
depolarization with a subsequent reduction of net inward Ca2+ current. This finding 
supports the view that adenosine may play a role in hyperkalemic cardioplegia via 
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reduction of ~ - induced intracellular Ca2+ loading. This is an important finding in 
view of the idea that intracellular Ca2+ loading in cardiomyocytes has been 
considered to represent a precipitating factor that could lead to diastolic dysfunction 
and cellular impairment (Harman, 1995; Tani, 1990). This finding in an isolated 
myocardial cell preparation supports the observed improvements found especially in 
diastolic myocardial function in the study of Hudspeth. Our dose response study did 
not, however, employ sensitive parameters for diastolic cardiac performance. 
Initial clinical trials have shown, that adenosine can safely be added to existing 
crystalloid cardioplegic solutions (Mentzer, 1996; Fremes, 1996). The clinically 
added concentrations of 200 µM of adenosine to blood cardioplegia (Hudspeth, 
1994) are, however, five times lower than the optimal concentration found at 1 mM in 
this study. Considering the fact that we also found a five times lower activity of 
adenosine deaminase in human, compared to baboon erythrocytes, this 
concentration might well be optimal for the human heart. 
7.2. Adenosine vs high potassium in the isolated rat heart 
Adenosine has been reported to depress impulse formation and conduction in the 
sinus and AV node respectively (Szentmiklosi, 1980; Urthaler, 1972) via 
hyperpolarization of the sarcommal membrane of these pacemaker cells. In 
combination with an adenosine desaminase inhibitor, adenosine was shown to 
enhance myocardial recovery after ischemia (Humphrey, 1982), when used as 
pretreatment. While the investigators emphasized slowed ATP degradation and 
faster ATP and phosphocreatine resynthesis, our experiments were additionally 
based on the idea of energy preservation by a rapid cardiac arrest. 
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Effect on cardiac arrest 
Comparing the features of the induction of cardiac arrest with adenosine 
cardioplegia with commonly used arresting agents like high potassium, one 
outstanding difference is obvious: there is nearly immediate heart arrest with 
adenosine cardioplegia. The hearts stop beating about 20 times faster in the 
Langendorff and about 10 times faster in the working mode. The number of arrest 
beats differed accordingly. The addition of adenosine to potassium cardioplegia 
enhanced cardiac arrest. Increasing the adenosine adjunct enhanced cardiac arrest 
even more. Potassium plus 10 mM of adenosine was nearly as effective as 
adenosine in causing cardiac arrest. 
Effect on hemodynamic recovery 
In the experiments with 30 minutes of hypothermic ischemia, adenosine cardioplegia 
was superior to the control and there was a trend for better recovery compared to the 
other treatment groups. As the ischemic time was relatively short, more than 80 % of 
the control group hearts recovered, with no statistical significance between the 
groups. Furthermore it was impossible to judge the effectiveness of the combination 
of adenosine and potassium. Therefore, the experiments were repeated with an 
extended ischemic period of 90 minutes. Again adenosine cardioplegia showed 
superior recovery. In these experiments a significant difference between the control 
group and the potassium group was demonstrated. Interestingly, the combination of 
adenosine and potassium showed depressed recovery for aortic output and for heart 
rate-mean pressure product compared with potassium cardioplegia. 
It is important to point out that all of our adenosine cardioplegic solutions had to be 
washed out immediately after infusion. If this was omitted, all hearts began beating 
with a low heart rate and a low cardiac output immediately after reperfusion, 
indicating a persistent action of adenosine on the conduction system. Accordingly, 
the ATP and phosphocreatine stores were depressed and recovery parameters 
diminished. 
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Effect on energy status 
The energy status after infusion of the various cardioplegic solutions prior to the 
onset of ischemia showed no significant differences for ATP, but there were 
differences in phosphocreatine levels. The phosphocreatine levels were superior for 
adenosine in both concentrations as well as with the adenosine supplement 
compared with potassium cardioplegia. After 30 minutes of ischemia 
phosphocreatine was again superior to all other cardioplegic groups. Now even ATP 
stores were significantly increased. The lowest values were reached for the 
combination of adenosine and potassium for either group. 
Possible mechanisms 
The mechanism by which adenosine improves myocardial preservation after global 
ischemic heart arrest is not clear. Adenosine hastens cardiac arrest and thus 
shortens the period of ischemic myocardial contractions after aortic cross-clamping. 
Regarding the energy status prior to ischemia, ATP stores were not significantly 
different, whereas phosphocreatine seems to be a better parameter for preservation, 
as suggested in previous studies (Rosenkranz, 1986). Along with an increase of 
adenosine and with an increasing concentration of adenosine supplemented to 
potassium cardioplegia, phosphocreatine levels prior to ischemia rose. In trials with 
pure potassium cardioplegia phosphocreatine levels even dropped below the pre-
cardioplegia control values. 
While these experiments emphasize the effectiveness of adenosine and adenosine 
admixture respectively, our hemodynamic data confirmed superior recovery only for 
pure adenosine cardioplegia. Potassium cardioplegic solutions supplemented with 
various amounts of adenosine showed worse recovery than adenosine alone and 
were not different from high potassium. 
The fact that the combination of adenosine and high potassium accelerated cardiac 
arrest in a similar way as pure adenosine excludes this effect as an explanation for 
the improved preservation. It seems more likely that high potassium limits the 
protective effects of adenosine. Adenosine has been linked to preconditioning via 
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stimulation of A1 receptor-mediated Gi protein induction and opening of ~TP 
channels. Opening of ATP-sensitive potassium channels with selective channel 
openers is, however, only cardioprotective in the absence of high potassium 
cardioplegia (Galinanes, 1992). This indicates that adenosine A1-mediated 
cardioprotection via activation of ATP or ADO-sensitive potassium channels might 
be equally limited in the presence of high potassium. This suggests that part of the 
cardioprotective qualities could be lost when adenosine is used in conjunction with 
high potassium cardioplegia. This would depolarize sarcolemmal membranes and 
antagonize the hyperpolarizing forces of adenosine, as shown by de Jong in studies 
of isolated SA nodes (de Jong, 1990). Several authors have stated in the past that 
cardiac membrane polarization during cardiac ischemia is energetically 
advantageous, as it represents the normal resting state of the myocardium and 
decreases energy consuming transmembrane ionic exchange system activity 
(Sternbergh, 1989). Similarly, a study by Ely (Ely, 1990), using adenosine as 
pretreatment in an isolated rat heart model, demonstrated superior functional and 
metabolic recovery compared to non-treated normothermic ischemia. 
From these experiments we conclude that high adenosine cardioplegia, i.e. 10 mM 
of adenosine, is an efficient cardioplegic solution in this model. It induces cardiac 
arrest more rapidly than cardioplegic solutions based on high potassium and 
preserves myocardial function safely. The combination of potassium and adenosine 
cardioplegia is less effective than expected. 
7.3. Comparison of cardioplegic solutions used in South Africa 
Comparison of hemodynamic recovery 
This study, carried out under conditions which closely resemble the clinical situation, 
shows that the indices of hemodynamic recovery (cardiac index, stroke volume index 
and stroke work index) in hearts protected with St. Thomas' Hospital solution No.2 
was above 95%, whilst in hearts protected with SABAX solution, recovery was 
between 70-85%, with the GSH solution between 51-80% and with Krebs-Henseleit 
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buffer between 34-60%. The St. Thomas' Hospital solution No.2 cardioplegia was 
superior to the SABAX solution in stroke volume index and to the GSH solution in 
the majority of measured hemodynamic variables. Left ventricular curves of stroke 
work index calculated at left atrial pressures of 5, 10, 15 and 20 mm Hg showed that 
hearts protected with St. Thomas' Hospital solution No. 2 had good recovery in 
contrast to the hearts perfused with Groote Schuur Hospital solution or Krebs 
Henseleit buffer. These findings confirm the importance of thorough laboratory 
testing of any cardioplegic solution. The St. Thomas' Hospital solution No.2 was 
extensively investigated in two different animal species and the electrolyte content 
was formulated according to dose-response curves for each ion (Jynge, 1981; 
Jynge, 1980; Jynge, 1978; Hearse, 1978). 
Comparison of metabolic recovery 
Although there was no significant difference in the various series in the post-
ischemic recovery of ATP at 5 and 30 minutes, previous studies have shown that 
ATP levels are not the only factor controlling viability (Rosenkranz, 1986), and that 
the rate of ATP synthesis may be more important. 
Although ATP and CP levels decreased during the ischemic period, they were 
quickly restored to acceptable levels during reperfusion in hearts protected with ST2 
cardioplegia. However, post-ischemic ATP and CP levels observed in the other 
groups in this study do not correlate with the functional recoveries. 
Comparison of composition 
The Plasmalyte B with added potassium used in some centers in South Africa has a 
similar electrolyte content to Ringer's lactate except that Plasmalyte B is calcium-
free. Coronary perfusion with a calcium-free solution may lead to increased 
sarcolemmal permeability to calcium, and when the myocardium is reperfused with a 
calcium-containing solution a massive influx of calcium can occur causing severe 
cellular damage (Jynge, 1977; Ruigrok, 1983; Torchiana, 1987, Yamamoto, 1984). 
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The addition of 200 ml pump blood to the maintenance Plasmalyte B cardioplegic 
solution (thus introducing a minimal concentration of calcium), as practised by one 
unit, could prevent this calcium paradox and consequently be beneficial. 
Furthermore, part of the beneficial actions of calcium-free Plasmalyte B may be 
attributed to the fact that hypothermia protects against the calcium paradox. In 
addition, the Plasmalyte B cardioplegia contains a high potassium concentration. It 
has been shown that the optimal potassium concentration for a crystalloid 
cardioplegic solution is approximately 15 mM/L and that higher potassium 
concentrations may be damaging (Rousou, 1981; Dewar, 1987; Chiavarelli, 1982). 
For these reasons this solution was not included in this study. 
Clinical situation 
In the clinical situation, because of the large number of variables such as coronary 
artery anatomy, L V dysfunction, cross clamp time, non-collateral flow and the extent 
of the procedure, it is difficult to objectively evaluate the performance of any one 
myocardial protection regimen. Variability of non-collateral coronary flow in the 
diseased heart may influence the rate of "wash-out" of the cardioplegic solution so 
diminishing its advantages; likewise the "wash-in" of substances (e.g. calcium) may 
be beneficial when using a calcium-free cardioplegic solution. It is not yet known 
whether undetected myocardial damage, resulting from poor myocardial protection, 
will result in late myocardial fibrosis and decreased left ventricular function. 
Therefore, we should continue to seek improvements in our techniques of 
myocardial preservation. 
The result of this comparative control study, taken in conjunction with other reports 
in the literature, lead us to propose that the optimum crystalloid cardioplegic solution 
for use in South Africa today should be based on the St. Thomas' Hospital 
cardioplegic solution No. 2. Even minor alterations to this solution should be fully 
evaluated experimentally before clinical use. The Cardio-Thoracic Department at 
Groote Schuur Hospital now uses St. Thomas' solution No. 2 cardioplegic solution. 
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All further studies in the primate model were conducted with St. Thomas' Hospital 
solution No. 2 and modifications thereof. 
7.4. Adenosine as cardioplegic agent in the in-vivo baboon model 
Effect on hemodynamic recovery 
These results obtained in an in-vivo baboon model confirm findings in the isolated 
rat heart (De Jong, 1990; Schubert, 1989}, that adenosine improved post-ischemic 
hemodynamic recovery when added to a non-cardioplegic solution such as Krebs-
Henseleit buffer for induction. The improvement was sufficient to make the ADO 
solution comparable to the internationally used St. Thomas' Hospital solution No 2 in 
the hemodynamic recovery of Cl and SVI. ADO and ST2 were significantly better in 
all measured parameters than KHB alone. 
Effect on cardiac arrest 
However, in contradistinction to the isolated rat heart model (De Jong, 1990; 
Schubert, 1989), adenosine did not act by inducing fast cardiac arrest since it was 
ineffective in preventing ventricular fibrillation or arresting the fibrillating heart. 
Complete electromechanical arrest was delayed by 47 seconds with adenosine 
when compared with potassium arrested hearts (p < 0.001 }, but 25 seconds faster 
than with the low potassium KHB alone (55.0 ± 5.6 sec vs 80.0 ± 6.4 sec) (p < 0.01) 
respectively. This finding, which is at variance with results obtained in the isolated 
rat heart (Schubert, 1989), could be due to the fact that the effects of adenosine on 
heart rate and AV-nodal conduction are species-dependent and there might be a 
species-specific sensitivity (Fabiato, 1978). The possibility of a higher fibrillation 
threshold in rat hearts might account for this difference. 
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Effect on energy status 
Recovery of high energy phosphates showed no significant advantage from adding 
adenosine although ATP and CP levels were well maintained in the adenosine 
group. This is in contradistinction to Bolling (1989) who attributes the beneficial 
effect of adding adenosine to cardioplegic solutions to an increase in myocardial 
ATP. Significant differences between the various groups may, however, have been 
hindered by the energy-wasting fibrillation seen in the KHB and adenosine groups. 
Effect on ultrastructure 
Interpretation of the preliminary ultrastructural studies showing normal cardiac 
ultrastructure in the adenosine-treated hearts at reperfusion suggests that 
adenosine might be beneficial by other mechanisms than restoring high energy 
phosphates (Petsikas, 1990). 
It has been shown by Cronstein (1986) to inhibit neutrophil-mediated injury to 
endothelial cells and to modulate superoxide anion generation by human neutrophils 
(Cronstein, 1983). 
Olafsson confirmed these in vitro findings by showing a reduction of reperfusion 
injury in a canine preparation by intracoronary adenosine (Olafsson, 1987). 
Interpretation of the preliminary ultrastructural studies showing normal cardiac 
ultrastructure in the adenosine treated hearts at the end of ischemia and after 
reperfusion suggests that adenosine might be beneficial by other mechanisms than 
restoring high energy phosphates (Ledingham, 1990; Olafsson, 1987; Petsikas, 
1990; Babbitt, 1989). Further beneficial effects of adenosine could be the reduction 
of platelet aggregation and prevention of the "no-reflow" phenomenon through 
prevention of plugging of the microvascular bed (Pitarys, 1991 ). Additionally the 
calcium antagonistic properties (Kato, 1990) of adenosine might be beneficial in 
preventing intracellular calcium overload, which is the one of the contributing factors 
to reperfusion injury apart from oxygen free radicals (Opie, 1989). 
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A further possible mechanism of adenosine is its action as a potent coronary 
vasodilator (Ledingham, 1990; Wilson, 1990). This could have improved, on the one 
hand, cardioplegia delivery with more rapid and uniform cooling as evidenced by the 
shorter infusion times for cardioplegia in the treatment groups with 1 and 10 mM of 
adenosine added to St. Thomas' Hospital cardioplegia No. 2. On the other hand, it 
could maximize coronary flow in the reperfusion period, which was not measured in 
this study. This effect, in addition to the prevention of microvascular plugging, might 
improve post-ischemic flow and delivery of oxygen and substrates substantially. 
Ledingham concluded from his study, in which he used adenosine during reperfusion 
in an isolated rat heart model, that the beneficial effect is likely to be due to an 
increase in coronary flow rather than to an increase in myocardial ATP. 
Of further importance is that no adverse effects from adenosine at the concentration 
used were observed in the treated animals. However, systemic hypotension, renal 
vasoconstriction and AV-block have been reported when using high concentrations 
(Owall, 1988; Osswald, 1978; Richardt, 1987). 
In conclusion, adenosine was effective in improving post-ischemic hemodynamic 
recovery when added to a non-cardioplegic solution. However, it did not prove to be 
a cardioplegic agent in this model due to its failure to prevent ventricular fibrillation. 
Preliminary ultrastructural findings together with reports in the literature suggest that 
adenosine might modulate reperfusion and endothelial cell injury (Babitt, 1989; 
Crostein, 1983; Cronstein, 1986; Ledingham, 1990; Olafsson, 1987). 
Further studies are, however, required to test the beneficial effects of adenosine in 
the presence of high potassium concentrations and to elucidate the mechanism or 
mechanisms by which adenosine exerts its beneficial effects. Once these studies are 
complete, adenosine, in an appropriate concentration, may well prove to be a 
beneficial additive to cardioplegic or reperfusion solutions. 
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7 .5. Adenosine as cardioplegic adjunct in the in-vivo baboon model 
Effect on hemodynamic recovery 
These results were obtained in an in vivo baboon model closely simulating the 
clinical procedure. They are similar to findings in the isolated rat heart (De Jong, 
1990) and isolated rabbit heart (Bolling, 1989) confirming that adenosine improves 
post-ischemic hemodynamic recovery when used as adjunct to a hyperkalemic 
cardioplegic formulation such as the St. Thomas' Hospital Solution. Addition of 
adenosine at a moderate concentration of 1 mM/L resulted in marked improvement 
of cardiac output and derived ejection phase indices when compared to St. Thomas' 
Hospital cardioplegia No. 2 alone: the measured and derived parameters were close 
to 100% or above. Addition of adenosine at the lower concentration of 0.1 mM/L, 
however, did not improve recovery compared to St. Thomas' Hospital solution No. 2 
alone and adenosine supplementation at a concentration of 10 mM/L even resulted 
in inferior recovery. 
However, the improvement in postischemic ejection phase indices was not related to 
a shortened time interval for induction of electromechanical cardiac arrest as 
demonstrated in the isolated rat heart model (Schubert, 1989; De Jong, 1990). It 
seemed to be mediated by a dose-dependent reduction in afterload as measured by 
systemic vascular resistance (SVR) and mean arterial blood pressure (MAP), 
especially since contractile function measured with dP/dUDP was not different 
between the treatment groups. We realize that dP/dt is pre- and afterload 
dependent, but since we kept the preload constant and corrected for changes in 
afterload by calculating dP/dt over the developed pressure DP, the index should give 
a fairly reliable indication of contractile function (Mason, 1971 ). 
Adenosine, apart from being a coronary vasodilator (Berne, 1980), also causes 
systemic vasodilatation (Oewall, 1988). The pronounced effect on systemic 
resistance in our model might have been aggravated by two important factors: 
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1 . The adenosine -containing cardioplegic solution was not released from the right 
atrium, but was drained into the cardiopulmonary bypass circuit and subsequently 
into the systemic circulation. Although adenosine was not detected in arterial 
blood samples during reperfusion using a spectrophotometric assay ( detection 
threshold 0.01 mM) (Boehm, unpublished data) trace concentrations of adenosine 
may have been present. Normal arterial and venous plasma levels of adenosine 
in humans are in the range of 0.1- 0.3 µMIL (Sollevi, 1984). Sollevi reported that 
intravenous adenosine infusion of 150-350 µg/kg/min induced a marked reduction 
of the mean arterial blood pressure of 40-50%, mediated by a 55-65% reduction in 
systemic vascular resistance (Sollevi, 1984). This effect was used therapeutically 
to induce hypotension during anesthesia in patients with peripheral vascular 
disease and during neurosurgical procedures(Oewall, 1988; Sollevi, 1984). 
However, rapid breakdown would be expected via adenosine deaminase, an 
enzyme which was found to have higher activity in baboon blood than in human or 
rat blood (chapter 6) (De Jong, 1992). Metabolism could, however, have been 
delayed by the hypothermic temperatures. Another option is the possible binding 
of adenosine to vascular receptors or to fat tissue explaining its long-lasting effect 
which was still present 50 minutes after infusion of adenosine containing-
cardioplegic solution. 
2. Systemic ionized calcium concentrations during cardiopulmonary bypass and 
reperfusion varied between 0.3 and 0.5 mM/L, which is one half to one third of the 
normal range measured in the baboon. This was due to large priming volumes in 
relation to body size and to additional volume loading for determination of Starling 
function curves with a calcium-free crystalloid solution (Plasmalyte B). A similar 
observation has been noted by clinicians in pediatric cardiac surgery (Mayer, 
1990). However, any attempt at correction was avoided due to a potential 
beneficial effect on preventing calcium overload during ischemia and reperfusion. 
Adenosine in conjunction with low calcium levels has an even stronger 
vasodilatory effect on the coronary system (Humphrey, 1982). The same effect 
could be expected for the systemic circulation. 
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Nevertheless, adenosine proved to be beneficial in several isolated heart studies 
(Bolling, 1989; Bolling, 1991) when given during the ischemic period, an effect which 
was not related to coronary or systemic vasodilatation. To separate the influence of 
systemic vasodilatation from other potentially beneficial properties in our model it 
might be necessary to drain the adenosine-containing cardioplegic solution or to 
correct the calcium concentration of the systemic perfusate. Recent evidence from 
our laboratory indicates that adenosine 1 mM/L as adjunct to St. Thomas' Hospital 
cardioplegia No. 2 in the same model does not reduce systemic vascular resistance 
if the systemic calcium concentration is normalized (Boehm, unpublished data) 
However, in the previous study we were able to show an improvement in 
hemodynamic recovery when adenosine was added to Krebs-Henseleit-Buffer as an 
induction cardioplegia. This effect was demonstrated in terms of ejection phase 
parameters such as cardiac output as well as in terms of contractile function 
measured with dP/dt. The results of the above mentioned study revealed no change 
in systemic vascular resistance, probably because adenosine was given once only 
for induction. On the other hand, there were no differences in postischemic high-
energy phosphate content, possibly due to the long period of ventricular fibrillation 
prior to electromechanical arrest and/or because of the single application of 
adenosine. 
Possible mechanisms 
Several facts may explain why adenosine failed to improve cardiac contractile 
function in this study: 
1. As evidenced when using the control solution (ST2) recovery of contractile 
function ( dP/dt) was 100% or above. This demonstrates adequate protection of 
these baboon hearts during three hours of global hypothermic ischemia. Takahasi 
and Hearse (1990) emphasize that the control group should ideally recover to 
only approximately 50% of preischemic control values in order to reveal any 
beneficial or deleterious effects of any given intervention. Therefore, to lower the 
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recovery of control hearts in this study, a more severe ischemic insult would have 
been required. In our previous study recovery with Krebs Henseleit buffer was 
poor (55%) when compared to the treatment group with adenosine-containing 
Krebs Henseleit buffer, indicating that more ischemic/reperfusion damage 
occurred than in this dose-response study. Reviewing the literature, beneficial 
effects of adenosine are reported when the recovery with the control solution was 
poor, as for instance 40% in the study of Bolling (Bolling, 1989). Therefore a 
contractile recovery of more than 100% as in this study can hardly be expected 
after a prolonged period of global cardiac ischemia. 
2. Our measurements of cardiac contractile function might have been not sensitive 
enough to detect any differences between the various treatment groups. Most 
investigators make use of pressure volume relationships for determination of 
systolic and diastolic cardiac function. A recent study performed at the University 
of North Carolina using adenosine-supplemented blood cardioplegia in an in vivo 
dog model showed decreased left ventricular systolic pressure at reperfusion 
compared to standard blood cardioplegia (Hudspeth, 1994). There was no change 
in dP/dt recorded before and after ischemia or between the different groups. 
However, end-diastolic pressure volume relations as measured via impedance 
catheter technique were improved in the adenosine-supplemented group, 
indicating that more sensitive parameters of cardiac contractile function might be 
necessary to detect differences in myocardial performance. 
3. Adenosine has been linked to preconditioning via stimulation of A 1 receptor-
mediated Gi protein induction and opening of KA TP channels. However, opening 
of ATP-sensitive potassium channels with selective channel openers is only 
cardioprotective in the absence of high potassium cardioplegia (Galinanes, 1992). 
This indicates that adenosine A 1 mediated cardioprotection via activation of ATP 
or ADO sensitive potassium channels might be equally limited in the presence of 
high potassium. In Schubert's study using the isolated rat heart, the combination 
of adenosine and high potassium was not superior to potassium arrest alone in 
contrast to low potassium adenosine cardioplegia which showed superior 
hemodynamic and biochemical refunction (Schubert, 1989). This finding suggests 
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that part of the cardioprotective qualities could be lost in conjunction with high 
potassium cardioplegia, leading to depolarization of sarcolemmal membranes and 
antagonizing the hyperpolarizing forces of adenosine, as shown by de Jong in 
studies of isolated SA nodes (de Jong, 1990). Several authors have stated in the 
past that cardiac membrane polarization during cardiac ischemia is energetically 
advantageous, as it represents the normal resting state of the myocardium and 
decreases energy consuming transmembrane ionic exchange mechanisms 
(Sternbergh, 1989; Cohen, 1993, 1994 ). However, a very recent study by Alekseev 
(1996) demonstrated that adenosine slowed the rate of K+-induced membrane 
depolarization and reduced K+-induced intracellular Ca2+ loading in ventricular 
myocytes during hyperkalemic cardioplegia. Blocking of the ATP-sensitive K+ 
channels with glyburide did not modify this effect, suggesting no involvement of 
opening of ATP-sensitive K+ channels in this action of adenosine. The authors 
concluded that at least in part a decrease in the net Ca2+ influx during K+ 
mediated depolarization might be the mechanism involved, although the 
phenomenon needs further investigation. This report supports our findings of an 
improved recovery with adenosine as adjunct to St. Thomas' Hospital 
cardioplegia, but it was less pronounced than in the studies with normokalemic 
solutions(Krebs Henseleit buffer) and those of other investigators showing 
superior recovery with adenosine and high K+ (Hudspeth, 1994; Mentzer, 1995; 
Fremes, 1996). 
Other mechanisms 
However, we cannot exclude the possibility that adenosine may offer additional 
benefits as suggested in this study by the reduced postischemic requirement for 
defibrillation in the group treated with 1 mM/L adenosine. This improvement cannot 
be attributed to reduced afterload, but rather indicates amelioration of myocardial 
stunning, which Forman (1991) suggested as the likely role of adenosine. The 
previously cited study of Bolling found a 100% spontaneous defibrillation rate in 
adenosine treated rabbit hearts compared to a rate of only 87% in the control group. 
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However, only the intermediate adenosine concentration of 1 mM/L gave superior 
results, whereas the lower (0.1 mM/L) concentration gave no improvement and the 
higher (1 OmM/L) concentration resulted in increased requirements for postischemic 
defibrillation, when compared to St. Thomas' solution alone. This indicates a dose-
dependent mechanism and stresses the importance of optimizing the concentration. 
The optimal dose found in our experiments seems to differ from the 200µM/L 
established in an isolated rabbit heart preparation (Bolling, 1989). 
Considering that isolated heart models employ a blood-free perfusate , our five times 
higher concentration for optimal effect might reflect the necessity for administering 
higher doses in in-vivo models in order to anticipate the adenosine breakdown via 
adenosine deaminase. Lasley and Mentzer also stress the importance of a high 
dose in in vivo models in a similar way (Mentzer, 1993). 
In group IV ( 10 mM/L adenosine) mean arterial blood pressure five minutes after 
termination of cardiopulmonary bypass was 54 ± 8,4 mmHg. This might have 
reduced coronary perfusion pressure below the critical level necessary to maintain 
adequate cardiac perfusion and function. Therefore reduced dP/dt/DP in this group 
can be either a result of the decreased perfusion or the result of a direct negative 
inotropic effect. Adenosine exerts this indirect negative inotropic effect on ventricular 
myocardium only when simultaneous ~-adrenergic stimulation is present (Schrader, 
1977), which is the case in our experiments during reperfusion, rewarming and 
weaning from cardiopulmonary bypass. Under baseline conditions, adenosine is 
reported to have a mild positive or no inotropic effect on ventricular myocardium 
(Belardinelli, 1988). An additional negative chronotropic effect is evident with the 
1 OmM/L concentration as reflected in the heart rate having a recovery of 92% (p< 
0.05 vs control) of preischemic control. Two animals out of four (50%) had transient 
AV-conduction delay upon reperfusion as diagnosed on limb lead ECG. 
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Effect on energy status 
High energy phosphate content as measured by tissue ATP and CP content failed to 
show a direct statistical correlation to functional recovery; although ATP preservation 
was best in the group treated with 1 mM/L at early reperfusion, the group which also 
had the best hemodynamic recovery. Influence of the reduced afterload, resulting in 
reduced myocardial work, in this group on high-energy-phosphate preservation is 
possible, but seems unlikely as preservation tended to be better already at the end 
of the ischemic period. However, Mentzer suggested that higher ATP levels during 
reperfusion associated with adenosine pretreatment are at least in part the result of 
improved ischemic protection (Mentzer, 1993). It now seems established that total 
tissue ATP content per se is of limited value in predicting postischemic recovery of 
function (Mallet, 1990; Neely, 1984; Hohlfeld, 1989) 
There have been conflicting reports about the ability of intracoronary administered 
adenosine to enhance intra-myocardial high energy phosphates depending on the 
model and preservation temperature used. Bolling (Bolling 1989, 1990, 1991) 
attributed the improved functional recovery found in an isolated rabbit heart model to 
the role of adenosine as a substrate for nucleotide resynthesis. Faker (1980) found 
improved high energy phosphate levels in a canine model of global normothermic 
ischemia only when adenosine supplementation was combined with an adenosine 
deaminase inhibitor (EHNA). Ledingham (1990) found no improvement on high 
energy phosphate content when adenosine was added during reperfusion, whereas 
Silverman (1983) detected improved high energy phosphates and increased 
coronary blood flow during reperfusion even without inhibition of adenosine 
catabolism in a dog model of global hypothermic ischemia. Ely (1985), in an isolated 
rat heart model of global normothermic ischemia, reported a reduction in net 
degradation of ATP during ischemia and found that adenosine facilitated repletion 
during reperfusion when it was infused throughout the experiment. Mentzer 
concluded in 1993 (Mentzer, 1993) that adenosine does not improve postischemic 
ventricular function via enhanced ATP content but rather via improvement of the 
creatine phosphate phosphorylation potential. Hohlfeld (1989) found an increase in 
an isolated rat heart model, but concluded that "total tissue ATP is not necessarily a 
good indicator of functional capabilities under conditions of normothermic ischemia 
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and reperfusion in the isolated rat heart". The author claims, however, the 
uncontradicted value of ATP as a parameter of ischemia-related tissue damage. 
Other studies found that increased interstitial adenosine levels by intracoronary 
application of adenosine facilitated ATP recovery only late in reperfusion (Mentzer, 
1993). However, our experiment was not designed to evaluate cardiac biochemical 
recovery in the late reperfusion phase. 
If the main action of adenosine in protecting the ischemic heart is not the 
maintenance and restoration of an adequate intramyocardial ATP level above a 
postulated critical level, there might be other mechanisms involved: 
Adenosine is a physiological coronary vasodilator (Berne, 1963). The small arteries 
are most sensitive, and especially when they have been preconstricted with 
potassium adenosine still mediates this vasodilating effect (Sabouni, 1990). This 
might enhance cardioplegic delivery and the velocity and uniform distribution of 
hypothermia. During the reperfusion period this effect might be essential in 
maintaining an improved oxygen supply - demand ratio. Forman (1991) and 
Ledingham (1990) confirmed this theory in isolated rat hearts where improvement of 
post-ischemic functional recovery was mainly attributed to a substantial increase in 
flow in the coronary micro-vasculature rather than to an increase in intramyocardial 
ATP when adenosine was used in the reperfusion period. 
Our results indicate an increase in coronary vasodilatation during ischemia as 
indirectly measured by the cardioplegic infusion times for adenosine concentrations 
of 1 and 10 mM/L, whereas the 0.1 mM/L concentration had no additional effect 
compared to ST2. We had, however, no facilities to investigate whether the coronary 
vasodilatation was maintained in the reperfusion period. There is experimental 
evidence that adenosine leads to maximal coronary vasodilatation in the reperfusion 
period (Ledingham, 1990), which might be substantially more than the reactive 
hyperemia expected. This is supported by other studies, which have shown 
(Saldanha, 1989) that regulation of vasomotor tone is impaired postischemia 
especially in conjunction with high potassium cardioplegia (Lefer, 1991) 
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Effect on ultrastructure 
In addition to maximal coronary vasodilatation a further benefit of adenosine might 
contribute to the improved recovery: adenosine has been shown to reduce platelet 
aggregation and to inhibit neutrophil-mediated damage to endothelial cells via 
inhibition of oxygen-free radicals (Cronstein, 1983; Cronstein, 1986; Gruber, 1989). 
This mechanism might lead to prevention of the "no-reflow" phenomenon especially 
in the microvasculature (Kitikaze, 1991; Olafsson, 1987; Grisham, 1989). 
Furthermore, it might be responsible for the better ultrastructural preservation with 
regard to mitochondrial integrity in the adenosine-treated hearts as found in our 
previous study (Table 5. 7.). 
Stimulation of K-A TP-channels 
A further mechanism by which adenosine might reduce myocardial stunning could be 
that it reduces post- and intraischemic calcium overload through stimulation of A1 
receptors, either by inhibiting potassium-dependent calcium uptake or by impeding 
further calcium entry through blockade of calcium-dependent channels (Kato, 1990). 
Additionally, adenosine can reduce myocardial oxygen consumption by protecting 
the myocardium from endogenous catecholamine stimulation via its action on 
A1 receptors (Forman, 1991 ). The resulting negative chronotropic and dromotropic 
effect would result in a lower myocardial oxygen consumption. In our experiments, 




A significant finding of this study is the sustained effect on systemic vasomotor tone 
as well as the importance of using the optimal adenosine concentration. Negative 
systemic effects such as constriction of renal arteries and decrease in glomerular 
filtration rate (Osswald, 1978), as measured indirectly from total urine output, were 
not observed. Inhibition of AV-conduction (Bellardinelli, 1990) was only detected in 
the 10mM/L group, where 2/4 animals had transient AV-conduction delay in the 
reperfusion period. 
In conclusion, adenosine might be a beneficial additive to cardioplegic solutions in 
an appropriate concentration. However, part of its cardioprotective effect might be 
lost in conjunction with high potassium cardioplegia. It appears to be advisable to 
drain either the adenosine-containing cardioplegic solution or to normalize systemic 
calcium concentrations in order to avoid systemic vasodilatation in the reperfusion 
period. On the other hand, however, this could be a desirable effect during clinical 
reperfusion of the cardioplegically arrested heart and during weaning from 
cardiopulmonary bypass, if it improves cardiac output and myocardial energy 
consumption. 
Findings of improved electrophysiological stability in the early reperfusion period in 
conjunction with reports in the literature suggest that adenosine might modulate 
reperfusion and endothelial cell injury. Further potential beneficial effects include 
coronary vasodilatation, improved 0 2 supply/demand ratio and prevention of calcium 
overload, all of which are unlikely to be mediated via maintenance of intramyocardial 
high-energy phosphate content or facilitated restoration in the early reperfusion 
phase in this model. However, further studies are required to test and to elucidate 
the mechanisms by which adenosine exerts its beneficial effects. 
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7.6 Summary and conclusions 
lntraoperative myocardial protection has evolved in parallel with the evolution of 
cardiac surgery from a technique to provide a still and bloodless field for the cardiac 
surgeon to an extensively investigated and clinically used method to additionally 
protect the myocardial, vascular and conductive tissues during global ischemic 
arrest. In view of the multitude of experimentally and clinically used cardioplegic 
solutions there is still an ongoing quest for further improvements in cardioplegic 
protection, especially as the extent of cardiac surgical repair is increasing and 
existing techniques still offer only limited time for cardiac repair and still lead to 
depressed postoperative myocardial function. 
Adenosine, a physiologic purine compound, has been shown to be an endogenous 
cardioprotective agent via multiple mechanisms during episodes of induced or 
spontaneous global or regional ischemia. This study was therefore designed to 
investigate the role of adenosine as cardioplegic agent and as cardioplegic additive 
to high potassium solutions. To achieve this aim two animal models in two species, 
rat and baboon, were developed. The isolated rat heart was used as a rapid 
screening model and to test the hypothesis that adenosine would induce 
electromechanical arrest and improve hemodynamic, metabolic and ultrastructural 
recovery after a prolonged period of ischemia. The in-vivo baboon model was 
designed to approximate the clinical situation as close as possible and to test the 
interventions in a species close to man. 
The study was restricted to the use of adenosine during ischemia and was not aimed 
at preischemic treatment with adenosine or adenosine supplementation during the 
reperfusion phase, representing episodes which might lead to improved preservation 
with adenosine supplementation. 
The results obtained in an isolated rat heart model and in an in vivo primate model 
show that adenosine cardioplegia had a significant effect on improvement of 
hemodynamic function post-ischemia when used without high potassium 
cardioplegia. However, the combination of adenosine and high potassium 
cardioplegia was less effective than expected. 
In the isolated rat heart adenosine in high concentrations (10 mM) is able to induce 
complete electromechanical cardiac arrest and appears to be a cardioplegic agent in 
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this model. In the in vivo baboon model, however, there was no induction of cardiac 
arrest because of the failure to limit ventricular fibrillation, but in both models 
improvements in hemodynamic recovery were demonstrated. That excludes the 
acceleration of cardiac arrest as the main mechanism involved. It appears possible 
that adenosine without high potassium acts as a preconditioning agent via activation 
of A1 receptors and opening of ATP-sensitive potassium channels. 
In the in vivo model with normal baboon hearts the improvement of cardiac ejection 
phase indices was mediated via a reduction of systemic vascular resistance with the 
intermediate concentration of 1 mM of adenosine added to St. Thomas' Hospital 
solution No. 2. Additionally we also demonstrated an improvement in 
electrophysiologic stability and coronary vasodilatation during cardioplegic perfusion 
with the addition of 1 mM adenosine. The addition of 0.1 mM did not improve 
hemodynamic recovery compared to St. Thomas' hospital solution, whereas addition 
of 10 mM showed depressed recovery of hemodynamic function. 
The results of this study show that the concentration of adenosine is important in 
relation to its effect in improving and protecting myocardial function during ischemia. 
Other studies have shown an improvement with 200 µM of adenosine added to high 
potassium solutions. Our rationale for using high doses of adenosine was based on 
the idea of inducing cardiac arrest. 
It appears, however, that in the primate and possibly also in man, cardiac arrest with 
adenosine can only be achieved with additional measures. That does not exclude, 
however, the possibility that a low dose of adenosine as mentioned in other studies 
with 200 µM might be beneficial as an additive to high potassium solutions. The 
optimal concentration is also species-dependent. Our in-vitro studies showed that 
baboon erythrocytes contain a five times higher rate of adenosine deaminase than 
human cells, which could explain the five times higher concentration found to be 
optimal in the baboon. On the other hand, Mentzer (1993) stresses the value of 
adding high doses of adenosine in cardiac preservation solutions such as the 
University of Wisconsin solution. However, as mentioned in previous chapters, there 
is a difference between storage and in vivo cardioplegic protection, and adenosine 
might be metabolized less at the low temperatures involved with storage of 4° C. 
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To conclude, adenosine alone is not effective as a cardioplegic agent in the primate, 
but it improves hemodynamic recovery post-ischemia. The combination of adenosine 
and high potassium improved hemodynamic recovery in terms of ejection phase 
indices mainly via reduction of systemic vascular resistance. However, the 
combination of high potassium and adenosine improved postischemic electrical 
stability, as shown by the reduced requirements for defibrillation to revert the hearts 
back to sinus rhythm. It appears that in the clinical setting adenosine in high 
concentrations can only be used as an induction agent for cardioplegia with 
additional measures or as a pre-treatment before ischemia. The combination of 
adenosine and high potassium is less beneficial in terms of hemodynamic recovery, 
but improved rhythm stability and coronary vasodilatation are desirable factors in 
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